CINXE.COM

<!DOCTYPE html> <html lang="en" xmlns:fb="http://www.facebook.com/2008/fbml" class="wf-loading"> <head prefix="og: https://ogp.me/ns# fb: https://ogp.me/ns/fb# academia: https://ogp.me/ns/fb/academia#"> <meta charset="utf-8"> <meta name=viewport content="width=device-width, initial-scale=1"> <meta rel="search" type="application/opensearchdescription+xml" href="/open_search.xml" title="Academia.edu"> <title>Maryse Lapeyre-mestre | University of Toulouse - Academia.edu</title>  <link href="//a.academia-assets.com/images/favicons/favicon-production.ico" rel="shortcut icon" type="image/vnd.microsoft.icon"> <link rel="apple-touch-icon" sizes="57x57" href="//a.academia-assets.com/images/favicons/apple-touch-icon-57x57.png"> <link rel="apple-touch-icon" sizes="60x60" href="//a.academia-assets.com/images/favicons/apple-touch-icon-60x60.png"> <link rel="apple-touch-icon" sizes="72x72" href="//a.academia-assets.com/images/favicons/apple-touch-icon-72x72.png"> <link rel="apple-touch-icon" sizes="76x76" href="//a.academia-assets.com/images/favicons/apple-touch-icon-76x76.png"> <link rel="apple-touch-icon" sizes="114x114" href="//a.academia-assets.com/images/favicons/apple-touch-icon-114x114.png"> <link rel="apple-touch-icon" sizes="120x120" href="//a.academia-assets.com/images/favicons/apple-touch-icon-120x120.png"> <link rel="apple-touch-icon" sizes="144x144" href="//a.academia-assets.com/images/favicons/apple-touch-icon-144x144.png"> <link rel="apple-touch-icon" sizes="152x152" href="//a.academia-assets.com/images/favicons/apple-touch-icon-152x152.png"> <link rel="apple-touch-icon" sizes="180x180" href="//a.academia-assets.com/images/favicons/apple-touch-icon-180x180.png"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-32x32.png" sizes="32x32"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-194x194.png" sizes="194x194"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-96x96.png" sizes="96x96"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/android-chrome-192x192.png" sizes="192x192"> <link rel="icon" type="image/png" href="//a.academia-assets.com/images/favicons/favicon-16x16.png" sizes="16x16"> <link rel="manifest" href="//a.academia-assets.com/images/favicons/manifest.json"> <meta name="msapplication-TileColor" content="#2b5797"> <meta name="msapplication-TileImage" content="//a.academia-assets.com/images/favicons/mstile-144x144.png"> <meta name="theme-color" content="#ffffff"> <script> window.performance && window.performance.measure && window.performance.measure("Time To First Byte", "requestStart", "responseStart"); </script> <script> (function() { if (!window.URLSearchParams || !window.history || !window.history.replaceState) { return; } var searchParams = new URLSearchParams(window.location.search); var paramsToDelete = [ 'fs', 'sm', 'swp', 'iid', 'nbs', 'rcc', // related content category 'rcpos', // related content carousel position 'rcpg', // related carousel page 'rchid', // related content hit id 'f_ri', // research interest id, for SEO tracking 'f_fri', // featured research interest, for SEO tracking (param key without value) 'f_rid', // from research interest directory for SEO tracking 'f_loswp', // from research interest pills on LOSWP sidebar for SEO tracking 'rhid', // referrring hit id ]; if (paramsToDelete.every((key) => searchParams.get(key) === null)) { return; } paramsToDelete.forEach((key) => { searchParams.delete(key); }); var cleanUrl = new URL(window.location.href); cleanUrl.search = searchParams.toString(); history.replaceState({}, document.title, cleanUrl); })(); </script> <script async src="https://www.googletagmanager.com/gtag/js?id=G-5VKX33P2DS"></script> <script> window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-5VKX33P2DS', { cookie_domain: 'academia.edu', send_page_view: false, }); gtag('event', 'page_view', { 'controller': "profiles/works", 'action': "summary", 'controller_action': 'profiles/works#summary', 'logged_in': 'false', 'edge': 'unknown', // Send nil if there is no A/B test bucket, in case some records get logged // with missing data - that way we can distinguish between the two cases. // ab_test_bucket should be of the form <ab_test_name>:<bucket> 'ab_test_bucket': null, }) </script> <script type="text/javascript"> window.sendUserTiming = function(timingName) { if (!(window.performance && window.performance.measure)) return; var entries = window.performance.getEntriesByName(timingName, "measure"); if (entries.length !== 1) return; var timingValue = Math.round(entries[0].duration); gtag('event', 'timing_complete', { name: timingName, value: timingValue, event_category: 'User-centric', }); }; window.sendUserTiming("Time To First Byte"); </script> <meta name="csrf-param" content="authenticity_token" /> <meta name="csrf-token" content="ahwMgibID07OnSl2rxdNu5arybgIj517q+NW1bl6wX8zwmMOcY16hfpgdiROEqXpRaPvlGrOjibSWxgIWjrA5w==" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/wow-77f7b87cb1583fc59aa8f94756ebfe913345937eb932042b4077563bebb5fb4b.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/social/home-1c712297ae3ac71207193b1bae0ecf1aae125886850f62c9c0139dd867630797.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/heading-b2b823dd904da60a48fd1bfa1defd840610c2ff414d3f39ed3af46277ab8df3b.css" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/button-3cea6e0ad4715ed965c49bfb15dedfc632787b32ff6d8c3a474182b231146ab7.css" /><link crossorigin="" href="https://fonts.gstatic.com/" rel="preconnect" /><link href="https://fonts.googleapis.com/css2?family=DM+Sans:ital,opsz,wght@0,9..40,100..1000;1,9..40,100..1000&family=Gupter:wght@400;500;700&family=IBM+Plex+Mono:wght@300;400&family=Material+Symbols+Outlined:opsz,wght,FILL,GRAD@20,400,0,0&display=swap" rel="stylesheet" /><link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system/common-10fa40af19d25203774df2d4a03b9b5771b45109c2304968038e88a81d1215c5.css" /> <meta name="author" content="maryse lapeyre-mestre" /> <meta name="description" content="Maryse Lapeyre-mestre, University of Toulouse: 101 Followers, 29 Following, 361 Research papers. Research interests: Event-Related Potentials, Paediatrics,…" /> <meta name="google-site-verification" content="bKJMBZA7E43xhDOopFZkssMMkBRjvYERV-NaN4R6mrs" /> <script> var $controller_name = 'works'; var $action_name = "summary"; var $rails_env = 'production'; var $app_rev = '49879c2402910372f4abc62630a427bbe033d190'; var $domain = 'academia.edu'; var $app_host = "academia.edu"; var $asset_host = "academia-assets.com"; var $start_time = new Date().getTime(); var $recaptcha_key = "6LdxlRMTAAAAADnu_zyLhLg0YF9uACwz78shpjJB"; var $recaptcha_invisible_key = "6Lf3KHUUAAAAACggoMpmGJdQDtiyrjVlvGJ6BbAj"; var $disableClientRecordHit = false; </script> <script> window.Aedu = { hit_data: null }; window.Aedu.SiteStats = {"premium_universities_count":15276,"monthly_visitors":"112 million","monthly_visitor_count":112794806,"monthly_visitor_count_in_millions":112,"user_count":277174129,"paper_count":55203019,"paper_count_in_millions":55,"page_count":432000000,"page_count_in_millions":432,"pdf_count":16500000,"pdf_count_in_millions":16}; window.Aedu.serverRenderTime = new Date(1732448903000); window.Aedu.timeDifference = new Date().getTime() - 1732448903000; window.Aedu.isUsingCssV1 = false; window.Aedu.enableLocalization = true; window.Aedu.activateFullstory = false; window.Aedu.serviceAvailability = { status: {"attention_db":"on","bibliography_db":"on","contacts_db":"on","email_db":"on","indexability_db":"on","mentions_db":"on","news_db":"on","notifications_db":"on","offsite_mentions_db":"on","redshift":"on","redshift_exports_db":"on","related_works_db":"on","ring_db":"on","user_tests_db":"on"}, serviceEnabled: function(service) { return this.status[service] === "on"; }, readEnabled: function(service) { return this.serviceEnabled(service) || this.status[service] === "read_only"; }, }; window.Aedu.viewApmTrace = function() { // Check if x-apm-trace-id meta tag is set, and open the trace in APM // in a new window if it is. var apmTraceId = document.head.querySelector('meta[name="x-apm-trace-id"]'); if (apmTraceId) { var traceId = apmTraceId.content; // Use trace ID to construct URL, an example URL looks like: // https://app.datadoghq.com/apm/traces?query=trace_id%31298410148923562634 var apmUrl = 'https://app.datadoghq.com/apm/traces?query=trace_id%3A' + traceId; window.open(apmUrl, '_blank'); } }; </script>  <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet"> <link href="//maxcdn.bootstrapcdn.com/font-awesome/4.3.0/css/font-awesome.min.css" rel="stylesheet"> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/libraries-a9675dcb01ec4ef6aa807ba772c7a5a00c1820d3ff661c1038a20f80d06bb4e4.css" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/academia-296162c7af6fd81dcdd76f1a94f1fad04fb5f647401337d136fe8b68742170b1.css" /> <link rel="stylesheet" media="all" href="//a.academia-assets.com/assets/design_system_legacy-056a9113b9a0f5343d013b29ee1929d5a18be35fdcdceb616600b4db8bd20054.css" /> <script src="//a.academia-assets.com/assets/webpack_bundles/runtime-bundle-005434038af4252ca37c527588411a3d6a0eabb5f727fac83f8bbe7fd88d93bb.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/webpack_libraries_and_infrequently_changed.wjs-bundle-8d53a22151f33ab413d88fa1c02f979c3f8706d470fc1bced09852c72a9f3454.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/core_webpack.wjs-bundle-f8fe82512740391f81c9e8cc48220144024b425b359b08194e316f4de070b9e8.js"></script> <script src="//a.academia-assets.com/assets/webpack_bundles/sentry.wjs-bundle-5fe03fddca915c8ba0f7edbe64c194308e8ce5abaed7bffe1255ff37549c4808.js"></script> <script> jade = window.jade || {}; jade.helpers = window.$h; jade._ = window._; </script>  <script id="tag-manager-head-root">(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer_old','GTM-5G9JF7Z');</script>  <script> window.gptadslots = []; window.googletag = window.googletag || {}; window.googletag.cmd = window.googletag.cmd || []; </script> <script type="text/javascript"> // TODO(jacob): This should be defined, may be rare load order problem. // Checking if null is just a quick fix, will default to en if unset. // Better fix is to run this immedietely after I18n is set. if (window.I18n != null) { I18n.defaultLocale = "en"; I18n.locale = "en"; I18n.fallbacks = true; } </script> <link rel="canonical" href="https://univ-toulouse.academia.edu/MaryseLapeyremestre" /> </head>   <body class='c-profiles/works a-summary logged_out'>  <div id="fb-root"></div><script>window.fbAsyncInit = function() { FB.init({ appId: "2369844204", version: "v8.0", status: true, cookie: true, xfbml: true }); // Additional initialization code. if (window.InitFacebook) { // facebook.ts already loaded, set it up. window.InitFacebook(); } else { // Set a flag for facebook.ts to find when it loads. window.academiaAuthReadyFacebook = true; } };</script><script>window.fbAsyncLoad = function() { // Protection against double calling of this function if (window.FB) { return; } (function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "//connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk')); } if (!window.defer_facebook) { // Autoload if not deferred window.fbAsyncLoad(); } else { // Defer loading by 5 seconds setTimeout(function() { window.fbAsyncLoad(); }, 5000); }</script> <div id="google-root"></div><script>window.loadGoogle = function() { if (window.InitGoogle) { // google.ts already loaded, set it up. window.InitGoogle("331998490334-rsn3chp12mbkiqhl6e7lu2q0mlbu0f1b"); } else { // Set a flag for google.ts to use when it loads. window.GoogleClientID = "331998490334-rsn3chp12mbkiqhl6e7lu2q0mlbu0f1b"; } };</script><script>window.googleAsyncLoad = function() { // Protection against double calling of this function (function(d) { var js; var id = 'google-jssdk'; var ref = d.getElementsByTagName('script')[0]; if (d.getElementById(id)) { return; } js = d.createElement('script'); js.id = id; js.async = true; js.onload = loadGoogle; js.src = "https://accounts.google.com/gsi/client" ref.parentNode.insertBefore(js, ref); }(document)); } if (!window.defer_google) { // Autoload if not deferred window.googleAsyncLoad(); } else { // Defer loading by 5 seconds setTimeout(function() { window.googleAsyncLoad(); }, 5000); }</script> <div id="tag-manager-body-root">  <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-5G9JF7Z" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>   <script> window.addEventListener('load', function() { if (document.querySelector('input[name="commit"]')) { document.querySelector('input[name="commit"]').addEventListener('click', function() { gtag('event', 'click', { event_category: 'button', event_label: 'Log In' }) }) } }); </script> </div> <script>var _comscore = _comscore || []; _comscore.push({ c1: "2", c2: "26766707" }); (function() { var s = document.createElement("script"), el = document.getElementsByTagName("script")[0]; s.async = true; s.src = (document.location.protocol == "https:" ? "https://sb" : "http://b") + ".scorecardresearch.com/beacon.js"; el.parentNode.insertBefore(s, el); })();</script><img src="https://sb.scorecardresearch.com/p?c1=2&c2=26766707&cv=2.0&cj=1" style="position: absolute; visibility: hidden" /> <div id='react-modal'></div> <div class='DesignSystem'> <a class='u-showOnFocus' href='#site'> Skip to main content </a> </div> <div id="upgrade_ie_banner" style="display: none;"><p>Academia.edu no longer supports Internet Explorer.</p><p>To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to <a href="https://www.academia.edu/upgrade-browser">upgrade your browser</a>.</p></div><script>// Show this banner for all versions of IE if (!!window.MSInputMethodContext || /(MSIE)/.test(navigator.userAgent)) { document.getElementById('upgrade_ie_banner').style.display = 'block'; }</script> <div class="DesignSystem bootstrap ShrinkableNav"><div class="navbar navbar-default main-header"><div class="container-wrapper" id="main-header-container"><div class="container"><div class="navbar-header"><div class="nav-left-wrapper u-mt0x"><div class="nav-logo"><a data-main-header-link-target="logo_home" href="https://www.academia.edu/"><img class="visible-xs-inline-block" style="height: 24px;" alt="Academia.edu" src="//a.academia-assets.com/images/academia-logo-redesign-2015-A.svg" width="24" height="24" /><img width="145.2" height="18" class="hidden-xs" style="height: 24px;" alt="Academia.edu" src="//a.academia-assets.com/images/academia-logo-redesign-2015.svg" /></a></div><div class="nav-search"><div class="SiteSearch-wrapper select2-no-default-pills"><form class="js-SiteSearch-form DesignSystem" action="https://www.academia.edu/search" accept-charset="UTF-8" method="get"><input name="utf8" type="hidden" value="✓" autocomplete="off" /><i class="SiteSearch-icon fa fa-search u-fw700 u-positionAbsolute u-tcGrayDark"></i><input class="js-SiteSearch-form-input SiteSearch-form-input form-control" data-main-header-click-target="search_input" name="q" placeholder="Search" type="text" value="" /></form></div></div></div><div class="nav-right-wrapper pull-right"><ul class="NavLinks js-main-nav list-unstyled"><li class="NavLinks-link"><a class="js-header-login-url Button Button--inverseGray Button--sm u-mb4x" id="nav_log_in" rel="nofollow" href="https://www.academia.edu/login">Log In</a></li><li class="NavLinks-link u-p0x"><a class="Button Button--inverseGray Button--sm u-mb4x" rel="nofollow" href="https://www.academia.edu/signup">Sign Up</a></li></ul><button class="hidden-lg hidden-md hidden-sm u-ml4x navbar-toggle collapsed" data-target=".js-mobile-header-links" data-toggle="collapse" type="button"><span class="icon-bar"></span><span class="icon-bar"></span><span class="icon-bar"></span></button></div></div><div class="collapse navbar-collapse js-mobile-header-links"><ul class="nav navbar-nav"><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/login">Log In</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/signup">Sign Up</a></li><li class="u-borderColorGrayLight u-borderBottom1 js-mobile-nav-expand-trigger"><a href="#">more&nbsp<span class="caret"></span></a></li><li><ul class="js-mobile-nav-expand-section nav navbar-nav u-m0x collapse"><li class="u-borderColorGrayLight u-borderBottom1"><a rel="false" href="https://www.academia.edu/about">About</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/press">Press</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://medium.com/@academia">Blog</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="false" href="https://www.academia.edu/documents">Papers</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/terms">Terms</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/privacy">Privacy</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/copyright">Copyright</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://www.academia.edu/hiring"><i class="fa fa-briefcase"></i> We're Hiring!</a></li><li class="u-borderColorGrayLight u-borderBottom1"><a rel="nofollow" href="https://support.academia.edu/"><i class="fa fa-question-circle"></i> Help Center</a></li><li class="js-mobile-nav-collapse-trigger u-borderColorGrayLight u-borderBottom1 dropup" style="display:none"><a href="#">less&nbsp<span class="caret"></span></a></li></ul></li></ul></div></div></div><script>(function(){ var $moreLink = $(".js-mobile-nav-expand-trigger"); var $lessLink = $(".js-mobile-nav-collapse-trigger"); var $section = $('.js-mobile-nav-expand-section'); $moreLink.click(function(ev){ ev.preventDefault(); $moreLink.hide(); $lessLink.show(); $section.collapse('show'); }); $lessLink.click(function(ev){ ev.preventDefault(); $moreLink.show(); $lessLink.hide(); $section.collapse('hide'); }); })() if ($a.is_logged_in() || false) { new Aedu.NavigationController({ el: '.js-main-nav', showHighlightedNotification: false }); } else { $(".js-header-login-url").attr("href", $a.loginUrlWithRedirect()); } Aedu.autocompleteSearch = new AutocompleteSearch({el: '.js-SiteSearch-form'});</script></div></div> <div id='site' class='fixed'> <div id="content" class="clearfix"> <script>document.addEventListener('DOMContentLoaded', function(){ var $dismissible = $(".dismissible_banner"); $dismissible.click(function(ev) { $dismissible.hide(); }); });</script> <script src="//a.academia-assets.com/assets/webpack_bundles/profile.wjs-bundle-9601d1cc3d68aa07c0a9901d03d3611aec04cc07d2a2039718ebef4ad4d148ca.js" defer="defer"></script><script>Aedu.rankings = { showPaperRankingsLink: false } $viewedUser = Aedu.User.set_viewed( {"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre","photo":"/images/s65_no_pic.png","has_photo":false,"department":{"id":1534450,"name":"Medical and Clinical Pharmacology","url":"https://univ-toulouse.academia.edu/Departments/Medical_and_Clinical_Pharmacology/Documents","university":{"id":2401,"name":"University of Toulouse","url":"https://univ-toulouse.academia.edu/"}},"position":"Faculty Member","position_id":1,"is_analytics_public":false,"interests":[{"id":51870,"name":"Event-Related Potentials","url":"https://www.academia.edu/Documents/in/Event-Related_Potentials"},{"id":46131,"name":"Paediatrics","url":"https://www.academia.edu/Documents/in/Paediatrics"},{"id":52763,"name":"Functional Connectivity","url":"https://www.academia.edu/Documents/in/Functional_Connectivity"},{"id":131640,"name":"Student Learning","url":"https://www.academia.edu/Documents/in/Student_Learning"},{"id":11749,"name":"Affective Computing","url":"https://www.academia.edu/Documents/in/Affective_Computing"}]} ); if ($a.is_logged_in() && $viewedUser.is_current_user()) { $('body').addClass('profile-viewed-by-owner'); } $socialProfiles = []</script><div id="js-react-on-rails-context" style="display:none" data-rails-context="{"inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://univ-toulouse.academia.edu/MaryseLapeyremestre","location":"/MaryseLapeyremestre","scheme":"https","host":"univ-toulouse.academia.edu","port":null,"pathname":"/MaryseLapeyremestre","search":null,"httpAcceptLanguage":null,"serverSide":false}"></div> <div class="js-react-on-rails-component" style="display:none" data-component-name="ProfileCheckPaperUpdate" data-props="{}" data-trace="false" data-dom-id="ProfileCheckPaperUpdate-react-component-d9d2656c-9d00-4d11-8875-aabe5117b88d"></div> <div id="ProfileCheckPaperUpdate-react-component-d9d2656c-9d00-4d11-8875-aabe5117b88d"></div> <div class="DesignSystem"><div class="onsite-ping" id="onsite-ping"></div></div><div class="profile-user-info DesignSystem"><div class="social-profile-container"><div class="left-panel-container"><div class="user-info-component-wrapper"><div class="user-summary-cta-container"><div class="user-summary-container"><div class="social-profile-avatar-container"><img class="profile-avatar u-positionAbsolute" border="0" alt="" src="//a.academia-assets.com/images/s200_no_pic.png" /></div><div class="title-container"><h1 class="ds2-5-heading-sans-serif-sm">Maryse Lapeyre-mestre</h1><div class="affiliations-container fake-truncate js-profile-affiliations"><div><a class="u-tcGrayDarker" href="https://univ-toulouse.academia.edu/">University of Toulouse</a>, <a class="u-tcGrayDarker" href="https://univ-toulouse.academia.edu/Departments/Medical_and_Clinical_Pharmacology/Documents">Medical and Clinical Pharmacology</a>, <span class="u-tcGrayDarker">Faculty Member</span></div></div></div></div><div class="sidebar-cta-container"><button class="ds2-5-button hidden profile-cta-button grow js-profile-follow-button" data-broccoli-component="user-info.follow-button" data-click-track="profile-user-info-follow-button" data-follow-user-fname="Maryse" data-follow-user-id="32462798" data-follow-user-source="profile_button" data-has-google="false"><span class="material-symbols-outlined" style="font-size: 20px" translate="no">add</span>Follow</button><button class="ds2-5-button hidden profile-cta-button grow js-profile-unfollow-button" data-broccoli-component="user-info.unfollow-button" data-click-track="profile-user-info-unfollow-button" data-unfollow-user-id="32462798"><span class="material-symbols-outlined" style="font-size: 20px" translate="no">done</span>Following</button></div></div><div class="user-stats-container"><a><div class="stat-container js-profile-followers"><p class="label">Followers</p><p class="data">101</p></div></a><a><div class="stat-container js-profile-followees" data-broccoli-component="user-info.followees-count" data-click-track="profile-expand-user-info-following"><p class="label">Following</p><p class="data">29</p></div></a><a><div class="stat-container js-profile-coauthors" data-broccoli-component="user-info.coauthors-count" data-click-track="profile-expand-user-info-coauthors"><p class="label">Co-authors</p><p class="data">31</p></div></a><span><div class="stat-container"><p class="label"><span class="js-profile-total-view-text">Public Views</span></p><p class="data"><span class="js-profile-view-count"></span></p></div></span></div><div class="ri-section"><div class="ri-section-header"><span>Interests</span></div><div class="ri-tags-container"><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="32462798" href="https://www.academia.edu/Documents/in/Event-Related_Potentials"><div id="js-react-on-rails-context" style="display:none" data-rails-context="{"inMailer":false,"i18nLocale":"en","i18nDefaultLocale":"en","href":"https://univ-toulouse.academia.edu/MaryseLapeyremestre","location":"/MaryseLapeyremestre","scheme":"https","host":"univ-toulouse.academia.edu","port":null,"pathname":"/MaryseLapeyremestre","search":null,"httpAcceptLanguage":null,"serverSide":false}"></div> <div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Event-Related Potentials"]}" data-trace="false" data-dom-id="Pill-react-component-e9d091b7-81e4-4b65-85be-7df4e4669d23"></div> <div id="Pill-react-component-e9d091b7-81e4-4b65-85be-7df4e4669d23"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="32462798" href="https://www.academia.edu/Documents/in/Paediatrics"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Paediatrics"]}" data-trace="false" data-dom-id="Pill-react-component-58e8d444-6f44-44ba-a30a-8e5397d5d612"></div> <div id="Pill-react-component-58e8d444-6f44-44ba-a30a-8e5397d5d612"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="32462798" href="https://www.academia.edu/Documents/in/Functional_Connectivity"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Functional Connectivity"]}" data-trace="false" data-dom-id="Pill-react-component-14df5e32-56f8-4731-91a7-dce872a565ff"></div> <div id="Pill-react-component-14df5e32-56f8-4731-91a7-dce872a565ff"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="32462798" href="https://www.academia.edu/Documents/in/Student_Learning"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Student Learning"]}" data-trace="false" data-dom-id="Pill-react-component-fbc60fd9-d6c6-48cd-908a-4b2ec4cd7804"></div> <div id="Pill-react-component-fbc60fd9-d6c6-48cd-908a-4b2ec4cd7804"></div> </a><a data-click-track="profile-user-info-expand-research-interests" data-has-card-for-ri-list="32462798" href="https://www.academia.edu/Documents/in/Affective_Computing"><div class="js-react-on-rails-component" style="display:none" data-component-name="Pill" data-props="{"color":"gray","children":["Affective Computing"]}" data-trace="false" data-dom-id="Pill-react-component-d3f2d6f5-0b5a-4f7b-9933-9bc318c3e30d"></div> <div id="Pill-react-component-d3f2d6f5-0b5a-4f7b-9933-9bc318c3e30d"></div> </a></div></div></div></div><div class="right-panel-container"><div class="user-content-wrapper"><div class="uploads-container" id="social-redesign-work-container"><div class="upload-header"><h2 class="ds2-5-heading-sans-serif-xs">Uploads</h2></div><div class="documents-container backbone-social-profile-documents" style="width: 100%;"><div class="u-taCenter"></div><div class="profile--tab_content_container js-tab-pane tab-pane active" id="all"><div class="profile--tab_heading_container js-section-heading" data-section="Papers" id="Papers"><h3 class="profile--tab_heading_container">Papers by Maryse Lapeyre-mestre</h3></div><div class="js-work-strip profile--work_container" data-work-id="122114365"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114365/Risque_de_cancer_sous_anti_TNF_%CE%B1_chez_les_patients_adultes_atteints_de_polyarthrite_rhumato%C3%AFde_m%C3%A9ta_analyse_de_33_essais_cliniques_randomis%C3%A9s"><img alt="Research paper thumbnail of Risque de cancer sous anti-TNF-α chez les patients adultes atteints de polyarthrite rhumatoïde : méta-analyse de 33 essais cliniques randomisés" class="work-thumbnail" src="https://attachments.academia-assets.com/116843218/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114365/Risque_de_cancer_sous_anti_TNF_%CE%B1_chez_les_patients_adultes_atteints_de_polyarthrite_rhumato%C3%AFde_m%C3%A9ta_analyse_de_33_essais_cliniques_randomis%C3%A9s">Risque de cancer sous anti-TNF-α chez les patients adultes atteints de polyarthrite rhumatoïde : méta-analyse de 33 essais cliniques randomisés</a></div><div class="wp-workCard_item"><span>Revue de Médecine Interne</span><span>, Dec 1, 2011</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="bf542336d70865175bf22a683d741d47" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843218,"asset_id":122114365,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843218/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114365"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114365"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114365; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114365]").text(description); $(".js-view-count[data-work-id=122114365]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114365; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114365']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114365, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "bf542336d70865175bf22a683d741d47" } } $('.js-work-strip[data-work-id=122114365]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114365,"title":"Risque de cancer sous anti-TNF-α chez les patients adultes atteints de polyarthrite rhumatoïde : méta-analyse de 33 essais cliniques randomisés","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":12,"year":2011,"errors":{}},"publication_name":"Revue de Médecine Interne"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114365/Risque_de_cancer_sous_anti_TNF_%CE%B1_chez_les_patients_adultes_atteints_de_polyarthrite_rhumato%C3%AFde_m%C3%A9ta_analyse_de_33_essais_cliniques_randomis%C3%A9s","translated_internal_url":"","created_at":"2024-07-16T22:20:07.037-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843218,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843218/thumbnails/1.jpg","file_name":"j.revmed.2011.10.32220240717-1-b8ydjk.pdf","download_url":"https://www.academia.edu/attachments/116843218/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Risque_de_cancer_sous_anti_TNF__chez_le.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843218/j.revmed.2011.10.32220240717-1-b8ydjk-libre.pdf?1721196832=\u0026response-content-disposition=attachment%3B+filename%3DRisque_de_cancer_sous_anti_TNF__chez_le.pdf\u0026Expires=1732431771\u0026Signature=UM5JlYE8HKVhP2VZ7~aIPAciKKqdwRd0I1RLE7FaK5MHdzoCaYKQBV--LgsixOeLHFk2NBdL3R8vY-IZUrWCKlBJhSoUIkPYp0e3gA5lUmy5dSXfo2Bm5XwgskKStvrC-2WmEkNIu5bwV8U7ITRC6nlIkhVa6xFMb2xr4rFwedCFFpiOeBeTbuSXZ74KfQlJn~~Piim73Anf1SEQ9R1fm3gUCFf0sWRQAsL5-1cH7cmAg~IqG3M-OWkbanteu-QH5c8IbViwybCvMJ5vwckCieT8q8Vugii9tgdG-zY8JpMGRpQ-E0bw640d8ADOcR6Z2oGJOrn-mzAjShO6Biy-BA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Risque_de_cancer_sous_anti_TNF_α_chez_les_patients_adultes_atteints_de_polyarthrite_rhumatoïde_méta_analyse_de_33_essais_cliniques_randomisés","translated_slug":"","page_count":2,"language":"fr","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843218,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843218/thumbnails/1.jpg","file_name":"j.revmed.2011.10.32220240717-1-b8ydjk.pdf","download_url":"https://www.academia.edu/attachments/116843218/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Risque_de_cancer_sous_anti_TNF__chez_le.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843218/j.revmed.2011.10.32220240717-1-b8ydjk-libre.pdf?1721196832=\u0026response-content-disposition=attachment%3B+filename%3DRisque_de_cancer_sous_anti_TNF__chez_le.pdf\u0026Expires=1732431771\u0026Signature=UM5JlYE8HKVhP2VZ7~aIPAciKKqdwRd0I1RLE7FaK5MHdzoCaYKQBV--LgsixOeLHFk2NBdL3R8vY-IZUrWCKlBJhSoUIkPYp0e3gA5lUmy5dSXfo2Bm5XwgskKStvrC-2WmEkNIu5bwV8U7ITRC6nlIkhVa6xFMb2xr4rFwedCFFpiOeBeTbuSXZ74KfQlJn~~Piim73Anf1SEQ9R1fm3gUCFf0sWRQAsL5-1cH7cmAg~IqG3M-OWkbanteu-QH5c8IbViwybCvMJ5vwckCieT8q8Vugii9tgdG-zY8JpMGRpQ-E0bw640d8ADOcR6Z2oGJOrn-mzAjShO6Biy-BA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"}],"urls":[{"id":43558007,"url":"https://doi.org/10.1016/j.revmed.2011.10.322"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114363"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114363/Dermatological_adverse_drug_reactions_of_anticancer_drugs_International_data_of_pharmacovigilance_VigiBase_"><img alt="Research paper thumbnail of Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114363/Dermatological_adverse_drug_reactions_of_anticancer_drugs_International_data_of_pharmacovigilance_VigiBase_">Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®</a></div><div class="wp-workCard_item"><span>Therapie</span><span>, Mar 1, 2022</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">In the 2000s, newer generations of drugs appeared on the market called drugs of targeted therapy ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">In the 2000s, newer generations of drugs appeared on the market called drugs of targeted therapy (TT) drugs. The introduction of TT in oncology has profoundly changed the prognosis of many cancers but also introduced a wide variety of adverse drugs reactions (ADR), including in particular dermatological adverse drug reactions (DADRs). We investigated the evolutions of the notifications of DADRs of anticancer drugs since 2000s in international pharmacovigilance data. For this purpose, we separated non-targeted therapy and targeted therapy. During the period from 01/01/2000 to 31/12/2017, 1,226,252 ICSRs (8.7%) were related to anticancer drugs, among them concerning anticancer drugs, 192,108 cases (15.6%) contained at least one MedDRA term for &quot;skin and subcutaneous tissue disorders&quot; system organ classes. The DADRs of anticancer drugs are in constant increase on the period 2000 to 2017, from 0.91% to 1.90% of the total ADR of Vigibase®. The number of DADRs drugs in the non-targeted therapies class remained stable during this period, while the DADRs of targeted therapy drugs increased and exceeded those of non-targeted therapy in recent years. Using a disproportionality analysis, we found that targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: dermatitis acneiform, hair color changes, acne, and hyperkeratosis and skin toxicity. While, non-targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: skin hyperpigmentation, nail discoloration, dermatitis exfoliative, Hyperhidrosis and alopecia. TT drugs are used more and more for cancer indications and even beyond. This problematic of DADR will become more and more common and should benefit from specialized support with the organization of a coordinated network of professionals.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114363"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114363"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114363; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114363]").text(description); $(".js-view-count[data-work-id=122114363]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114363; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114363']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114363, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114363]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114363,"title":"Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®","translated_title":"","metadata":{"abstract":"In the 2000s, newer generations of drugs appeared on the market called drugs of targeted therapy (TT) drugs. The introduction of TT in oncology has profoundly changed the prognosis of many cancers but also introduced a wide variety of adverse drugs reactions (ADR), including in particular dermatological adverse drug reactions (DADRs). We investigated the evolutions of the notifications of DADRs of anticancer drugs since 2000s in international pharmacovigilance data. For this purpose, we separated non-targeted therapy and targeted therapy. During the period from 01/01/2000 to 31/12/2017, 1,226,252 ICSRs (8.7%) were related to anticancer drugs, among them concerning anticancer drugs, 192,108 cases (15.6%) contained at least one MedDRA term for \u0026quot;skin and subcutaneous tissue disorders\u0026quot; system organ classes. The DADRs of anticancer drugs are in constant increase on the period 2000 to 2017, from 0.91% to 1.90% of the total ADR of Vigibase®. The number of DADRs drugs in the non-targeted therapies class remained stable during this period, while the DADRs of targeted therapy drugs increased and exceeded those of non-targeted therapy in recent years. Using a disproportionality analysis, we found that targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: dermatitis acneiform, hair color changes, acne, and hyperkeratosis and skin toxicity. While, non-targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: skin hyperpigmentation, nail discoloration, dermatitis exfoliative, Hyperhidrosis and alopecia. TT drugs are used more and more for cancer indications and even beyond. This problematic of DADR will become more and more common and should benefit from specialized support with the organization of a coordinated network of professionals.","publisher":"Elsevier BV","publication_date":{"day":1,"month":3,"year":2022,"errors":{}},"publication_name":"Therapie"},"translated_abstract":"In the 2000s, newer generations of drugs appeared on the market called drugs of targeted therapy (TT) drugs. The introduction of TT in oncology has profoundly changed the prognosis of many cancers but also introduced a wide variety of adverse drugs reactions (ADR), including in particular dermatological adverse drug reactions (DADRs). We investigated the evolutions of the notifications of DADRs of anticancer drugs since 2000s in international pharmacovigilance data. For this purpose, we separated non-targeted therapy and targeted therapy. During the period from 01/01/2000 to 31/12/2017, 1,226,252 ICSRs (8.7%) were related to anticancer drugs, among them concerning anticancer drugs, 192,108 cases (15.6%) contained at least one MedDRA term for \u0026quot;skin and subcutaneous tissue disorders\u0026quot; system organ classes. The DADRs of anticancer drugs are in constant increase on the period 2000 to 2017, from 0.91% to 1.90% of the total ADR of Vigibase®. The number of DADRs drugs in the non-targeted therapies class remained stable during this period, while the DADRs of targeted therapy drugs increased and exceeded those of non-targeted therapy in recent years. Using a disproportionality analysis, we found that targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: dermatitis acneiform, hair color changes, acne, and hyperkeratosis and skin toxicity. While, non-targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: skin hyperpigmentation, nail discoloration, dermatitis exfoliative, Hyperhidrosis and alopecia. TT drugs are used more and more for cancer indications and even beyond. This problematic of DADR will become more and more common and should benefit from specialized support with the organization of a coordinated network of professionals.","internal_url":"https://www.academia.edu/122114363/Dermatological_adverse_drug_reactions_of_anticancer_drugs_International_data_of_pharmacovigilance_VigiBase_","translated_internal_url":"","created_at":"2024-07-16T22:20:03.953-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Dermatological_adverse_drug_reactions_of_anticancer_drugs_International_data_of_pharmacovigilance_VigiBase_","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":140,"name":"Pharmacology","url":"https://www.academia.edu/Documents/in/Pharmacology"},{"id":10829,"name":"Pharmacovigilance","url":"https://www.academia.edu/Documents/in/Pharmacovigilance"},{"id":12729,"name":"Dermatology","url":"https://www.academia.edu/Documents/in/Dermatology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":42135,"name":"Drug","url":"https://www.academia.edu/Documents/in/Drug"},{"id":602602,"name":"Drug Reaction","url":"https://www.academia.edu/Documents/in/Drug_Reaction"},{"id":816770,"name":"Therapies","url":"https://www.academia.edu/Documents/in/Therapies"},{"id":2380530,"name":"Therapie","url":"https://www.academia.edu/Documents/in/Therapie"},{"id":2601211,"name":"Adverse effect","url":"https://www.academia.edu/Documents/in/Adverse_effect"}],"urls":[{"id":43558006,"url":"https://doi.org/10.1016/j.therap.2021.12.006"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114362"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114362/Les_facteurs_influen%C3%A7ant_la_prescription_de_benzodiaz%C3%A9pines_devant_une_plainte_anxieuse_chez_une_personne_%C3%A2g%C3%A9e"><img alt="Research paper thumbnail of Les facteurs influençant la prescription de benzodiazépines devant une plainte anxieuse chez une personne âgée" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114362/Les_facteurs_influen%C3%A7ant_la_prescription_de_benzodiaz%C3%A9pines_devant_une_plainte_anxieuse_chez_une_personne_%C3%A2g%C3%A9e">Les facteurs influençant la prescription de benzodiazépines devant une plainte anxieuse chez une personne âgée</a></div><div class="wp-workCard_item"><span>Médecine</span><span>, Apr 1, 2017</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Le nombre de prescriptions de benzodiazepines chez les personnes de plus de 65 ans semble superie...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Le nombre de prescriptions de benzodiazepines chez les personnes de plus de 65 ans semble superieur a la prevalence des pathologies repondant a l’autorisation de mise sur le marche. Les facteurs influencant la prescription de benzodiazepines anxiolytiques, en initiation ou en renouvellement, chez la personne de plus de 65 ans ne sont pas connus. L’objectif de cette etude etait de determiner les facteurs influencant l’initiation de ce type de traitement par un echantillon de medecins generalistes en France. Un scenario clinique a ete soumis (etude descriptive transversale) aux medecins generalistes d’un bassin de sante de la region Midi-Pyrenees. Sur l’ensemble des variables etudiees, une analyse univariee, puis en regression logistique multivariee a ete realisee. Trois types de facteurs significatifs (p ≤ 0,05), influencant la prescription, ont ete retrouves chez le medecin de famille : sa perception de la situation clinique, l’offre de soins autour de lui, ses croyances et ses connaissances dans le domaine. Ces facteurs ont permis de mieux expliquer le taux important de recours aux benzodiazepines dans cette population. Des etudes complementaires seraient necessaires pour mieux les expliquer.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114362"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114362"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114362; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114362]").text(description); $(".js-view-count[data-work-id=122114362]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114362; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114362']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114362, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114362]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114362,"title":"Les facteurs influençant la prescription de benzodiazépines devant une plainte anxieuse chez une personne âgée","translated_title":"","metadata":{"abstract":"Le nombre de prescriptions de benzodiazepines chez les personnes de plus de 65 ans semble superieur a la prevalence des pathologies repondant a l’autorisation de mise sur le marche. Les facteurs influencant la prescription de benzodiazepines anxiolytiques, en initiation ou en renouvellement, chez la personne de plus de 65 ans ne sont pas connus. L’objectif de cette etude etait de determiner les facteurs influencant l’initiation de ce type de traitement par un echantillon de medecins generalistes en France. Un scenario clinique a ete soumis (etude descriptive transversale) aux medecins generalistes d’un bassin de sante de la region Midi-Pyrenees. Sur l’ensemble des variables etudiees, une analyse univariee, puis en regression logistique multivariee a ete realisee. Trois types de facteurs significatifs (p ≤ 0,05), influencant la prescription, ont ete retrouves chez le medecin de famille : sa perception de la situation clinique, l’offre de soins autour de lui, ses croyances et ses connaissances dans le domaine. Ces facteurs ont permis de mieux expliquer le taux important de recours aux benzodiazepines dans cette population. Des etudes complementaires seraient necessaires pour mieux les expliquer.","publication_date":{"day":1,"month":4,"year":2017,"errors":{}},"publication_name":"Médecine"},"translated_abstract":"Le nombre de prescriptions de benzodiazepines chez les personnes de plus de 65 ans semble superieur a la prevalence des pathologies repondant a l’autorisation de mise sur le marche. Les facteurs influencant la prescription de benzodiazepines anxiolytiques, en initiation ou en renouvellement, chez la personne de plus de 65 ans ne sont pas connus. L’objectif de cette etude etait de determiner les facteurs influencant l’initiation de ce type de traitement par un echantillon de medecins generalistes en France. Un scenario clinique a ete soumis (etude descriptive transversale) aux medecins generalistes d’un bassin de sante de la region Midi-Pyrenees. Sur l’ensemble des variables etudiees, une analyse univariee, puis en regression logistique multivariee a ete realisee. Trois types de facteurs significatifs (p ≤ 0,05), influencant la prescription, ont ete retrouves chez le medecin de famille : sa perception de la situation clinique, l’offre de soins autour de lui, ses croyances et ses connaissances dans le domaine. Ces facteurs ont permis de mieux expliquer le taux important de recours aux benzodiazepines dans cette population. Des etudes complementaires seraient necessaires pour mieux les expliquer.","internal_url":"https://www.academia.edu/122114362/Les_facteurs_influen%C3%A7ant_la_prescription_de_benzodiaz%C3%A9pines_devant_une_plainte_anxieuse_chez_une_personne_%C3%A2g%C3%A9e","translated_internal_url":"","created_at":"2024-07-16T22:20:03.443-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Les_facteurs_influençant_la_prescription_de_benzodiazépines_devant_une_plainte_anxieuse_chez_une_personne_âgée","translated_slug":"","page_count":null,"language":"fr","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":356921,"name":"Médecine","url":"https://www.academia.edu/Documents/in/M%C3%A9decine"}],"urls":[{"id":43558005,"url":"http://www.jle.com/fr/revues/med/e-docs/les_facteurs_influencant_la_prescription_de_benzodiazepines_devant_une_plainte_anxieuse_chez_une_personne_agee_309540/article.phtml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114361"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114361/Thomboprophylaxis_In_Multiple_Myeloma_Patients_Treated_With_Lenalidomide_or_Thalidomide"><img alt="Research paper thumbnail of Thomboprophylaxis In Multiple Myeloma Patients Treated With Lenalidomide or Thalidomide" class="work-thumbnail" src="https://attachments.academia-assets.com/116843217/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114361/Thomboprophylaxis_In_Multiple_Myeloma_Patients_Treated_With_Lenalidomide_or_Thalidomide">Thomboprophylaxis In Multiple Myeloma Patients Treated With Lenalidomide or Thalidomide</a></div><div class="wp-workCard_item"><span>Clinical Therapeutics</span><span>, Aug 1, 2015</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="90f8d25fdc3adfef1b0a81df9237a784" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843217,"asset_id":122114361,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843217/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114361"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114361"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114361; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114361]").text(description); $(".js-view-count[data-work-id=122114361]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114361; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114361']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114361, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "90f8d25fdc3adfef1b0a81df9237a784" } } $('.js-work-strip[data-work-id=122114361]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114361,"title":"Thomboprophylaxis In Multiple Myeloma Patients Treated With Lenalidomide or Thalidomide","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":8,"year":2015,"errors":{}},"publication_name":"Clinical Therapeutics"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114361/Thomboprophylaxis_In_Multiple_Myeloma_Patients_Treated_With_Lenalidomide_or_Thalidomide","translated_internal_url":"","created_at":"2024-07-16T22:20:02.752-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843217,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843217/thumbnails/1.jpg","file_name":"j.clinthera.2015.05.19520240717-1-e7gj9z.pdf","download_url":"https://www.academia.edu/attachments/116843217/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Thomboprophylaxis_In_Multiple_Myeloma_Pa.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843217/j.clinthera.2015.05.19520240717-1-e7gj9z-libre.pdf?1721196832=\u0026response-content-disposition=attachment%3B+filename%3DThomboprophylaxis_In_Multiple_Myeloma_Pa.pdf\u0026Expires=1732431771\u0026Signature=AZygD5VuGHQeNtb4CstnHs8VDXfw5mmQJLhW4d7gI5toIbjexh8FWfKtymIfE4C1~3QFQzc721SnaKoCrV2NDDnsN7SzjdXiKDegSpl1qhaMKJKFlcpXiPieV6hqvoNjXfO1CX9QYG0vbHgLiz6-wdre12XsGo~NcMu1ySLtvgTcfyBX9GIdzp2fF6qrO7f1Oy9xy-XXUFQi-sDsmFDILIyQftprUMLshBfR0ebQsJhvWemOoJmLP6MCGks4Ezgq4D6TQMD0485P9fLKOow~fzxrQ3fmRHZ2QKgZ5tCP6vsudlZTM4TXN16xiPGTHU~QWa04QR3Vl~Ge-yNPStqRMg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Thomboprophylaxis_In_Multiple_Myeloma_Patients_Treated_With_Lenalidomide_or_Thalidomide","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843217,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843217/thumbnails/1.jpg","file_name":"j.clinthera.2015.05.19520240717-1-e7gj9z.pdf","download_url":"https://www.academia.edu/attachments/116843217/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Thomboprophylaxis_In_Multiple_Myeloma_Pa.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843217/j.clinthera.2015.05.19520240717-1-e7gj9z-libre.pdf?1721196832=\u0026response-content-disposition=attachment%3B+filename%3DThomboprophylaxis_In_Multiple_Myeloma_Pa.pdf\u0026Expires=1732431771\u0026Signature=AZygD5VuGHQeNtb4CstnHs8VDXfw5mmQJLhW4d7gI5toIbjexh8FWfKtymIfE4C1~3QFQzc721SnaKoCrV2NDDnsN7SzjdXiKDegSpl1qhaMKJKFlcpXiPieV6hqvoNjXfO1CX9QYG0vbHgLiz6-wdre12XsGo~NcMu1ySLtvgTcfyBX9GIdzp2fF6qrO7f1Oy9xy-XXUFQi-sDsmFDILIyQftprUMLshBfR0ebQsJhvWemOoJmLP6MCGks4Ezgq4D6TQMD0485P9fLKOow~fzxrQ3fmRHZ2QKgZ5tCP6vsudlZTM4TXN16xiPGTHU~QWa04QR3Vl~Ge-yNPStqRMg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":5500,"name":"Incidence Geometry","url":"https://www.academia.edu/Documents/in/Incidence_Geometry"},{"id":12733,"name":"Rheumatoid Arthritis","url":"https://www.academia.edu/Documents/in/Rheumatoid_Arthritis"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":111110,"name":"Multiple Myeloma","url":"https://www.academia.edu/Documents/in/Multiple_Myeloma"},{"id":220450,"name":"Carpal Tunnel Syndrome","url":"https://www.academia.edu/Documents/in/Carpal_Tunnel_Syndrome"},{"id":254203,"name":"Ambulatory","url":"https://www.academia.edu/Documents/in/Ambulatory"},{"id":711582,"name":"Opioid","url":"https://www.academia.edu/Documents/in/Opioid"},{"id":1451470,"name":"Thalidomide","url":"https://www.academia.edu/Documents/in/Thalidomide"},{"id":2484074,"name":"lenalidomide","url":"https://www.academia.edu/Documents/in/lenalidomide"},{"id":2815854,"name":"Clinical Pharmacology and Therapeutics","url":"https://www.academia.edu/Documents/in/Clinical_Pharmacology_and_Therapeutics"},{"id":3789884,"name":"Pharmacology and pharmaceutical sciences","url":"https://www.academia.edu/Documents/in/Pharmacology_and_pharmaceutical_sciences"}],"urls":[{"id":43558004,"url":"https://doi.org/10.1016/j.clinthera.2015.05.195"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114360"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114360/Identifying_Potential_Drug_Drug_Interactions_In_The_French_Health_Insurance_Databases_Application_In_Multiple_Myeloma_Patients"><img alt="Research paper thumbnail of Identifying Potential Drug–Drug Interactions In The French Health Insurance Databases: Application In Multiple Myeloma Patients" class="work-thumbnail" src="https://attachments.academia-assets.com/116843216/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114360/Identifying_Potential_Drug_Drug_Interactions_In_The_French_Health_Insurance_Databases_Application_In_Multiple_Myeloma_Patients">Identifying Potential Drug–Drug Interactions In The French Health Insurance Databases: Application In Multiple Myeloma Patients</a></div><div class="wp-workCard_item"><span>Clinical Therapeutics</span><span>, Aug 1, 2017</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="159539ce98befd1bf5ff09a2f353c09d" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843216,"asset_id":122114360,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843216/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114360"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114360"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114360; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114360]").text(description); $(".js-view-count[data-work-id=122114360]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114360; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114360']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114360, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "159539ce98befd1bf5ff09a2f353c09d" } } $('.js-work-strip[data-work-id=122114360]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114360,"title":"Identifying Potential Drug–Drug Interactions In The French Health Insurance Databases: Application In Multiple Myeloma Patients","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":8,"year":2017,"errors":{}},"publication_name":"Clinical Therapeutics"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114360/Identifying_Potential_Drug_Drug_Interactions_In_The_French_Health_Insurance_Databases_Application_In_Multiple_Myeloma_Patients","translated_internal_url":"","created_at":"2024-07-16T22:20:02.137-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843216,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843216/thumbnails/1.jpg","file_name":"j.clinthera.2017.05.10320240717-1-dydwpy.pdf","download_url":"https://www.academia.edu/attachments/116843216/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Identifying_Potential_Drug_Drug_Interact.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843216/j.clinthera.2017.05.10320240717-1-dydwpy-libre.pdf?1721196831=\u0026response-content-disposition=attachment%3B+filename%3DIdentifying_Potential_Drug_Drug_Interact.pdf\u0026Expires=1732452503\u0026Signature=b9ICrJtGV7gebc3YzWtYOTpkR~0oM2ABneyApGRtLHdLWCwBHCRPXaG9ZlsDg7wriyCPXgkNJ6SqBEmnQaPTx7jwItgKRANt9Dsar1xVHBva~wnFy2X0vDEy9kbq0TAYxnRIrbK4HMyjAIaIKyrLW1qXVi6nEomhbHtwn7DOSMtSgCTAvMHsgMi-HinOGnBsGsaTvxQsZIOJZEBOi1UqtXQ0JLm7H6IGPcUmb12P1lCQwSRHb8hmht63BYtNsoDL5sPWdy-2-fGnBBux6TRG~OsryKp52OWpxRW4D1S2K1Bp0B7bG1gn7WCZYFNxh7D87HklPT2hSAlYhoYShNb7gg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Identifying_Potential_Drug_Drug_Interactions_In_The_French_Health_Insurance_Databases_Application_In_Multiple_Myeloma_Patients","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843216,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843216/thumbnails/1.jpg","file_name":"j.clinthera.2017.05.10320240717-1-dydwpy.pdf","download_url":"https://www.academia.edu/attachments/116843216/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Identifying_Potential_Drug_Drug_Interact.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843216/j.clinthera.2017.05.10320240717-1-dydwpy-libre.pdf?1721196831=\u0026response-content-disposition=attachment%3B+filename%3DIdentifying_Potential_Drug_Drug_Interact.pdf\u0026Expires=1732452503\u0026Signature=b9ICrJtGV7gebc3YzWtYOTpkR~0oM2ABneyApGRtLHdLWCwBHCRPXaG9ZlsDg7wriyCPXgkNJ6SqBEmnQaPTx7jwItgKRANt9Dsar1xVHBva~wnFy2X0vDEy9kbq0TAYxnRIrbK4HMyjAIaIKyrLW1qXVi6nEomhbHtwn7DOSMtSgCTAvMHsgMi-HinOGnBsGsaTvxQsZIOJZEBOi1UqtXQ0JLm7H6IGPcUmb12P1lCQwSRHb8hmht63BYtNsoDL5sPWdy-2-fGnBBux6TRG~OsryKp52OWpxRW4D1S2K1Bp0B7bG1gn7WCZYFNxh7D87HklPT2hSAlYhoYShNb7gg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":42135,"name":"Drug","url":"https://www.academia.edu/Documents/in/Drug"},{"id":111110,"name":"Multiple Myeloma","url":"https://www.academia.edu/Documents/in/Multiple_Myeloma"},{"id":2815854,"name":"Clinical Pharmacology and Therapeutics","url":"https://www.academia.edu/Documents/in/Clinical_Pharmacology_and_Therapeutics"},{"id":3789884,"name":"Pharmacology and pharmaceutical sciences","url":"https://www.academia.edu/Documents/in/Pharmacology_and_pharmaceutical_sciences"}],"urls":[{"id":43558003,"url":"http://www.clinicaltherapeutics.com/article/S0149291817304009/pdf"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114358"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114358/Infections_graves_et_non_graves_chez_les_patients_non_spl%C3%A9nectomis%C3%A9s_trait%C3%A9s_pour_une_thrombop%C3%A9nie_immunologique_persistante_ou_chronique_r%C3%B4les_des_traitements_et_effet_des_vaccins_antipneumococcique_et_antigrippal_%C3%89tude_dans_la_cohorte_FAITH"><img alt="Research paper thumbnail of Infections graves et non graves chez les patients non splénectomisés traités pour une thrombopénie immunologique persistante ou chronique : rôles des traitements et effet des vaccins antipneumococcique et antigrippal. Étude dans la cohorte FAITH" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114358/Infections_graves_et_non_graves_chez_les_patients_non_spl%C3%A9nectomis%C3%A9s_trait%C3%A9s_pour_une_thrombop%C3%A9nie_immunologique_persistante_ou_chronique_r%C3%B4les_des_traitements_et_effet_des_vaccins_antipneumococcique_et_antigrippal_%C3%89tude_dans_la_cohorte_FAITH">Infections graves et non graves chez les patients non splénectomisés traités pour une thrombopénie immunologique persistante ou chronique : rôles des traitements et effet des vaccins antipneumococcique et antigrippal. Étude dans la cohorte FAITH</a></div><div class="wp-workCard_item"><span>Revue de Médecine Interne</span><span>, Dec 1, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Introduction Les facteurs de risque d’infection chez les patients atteints de thrombopenie immuno...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Introduction Les facteurs de risque d’infection chez les patients atteints de thrombopenie immunologique (TI) depuis l’ere du rituximab sont mal connus, tout comme l’effet reel des vaccins antipneumococcique et antigrippal. L’objectif de cette etude etait d’evaluer les facteurs de risque d’infections graves (necessitant une hospitalisation) et non graves chez les patients adultes non splenectomises traites pour une TI persistante ou chronique (durant plus de 3 mois) et l’eventuel effet protecteur des vaccins antipneumococcique et antigrippal en vie reelle. Patients et methodes La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Resultats La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Conclusion Les infections graves sont essentiellement pulmonaires dans la TI. Une maladie pulmonaire chronique, l’exposition aux corticoides et au rituximab etaient les principaux facteurs de risque d’infection graves et non graves, alors que les vaccinations antipneumococcique et antigrippale etaient protectrices.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114358"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114358"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114358; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114358]").text(description); $(".js-view-count[data-work-id=122114358]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114358; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114358']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114358, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114358]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114358,"title":"Infections graves et non graves chez les patients non splénectomisés traités pour une thrombopénie immunologique persistante ou chronique : rôles des traitements et effet des vaccins antipneumococcique et antigrippal. Étude dans la cohorte FAITH","translated_title":"","metadata":{"abstract":"Introduction Les facteurs de risque d’infection chez les patients atteints de thrombopenie immunologique (TI) depuis l’ere du rituximab sont mal connus, tout comme l’effet reel des vaccins antipneumococcique et antigrippal. L’objectif de cette etude etait d’evaluer les facteurs de risque d’infections graves (necessitant une hospitalisation) et non graves chez les patients adultes non splenectomises traites pour une TI persistante ou chronique (durant plus de 3 mois) et l’eventuel effet protecteur des vaccins antipneumococcique et antigrippal en vie reelle. Patients et methodes La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Resultats La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Conclusion Les infections graves sont essentiellement pulmonaires dans la TI. Une maladie pulmonaire chronique, l’exposition aux corticoides et au rituximab etaient les principaux facteurs de risque d’infection graves et non graves, alors que les vaccinations antipneumococcique et antigrippale etaient protectrices.","publisher":"Elsevier BV","publication_date":{"day":1,"month":12,"year":2015,"errors":{}},"publication_name":"Revue de Médecine Interne"},"translated_abstract":"Introduction Les facteurs de risque d’infection chez les patients atteints de thrombopenie immunologique (TI) depuis l’ere du rituximab sont mal connus, tout comme l’effet reel des vaccins antipneumococcique et antigrippal. L’objectif de cette etude etait d’evaluer les facteurs de risque d’infections graves (necessitant une hospitalisation) et non graves chez les patients adultes non splenectomises traites pour une TI persistante ou chronique (durant plus de 3 mois) et l’eventuel effet protecteur des vaccins antipneumococcique et antigrippal en vie reelle. Patients et methodes La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Resultats La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Conclusion Les infections graves sont essentiellement pulmonaires dans la TI. Une maladie pulmonaire chronique, l’exposition aux corticoides et au rituximab etaient les principaux facteurs de risque d’infection graves et non graves, alors que les vaccinations antipneumococcique et antigrippale etaient protectrices.","internal_url":"https://www.academia.edu/122114358/Infections_graves_et_non_graves_chez_les_patients_non_spl%C3%A9nectomis%C3%A9s_trait%C3%A9s_pour_une_thrombop%C3%A9nie_immunologique_persistante_ou_chronique_r%C3%B4les_des_traitements_et_effet_des_vaccins_antipneumococcique_et_antigrippal_%C3%89tude_dans_la_cohorte_FAITH","translated_internal_url":"","created_at":"2024-07-16T22:20:01.434-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Infections_graves_et_non_graves_chez_les_patients_non_splénectomisés_traités_pour_une_thrombopénie_immunologique_persistante_ou_chronique_rôles_des_traitements_et_effet_des_vaccins_antipneumococcique_et_antigrippal_Étude_dans_la_cohorte_FAITH","translated_slug":"","page_count":null,"language":"fr","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":339107,"name":"Gynecology","url":"https://www.academia.edu/Documents/in/Gynecology"}],"urls":[{"id":43558002,"url":"https://doi.org/10.1016/j.revmed.2015.10.296"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114357"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114357/Analgesic_Drug_Prescription_After_Carpal_Tunnel_Surgery"><img alt="Research paper thumbnail of Analgesic Drug Prescription After Carpal Tunnel Surgery" class="work-thumbnail" src="https://attachments.academia-assets.com/116843220/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114357/Analgesic_Drug_Prescription_After_Carpal_Tunnel_Surgery">Analgesic Drug Prescription After Carpal Tunnel Surgery</a></div><div class="wp-workCard_item"><span>Regional Anesthesia and Pain Medicine</span><span>, 2018</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="7fce454dba613194e55c6eb592cfdb7b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843220,"asset_id":122114357,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843220/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114357"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114357"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114357; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114357]").text(description); $(".js-view-count[data-work-id=122114357]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114357; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114357']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114357, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "7fce454dba613194e55c6eb592cfdb7b" } } $('.js-work-strip[data-work-id=122114357]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114357,"title":"Analgesic Drug Prescription After Carpal Tunnel Surgery","translated_title":"","metadata":{"publisher":"Lippincott Williams \u0026 Wilkins","publication_date":{"day":null,"month":null,"year":2018,"errors":{}},"publication_name":"Regional Anesthesia and Pain Medicine"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114357/Analgesic_Drug_Prescription_After_Carpal_Tunnel_Surgery","translated_internal_url":"","created_at":"2024-07-16T22:20:00.949-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843220,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843220/thumbnails/1.jpg","file_name":"AAP.000000000000068520240717-1-8h9i04.pdf","download_url":"https://www.academia.edu/attachments/116843220/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Analgesic_Drug_Prescription_After_Carpal.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843220/AAP.000000000000068520240717-1-8h9i04-libre.pdf?1721196833=\u0026response-content-disposition=attachment%3B+filename%3DAnalgesic_Drug_Prescription_After_Carpal.pdf\u0026Expires=1732431771\u0026Signature=T6w00tStV-uX~V4sQoLItvuLaMD1o73QGX3TbK1lVKaY384hJJVTUuICif4puP7gOFNfzF5Ebxo0w0iEmLt6XoxhtmE7Q2g1bLedUeywPJw8HWITP7zOUOjwWRuEge05RWSbuSlaxsipEltezUwIiXWp6QYJJHECAx7bvLXwVSUXaF04Mg8hZ5gDoVgtZz3HTwR~CihAJZYL7DAcnmaABTdha6EOFKwO5eo45rJeOweZfVeod0RODxM~rEgJZi9KsTAPsLbuKHzA7zkXvLJerBYjudB0zigjX0PK32P5o-PRBw~9rc25IWhOa0zosIQg1KK0ex7wsonpLQE4dZiSWw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Analgesic_Drug_Prescription_After_Carpal_Tunnel_Surgery","translated_slug":"","page_count":6,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843220,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843220/thumbnails/1.jpg","file_name":"AAP.000000000000068520240717-1-8h9i04.pdf","download_url":"https://www.academia.edu/attachments/116843220/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Analgesic_Drug_Prescription_After_Carpal.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843220/AAP.000000000000068520240717-1-8h9i04-libre.pdf?1721196833=\u0026response-content-disposition=attachment%3B+filename%3DAnalgesic_Drug_Prescription_After_Carpal.pdf\u0026Expires=1732431771\u0026Signature=T6w00tStV-uX~V4sQoLItvuLaMD1o73QGX3TbK1lVKaY384hJJVTUuICif4puP7gOFNfzF5Ebxo0w0iEmLt6XoxhtmE7Q2g1bLedUeywPJw8HWITP7zOUOjwWRuEge05RWSbuSlaxsipEltezUwIiXWp6QYJJHECAx7bvLXwVSUXaF04Mg8hZ5gDoVgtZz3HTwR~CihAJZYL7DAcnmaABTdha6EOFKwO5eo45rJeOweZfVeod0RODxM~rEgJZi9KsTAPsLbuKHzA7zkXvLJerBYjudB0zigjX0PK32P5o-PRBw~9rc25IWhOa0zosIQg1KK0ex7wsonpLQE4dZiSWw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":27336,"name":"France","url":"https://www.academia.edu/Documents/in/France"},{"id":41482,"name":"Multivariate Analysis","url":"https://www.academia.edu/Documents/in/Multivariate_Analysis"},{"id":64568,"name":"Humans","url":"https://www.academia.edu/Documents/in/Humans"},{"id":83200,"name":"Neuropathic pain","url":"https://www.academia.edu/Documents/in/Neuropathic_pain"},{"id":98925,"name":"Female","url":"https://www.academia.edu/Documents/in/Female"},{"id":111545,"name":"Male","url":"https://www.academia.edu/Documents/in/Male"},{"id":129739,"name":"Anesthesia","url":"https://www.academia.edu/Documents/in/Anesthesia"},{"id":220450,"name":"Carpal Tunnel Syndrome","url":"https://www.academia.edu/Documents/in/Carpal_Tunnel_Syndrome"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":295155,"name":"Middle Aged","url":"https://www.academia.edu/Documents/in/Middle_Aged"},{"id":382075,"name":"Adult","url":"https://www.academia.edu/Documents/in/Adult"},{"id":437772,"name":"Odds ratio","url":"https://www.academia.edu/Documents/in/Odds_ratio"},{"id":584601,"name":"Chi Square Distribution","url":"https://www.academia.edu/Documents/in/Chi_Square_Distribution"},{"id":820245,"name":"Analgesic","url":"https://www.academia.edu/Documents/in/Analgesic"},{"id":1294607,"name":"Logistic Models","url":"https://www.academia.edu/Documents/in/Logistic_Models"},{"id":3809682,"name":"Drug utilization review","url":"https://www.academia.edu/Documents/in/Drug_utilization_review"},{"id":4053561,"name":"Drug prescriptions","url":"https://www.academia.edu/Documents/in/Drug_prescriptions"},{"id":4136525,"name":"Medical prescription","url":"https://www.academia.edu/Documents/in/Medical_prescription"}],"urls":[{"id":43558001,"url":"https://doi.org/10.1097/aap.0000000000000685"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114356"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114356/Cancer_Risk_of_Anti_TNF_%CE%B1_at_Recommended_Doses_in_Adult_Rheumatoid_Arthritis_A_Meta_Analysis_with_Intention_to_Treat_and_per_Protocol_Analyses"><img alt="Research paper thumbnail of Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses" class="work-thumbnail" src="https://attachments.academia-assets.com/116843176/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114356/Cancer_Risk_of_Anti_TNF_%CE%B1_at_Recommended_Doses_in_Adult_Rheumatoid_Arthritis_A_Meta_Analysis_with_Intention_to_Treat_and_per_Protocol_Analyses">Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses</a></div><div class="wp-workCard_item"><span>PLOS ONE</span><span>, Nov 14, 2012</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="993878b028b2539d06a7de71f0ddcf61" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843176,"asset_id":122114356,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843176/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114356"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114356"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114356; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114356]").text(description); $(".js-view-count[data-work-id=122114356]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114356; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114356']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114356, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "993878b028b2539d06a7de71f0ddcf61" } } $('.js-work-strip[data-work-id=122114356]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114356,"title":"Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses","translated_title":"","metadata":{"publisher":"Public Library of Science","publication_date":{"day":14,"month":11,"year":2012,"errors":{}},"publication_name":"PLOS ONE"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114356/Cancer_Risk_of_Anti_TNF_%CE%B1_at_Recommended_Doses_in_Adult_Rheumatoid_Arthritis_A_Meta_Analysis_with_Intention_to_Treat_and_per_Protocol_Analyses","translated_internal_url":"","created_at":"2024-07-16T22:20:00.663-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843176,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843176/thumbnails/1.jpg","file_name":"file.pdf","download_url":"https://www.academia.edu/attachments/116843176/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Cancer_Risk_of_Anti_TNF__at_Recommended.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843176/file-libre.pdf?1721196845=\u0026response-content-disposition=attachment%3B+filename%3DCancer_Risk_of_Anti_TNF__at_Recommended.pdf\u0026Expires=1732431771\u0026Signature=S0bKfBv4ytcnIRFVi7IEp3~IJPoYCoyb8HCnxkgNfb8oI0SuBvryaKiwxcQF57eNUz2q~O~aMEL1NzKINTW8YCptrpEZDnK4phj4dc4rK6ExMvD6vmyVr~RBeKam2sZMQql8zZZSgSOeIvETejVoubRaaqse3QHngHDDcaTxIfv1EvTaV3gmR5nECVLJKg5SHepIaI-MxsOVrcCdzkyrr84AzhjoitOQHcU054z5ZT8j83eytmNoEdSlAltXB8TeQy2D9uOO3FhyrQCiTE2r~dkLTBmYzVx54r8oOIwWpsfr1Hab3OtWdUazhBQqhGSfMXsPYIuPk2ij74uGD~00tw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Cancer_Risk_of_Anti_TNF_α_at_Recommended_Doses_in_Adult_Rheumatoid_Arthritis_A_Meta_Analysis_with_Intention_to_Treat_and_per_Protocol_Analyses","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843176,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843176/thumbnails/1.jpg","file_name":"file.pdf","download_url":"https://www.academia.edu/attachments/116843176/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Cancer_Risk_of_Anti_TNF__at_Recommended.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843176/file-libre.pdf?1721196845=\u0026response-content-disposition=attachment%3B+filename%3DCancer_Risk_of_Anti_TNF__at_Recommended.pdf\u0026Expires=1732431771\u0026Signature=S0bKfBv4ytcnIRFVi7IEp3~IJPoYCoyb8HCnxkgNfb8oI0SuBvryaKiwxcQF57eNUz2q~O~aMEL1NzKINTW8YCptrpEZDnK4phj4dc4rK6ExMvD6vmyVr~RBeKam2sZMQql8zZZSgSOeIvETejVoubRaaqse3QHngHDDcaTxIfv1EvTaV3gmR5nECVLJKg5SHepIaI-MxsOVrcCdzkyrr84AzhjoitOQHcU054z5ZT8j83eytmNoEdSlAltXB8TeQy2D9uOO3FhyrQCiTE2r~dkLTBmYzVx54r8oOIwWpsfr1Hab3OtWdUazhBQqhGSfMXsPYIuPk2ij74uGD~00tw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"},{"id":116843175,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843175/thumbnails/1.jpg","file_name":"file.pdf","download_url":"https://www.academia.edu/attachments/116843175/download_file","bulk_download_file_name":"Cancer_Risk_of_Anti_TNF__at_Recommended.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843175/file-libre.pdf?1721196847=\u0026response-content-disposition=attachment%3B+filename%3DCancer_Risk_of_Anti_TNF__at_Recommended.pdf\u0026Expires=1732431771\u0026Signature=JuXjka9B4WtYW~jVR5Vv0psBq22EHBMqc2k4G8nnZ2ijWzNQ6fz64DOnCxkHNfDvJuRp6uPRvD6aZxWimInPToTf6AsJ7~EI7fiHN3RTAzngn1tnJCORgKaDNEvrJnD-hvn-kWy25UvZy7fgYxinvtQEVo0Df8OEe80R~V66KcXba0KXggV7z2eFWKWX9uzvuss2MYOyt44lrqZrIYZH8GHWSItW-jkhAWStUjKbZ2Bnq0OemPSHNhxMESoDb7teRfCMvEhs9Xx0rmFHvk4TcdI6cgndICv5qqXI7PCSIqH1SW80247YniAiz0FM5a9fEmkiAizo4DxgD0WJEV2ZXw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":140,"name":"Pharmacology","url":"https://www.academia.edu/Documents/in/Pharmacology"},{"id":5398,"name":"Biotechnology","url":"https://www.academia.edu/Documents/in/Biotechnology"},{"id":6021,"name":"Cancer","url":"https://www.academia.edu/Documents/in/Cancer"},{"id":8207,"name":"Risk","url":"https://www.academia.edu/Documents/in/Risk"},{"id":9846,"name":"Ecology","url":"https://www.academia.edu/Documents/in/Ecology"},{"id":12733,"name":"Rheumatoid Arthritis","url":"https://www.academia.edu/Documents/in/Rheumatoid_Arthritis"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":28235,"name":"Multidisciplinary","url":"https://www.academia.edu/Documents/in/Multidisciplinary"},{"id":64568,"name":"Humans","url":"https://www.academia.edu/Documents/in/Humans"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":218206,"name":"Meta Analysis","url":"https://www.academia.edu/Documents/in/Meta_Analysis"},{"id":220780,"name":"PLoS one","url":"https://www.academia.edu/Documents/in/PLoS_one"},{"id":469018,"name":"Neoplasms","url":"https://www.academia.edu/Documents/in/Neoplasms"},{"id":969687,"name":"Rheumatoid","url":"https://www.academia.edu/Documents/in/Rheumatoid"},{"id":1009476,"name":"Analyses","url":"https://www.academia.edu/Documents/in/Analyses"},{"id":1946240,"name":"Adalimumab","url":"https://www.academia.edu/Documents/in/Adalimumab"},{"id":2189033,"name":"Etanercept","url":"https://www.academia.edu/Documents/in/Etanercept"},{"id":2844327,"name":"Infliximab","url":"https://www.academia.edu/Documents/in/Infliximab"},{"id":2956448,"name":"Doses","url":"https://www.academia.edu/Documents/in/Doses"},{"id":3495461,"name":"recommended","url":"https://www.academia.edu/Documents/in/recommended"}],"urls":[{"id":43558000,"url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0048991\u0026type=printable"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114355"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114355/Potential_inappropriate_use_of_strong_opioid_analgesics_in_cancer_outpatients_during_the_last_year_of_life_in_France_and_associated_factors"><img alt="Research paper thumbnail of Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors" class="work-thumbnail" src="https://attachments.academia-assets.com/116843215/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114355/Potential_inappropriate_use_of_strong_opioid_analgesics_in_cancer_outpatients_during_the_last_year_of_life_in_France_and_associated_factors">Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors</a></div><div class="wp-workCard_item"><span>British Journal of Clinical Pharmacology</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="2a83ca148a57d43a50aa44c8bee5a892" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843215,"asset_id":122114355,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843215/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114355"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114355"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114355; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114355]").text(description); $(".js-view-count[data-work-id=122114355]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114355; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114355']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114355, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "2a83ca148a57d43a50aa44c8bee5a892" } } $('.js-work-strip[data-work-id=122114355]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114355,"title":"Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors","translated_title":"","metadata":{"publisher":"Wiley","publication_name":"British Journal of Clinical Pharmacology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114355/Potential_inappropriate_use_of_strong_opioid_analgesics_in_cancer_outpatients_during_the_last_year_of_life_in_France_and_associated_factors","translated_internal_url":"","created_at":"2024-07-16T22:20:00.057-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843215,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843215/thumbnails/1.jpg","file_name":"au.162256051.pdf","download_url":"https://www.academia.edu/attachments/116843215/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Potential_inappropriate_use_of_strong_op.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843215/au.162256051-libre.pdf?1721196831=\u0026response-content-disposition=attachment%3B+filename%3DPotential_inappropriate_use_of_strong_op.pdf\u0026Expires=1732431771\u0026Signature=Z5U7fROaC7koE1Kzt2NGzJUm3vCZErAOSS8PZ004oceCRmJP7j~d9Bs2yGl0yr2j2fhWkM6wC~axufJiI~4EPtQeh9IfOFu-BTdo3x7PF-1nAwt4KFQcMezNCLItigZPaStlxZJviU3VKvPwtS9SRjO0lpnMYAjQChh9a7E4H3gGUFYovjrW7Cn-hyWqTTKXSCnYOwiD~wXRWkUbN3J0UVLD1C6ybIwbvr~9BA4YYXnH7ytM46ylv15OokgXvKKVFGJOcPurjE~DBwyIuJVRQidJWM-w5QpyX-bqGTx1N4PwnN-~LrMpI3mPk84y6P-y1iwMVce81LokcpAMg9uZ6w__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Potential_inappropriate_use_of_strong_opioid_analgesics_in_cancer_outpatients_during_the_last_year_of_life_in_France_and_associated_factors","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843215,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843215/thumbnails/1.jpg","file_name":"au.162256051.pdf","download_url":"https://www.academia.edu/attachments/116843215/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Potential_inappropriate_use_of_strong_op.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843215/au.162256051-libre.pdf?1721196831=\u0026response-content-disposition=attachment%3B+filename%3DPotential_inappropriate_use_of_strong_op.pdf\u0026Expires=1732431771\u0026Signature=Z5U7fROaC7koE1Kzt2NGzJUm3vCZErAOSS8PZ004oceCRmJP7j~d9Bs2yGl0yr2j2fhWkM6wC~axufJiI~4EPtQeh9IfOFu-BTdo3x7PF-1nAwt4KFQcMezNCLItigZPaStlxZJviU3VKvPwtS9SRjO0lpnMYAjQChh9a7E4H3gGUFYovjrW7Cn-hyWqTTKXSCnYOwiD~wXRWkUbN3J0UVLD1C6ybIwbvr~9BA4YYXnH7ytM46ylv15OokgXvKKVFGJOcPurjE~DBwyIuJVRQidJWM-w5QpyX-bqGTx1N4PwnN-~LrMpI3mPk84y6P-y1iwMVce81LokcpAMg9uZ6w__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":72845,"name":"Cancer pain","url":"https://www.academia.edu/Documents/in/Cancer_pain"},{"id":437772,"name":"Odds ratio","url":"https://www.academia.edu/Documents/in/Odds_ratio"},{"id":711582,"name":"Opioid","url":"https://www.academia.edu/Documents/in/Opioid"},{"id":820245,"name":"Analgesic","url":"https://www.academia.edu/Documents/in/Analgesic"},{"id":1223924,"name":"Fentanyl","url":"https://www.academia.edu/Documents/in/Fentanyl"},{"id":1587858,"name":"Confidence Interval","url":"https://www.academia.edu/Documents/in/Confidence_Interval"},{"id":1619700,"name":"Hydrocodone","url":"https://www.academia.edu/Documents/in/Hydrocodone"},{"id":3789884,"name":"Pharmacology and pharmaceutical sciences","url":"https://www.academia.edu/Documents/in/Pharmacology_and_pharmaceutical_sciences"},{"id":4136525,"name":"Medical prescription","url":"https://www.academia.edu/Documents/in/Medical_prescription"}],"urls":[{"id":43557999,"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15011"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114354"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114354/Cardiovascular_risk_factors_in_immune_thrombocytopenia_adults_Results_from_the_CARMEN_registry"><img alt="Research paper thumbnail of Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry" class="work-thumbnail" src="https://attachments.academia-assets.com/116843214/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114354/Cardiovascular_risk_factors_in_immune_thrombocytopenia_adults_Results_from_the_CARMEN_registry">Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry</a></div><div class="wp-workCard_item"><span>American Journal of Hematology</span><span>, 2018</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="4f9ee73ba0ccd4b09142d9c7fee8a50b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843214,"asset_id":122114354,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843214/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114354"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114354"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114354; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114354]").text(description); $(".js-view-count[data-work-id=122114354]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114354; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114354']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114354, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "4f9ee73ba0ccd4b09142d9c7fee8a50b" } } $('.js-work-strip[data-work-id=122114354]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114354,"title":"Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry","translated_title":"","metadata":{"publisher":"Wiley","publication_date":{"day":null,"month":null,"year":2018,"errors":{}},"publication_name":"American Journal of Hematology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114354/Cardiovascular_risk_factors_in_immune_thrombocytopenia_adults_Results_from_the_CARMEN_registry","translated_internal_url":"","created_at":"2024-07-16T22:19:59.479-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843214,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843214/thumbnails/1.jpg","file_name":"ajh.pdf","download_url":"https://www.academia.edu/attachments/116843214/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Cardiovascular_risk_factors_in_immune_th.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843214/ajh-libre.pdf?1721196849=\u0026response-content-disposition=attachment%3B+filename%3DCardiovascular_risk_factors_in_immune_th.pdf\u0026Expires=1732431771\u0026Signature=QlJwMVZWxxbfWrSINrodVx7j4lUdzaz4ZUvyEyokYC1hSMk21ufu4zYluDbI8eBcqo25Cg7GHK-WLx1tIvW1jOW4nSVthF-nnGpK4p~6RiTDCHyBnJ2~7kVhJg69thETeNAeKd5crt9MtdqQ2zQy6eeZopREFJbhiNJ4wSzJFL7xvWacEhFiR3PLLyaHb9AGOQYfKCDssWIeaReE~Y-bteTTE7EWGVZGesN7bqLa0UEot6AQ2yt9ex8kZW22SLIln~f7RfOlxxKqlSi6sUu4ozsTTiTB1vIty2JkmMBKU-D2RQvo6czYf6lszfCdfirGCGlCzqS9KGkcjV33NvjtXg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Cardiovascular_risk_factors_in_immune_thrombocytopenia_adults_Results_from_the_CARMEN_registry","translated_slug":"","page_count":26,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843214,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843214/thumbnails/1.jpg","file_name":"ajh.pdf","download_url":"https://www.academia.edu/attachments/116843214/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Cardiovascular_risk_factors_in_immune_th.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843214/ajh-libre.pdf?1721196849=\u0026response-content-disposition=attachment%3B+filename%3DCardiovascular_risk_factors_in_immune_th.pdf\u0026Expires=1732431771\u0026Signature=QlJwMVZWxxbfWrSINrodVx7j4lUdzaz4ZUvyEyokYC1hSMk21ufu4zYluDbI8eBcqo25Cg7GHK-WLx1tIvW1jOW4nSVthF-nnGpK4p~6RiTDCHyBnJ2~7kVhJg69thETeNAeKd5crt9MtdqQ2zQy6eeZopREFJbhiNJ4wSzJFL7xvWacEhFiR3PLLyaHb9AGOQYfKCDssWIeaReE~Y-bteTTE7EWGVZGesN7bqLa0UEot6AQ2yt9ex8kZW22SLIln~f7RfOlxxKqlSi6sUu4ozsTTiTB1vIty2JkmMBKU-D2RQvo6czYf6lszfCdfirGCGlCzqS9KGkcjV33NvjtXg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":2374856,"name":"Immune thrombocytopenia","url":"https://www.academia.edu/Documents/in/Immune_thrombocytopenia"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":43557998,"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25127"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114353"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114353/Correspondence_on_Risk_of_systemic_lupus_erythematosus_after_immune_thrombocytopenia_and_autoimmune_haemolytic_anaemia_a_nationwide_French_study_"><img alt="Research paper thumbnail of Correspondence on ‘Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study’" class="work-thumbnail" src="https://attachments.academia-assets.com/116843213/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114353/Correspondence_on_Risk_of_systemic_lupus_erythematosus_after_immune_thrombocytopenia_and_autoimmune_haemolytic_anaemia_a_nationwide_French_study_">Correspondence on ‘Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study’</a></div><div class="wp-workCard_item"><span>Annals of the Rheumatic Diseases</span><span>, 2020</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="362af78143375fe7cdd82d74f36d4bca" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843213,"asset_id":122114353,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843213/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114353"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114353"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114353; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114353]").text(description); $(".js-view-count[data-work-id=122114353]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114353; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114353']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114353, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "362af78143375fe7cdd82d74f36d4bca" } } $('.js-work-strip[data-work-id=122114353]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114353,"title":"Correspondence on ‘Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study’","translated_title":"","metadata":{"publisher":"BMJ","publication_date":{"day":null,"month":null,"year":2020,"errors":{}},"publication_name":"Annals of the Rheumatic Diseases"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114353/Correspondence_on_Risk_of_systemic_lupus_erythematosus_after_immune_thrombocytopenia_and_autoimmune_haemolytic_anaemia_a_nationwide_French_study_","translated_internal_url":"","created_at":"2024-07-16T22:19:58.982-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843213,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843213/thumbnails/1.jpg","file_name":"annrheumdis-2020-219470.full.pdf","download_url":"https://www.academia.edu/attachments/116843213/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Correspondence_on_Risk_of_systemic_lupus.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843213/annrheumdis-2020-219470.full-libre.pdf?1721196834=\u0026response-content-disposition=attachment%3B+filename%3DCorrespondence_on_Risk_of_systemic_lupus.pdf\u0026Expires=1732431771\u0026Signature=EoIedLbixZwWtcYT7Da83REXdz96wBqLq9MzZsEY80e181c3n5yY2eqtcN5fIE5aD2IKhpnfQtclAIoiJtOzwsQwQ0MpVaq2NnrlvpJiHK5Jr0og7cDhiO8ODl0f5ECXDsUPbTPyKvVkw95SD-ZZlxqTc~01dRwqlulzHhLnhMoCTowxZFvdoKWlKsvOI7wNUYlKRdM0X2vdRlY0JToHEgBfA8swJ3~IwVxtfFA8H3r8HY-Cx~r~CG8MkV1f~Yj2Ji5aDlBYk5PFcpAY8OX03i0Ybs69uS9hFcNCE4JZYEuinpBykj3scBS0lBiA-903hopljNLBu~CwTPi6XLRGZA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Correspondence_on_Risk_of_systemic_lupus_erythematosus_after_immune_thrombocytopenia_and_autoimmune_haemolytic_anaemia_a_nationwide_French_study_","translated_slug":"","page_count":2,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843213,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843213/thumbnails/1.jpg","file_name":"annrheumdis-2020-219470.full.pdf","download_url":"https://www.academia.edu/attachments/116843213/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Correspondence_on_Risk_of_systemic_lupus.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843213/annrheumdis-2020-219470.full-libre.pdf?1721196834=\u0026response-content-disposition=attachment%3B+filename%3DCorrespondence_on_Risk_of_systemic_lupus.pdf\u0026Expires=1732431771\u0026Signature=EoIedLbixZwWtcYT7Da83REXdz96wBqLq9MzZsEY80e181c3n5yY2eqtcN5fIE5aD2IKhpnfQtclAIoiJtOzwsQwQ0MpVaq2NnrlvpJiHK5Jr0og7cDhiO8ODl0f5ECXDsUPbTPyKvVkw95SD-ZZlxqTc~01dRwqlulzHhLnhMoCTowxZFvdoKWlKsvOI7wNUYlKRdM0X2vdRlY0JToHEgBfA8swJ3~IwVxtfFA8H3r8HY-Cx~r~CG8MkV1f~Yj2Ji5aDlBYk5PFcpAY8OX03i0Ybs69uS9hFcNCE4JZYEuinpBykj3scBS0lBiA-903hopljNLBu~CwTPi6XLRGZA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":1290,"name":"Immunology","url":"https://www.academia.edu/Documents/in/Immunology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":64336,"name":"Population","url":"https://www.academia.edu/Documents/in/Population"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":410370,"name":"Public health systems and services research","url":"https://www.academia.edu/Documents/in/Public_health_systems_and_services_research-1"},{"id":2374856,"name":"Immune thrombocytopenia","url":"https://www.academia.edu/Documents/in/Immune_thrombocytopenia"}],"urls":[{"id":43557997,"url":"https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-219470"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114352"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114352/Eltrombopag_in_adult_patients_with_immune_thrombocytopenia_in_the_real_world_in_France_including_off_label_use_before_6_months_of_disease_duration_The_multicenter_prospective_ELEXTRA_study"><img alt="Research paper thumbnail of Eltrombopag in adult patients with immune thrombocytopenia in the real‐world in France, including off‐label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114352/Eltrombopag_in_adult_patients_with_immune_thrombocytopenia_in_the_real_world_in_France_including_off_label_use_before_6_months_of_disease_duration_The_multicenter_prospective_ELEXTRA_study">Eltrombopag in adult patients with immune thrombocytopenia in the real‐world in France, including off‐label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study</a></div><div class="wp-workCard_item"><span>American Journal of Hematology</span><span>, 2021</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">kocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">kocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019; 3(11):1729-1737. 6. Shahneh F, Grill A, Klein M, et al. Specialized regulatory T cells control venous blood clot resolution through SPARC. Blood. 2021;137(11): 1517-1526. 7. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One. 2012;7(9):e45427. 8. Gadomska G, Stankowska K, Boinska J, Bartoszewska-Kubiak A, Haus O, Ro s c D. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Blood Coagul Fibrinolysis. 2016;27(7): 817-821. 9. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thrombosis Haemostasis. 2006;4(12):2593-2598.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114352"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114352"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114352; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114352]").text(description); $(".js-view-count[data-work-id=122114352]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114352; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114352']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114352, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114352]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114352,"title":"Eltrombopag in adult patients with immune thrombocytopenia in the real‐world in France, including off‐label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study","translated_title":"","metadata":{"abstract":"kocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019; 3(11):1729-1737. 6. Shahneh F, Grill A, Klein M, et al. Specialized regulatory T cells control venous blood clot resolution through SPARC. Blood. 2021;137(11): 1517-1526. 7. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One. 2012;7(9):e45427. 8. Gadomska G, Stankowska K, Boinska J, Bartoszewska-Kubiak A, Haus O, Ro s c D. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Blood Coagul Fibrinolysis. 2016;27(7): 817-821. 9. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thrombosis Haemostasis. 2006;4(12):2593-2598.","publisher":"Wiley","publication_date":{"day":null,"month":null,"year":2021,"errors":{}},"publication_name":"American Journal of Hematology"},"translated_abstract":"kocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019; 3(11):1729-1737. 6. Shahneh F, Grill A, Klein M, et al. Specialized regulatory T cells control venous blood clot resolution through SPARC. Blood. 2021;137(11): 1517-1526. 7. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One. 2012;7(9):e45427. 8. Gadomska G, Stankowska K, Boinska J, Bartoszewska-Kubiak A, Haus O, Ro s c D. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Blood Coagul Fibrinolysis. 2016;27(7): 817-821. 9. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thrombosis Haemostasis. 2006;4(12):2593-2598.","internal_url":"https://www.academia.edu/122114352/Eltrombopag_in_adult_patients_with_immune_thrombocytopenia_in_the_real_world_in_France_including_off_label_use_before_6_months_of_disease_duration_The_multicenter_prospective_ELEXTRA_study","translated_internal_url":"","created_at":"2024-07-16T22:19:58.456-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Eltrombopag_in_adult_patients_with_immune_thrombocytopenia_in_the_real_world_in_France_including_off_label_use_before_6_months_of_disease_duration_The_multicenter_prospective_ELEXTRA_study","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":99773,"name":"Disease","url":"https://www.academia.edu/Documents/in/Disease"},{"id":1423064,"name":"Multicenter Study","url":"https://www.academia.edu/Documents/in/Multicenter_Study"},{"id":2374856,"name":"Immune thrombocytopenia","url":"https://www.academia.edu/Documents/in/Immune_thrombocytopenia"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":43557996,"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26404"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114351"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114351/Vaccination_during_the_First_Diagnosis_of_Multiple_Myeloma_A_Cohort_Study_of_the_French_National_Health_Insurance_Database"><img alt="Research paper thumbnail of Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database" class="work-thumbnail" src="https://attachments.academia-assets.com/116843172/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114351/Vaccination_during_the_First_Diagnosis_of_Multiple_Myeloma_A_Cohort_Study_of_the_French_National_Health_Insurance_Database">Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database</a></div><div class="wp-workCard_item"><span>Vaccines</span><span>, 2020</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Purpose: Infections are frequent and often result in serious complications in patients with multi...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Purpose: Infections are frequent and often result in serious complications in patients with multiple myeloma (MM). Prophylactic vaccination is recommended for influenza virus, Streptococcus pneumoniae (SP), and Hemophilus influenzaeb (Hib). The aims of this study were to measure the vaccination rates within 24 months after the diagnosis of multiple myeloma and to identify factors associated with vaccine use. Methods: MM patients were selected through the French national health insurance database from 1 January 2010 to 31 December 2015. Patients with a previous history of MM were excluded. Results: Vaccination rates against influenza, SP, and Hib among 22,831 newly diagnosed MM patients were, respectively, 28.5%, 10.3%, and 1.4%. Only 0.7% received all three vaccines. Factors associated with vaccination were young age, male gender, an absence of comorbidity, a history of higher medication and vaccine consumption, Herpes simplex virus (HSV), Varicella zoster virus (VZV), and the use o...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="e6cfe67cf48d3f2616170fd44a209ef8" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843172,"asset_id":122114351,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843172/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114351"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114351"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114351; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114351]").text(description); $(".js-view-count[data-work-id=122114351]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114351; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114351']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114351, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "e6cfe67cf48d3f2616170fd44a209ef8" } } $('.js-work-strip[data-work-id=122114351]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114351,"title":"Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database","translated_title":"","metadata":{"abstract":"Purpose: Infections are frequent and often result in serious complications in patients with multiple myeloma (MM). Prophylactic vaccination is recommended for influenza virus, Streptococcus pneumoniae (SP), and Hemophilus influenzaeb (Hib). The aims of this study were to measure the vaccination rates within 24 months after the diagnosis of multiple myeloma and to identify factors associated with vaccine use. Methods: MM patients were selected through the French national health insurance database from 1 January 2010 to 31 December 2015. Patients with a previous history of MM were excluded. Results: Vaccination rates against influenza, SP, and Hib among 22,831 newly diagnosed MM patients were, respectively, 28.5%, 10.3%, and 1.4%. Only 0.7% received all three vaccines. Factors associated with vaccination were young age, male gender, an absence of comorbidity, a history of higher medication and vaccine consumption, Herpes simplex virus (HSV), Varicella zoster virus (VZV), and the use o...","publisher":"MDPI AG","publication_date":{"day":null,"month":null,"year":2020,"errors":{}},"publication_name":"Vaccines"},"translated_abstract":"Purpose: Infections are frequent and often result in serious complications in patients with multiple myeloma (MM). Prophylactic vaccination is recommended for influenza virus, Streptococcus pneumoniae (SP), and Hemophilus influenzaeb (Hib). The aims of this study were to measure the vaccination rates within 24 months after the diagnosis of multiple myeloma and to identify factors associated with vaccine use. Methods: MM patients were selected through the French national health insurance database from 1 January 2010 to 31 December 2015. Patients with a previous history of MM were excluded. Results: Vaccination rates against influenza, SP, and Hib among 22,831 newly diagnosed MM patients were, respectively, 28.5%, 10.3%, and 1.4%. Only 0.7% received all three vaccines. Factors associated with vaccination were young age, male gender, an absence of comorbidity, a history of higher medication and vaccine consumption, Herpes simplex virus (HSV), Varicella zoster virus (VZV), and the use o...","internal_url":"https://www.academia.edu/122114351/Vaccination_during_the_First_Diagnosis_of_Multiple_Myeloma_A_Cohort_Study_of_the_French_National_Health_Insurance_Database","translated_internal_url":"","created_at":"2024-07-16T22:19:56.036-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843172,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843172/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/116843172/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Vaccination_during_the_First_Diagnosis_o.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843172/pdf-libre.pdf?1721196858=\u0026response-content-disposition=attachment%3B+filename%3DVaccination_during_the_First_Diagnosis_o.pdf\u0026Expires=1732431771\u0026Signature=aOXpXRyPzta6~pQjQkLzyZTPRA6z-1elCe9Q87OaDjylnH5eNOec7J0Oy10M3grW6wEtK1G4iNndNfwNCjH3~mbv4m~MXClj9lqXqs42JFl8ijSCO1EguwrDFSQV7LREKvjfu-d9jAVwqBcSvsDQYbFIMsLYGUCqOlvjz71fwOsXWo9CPlsmBGKVl1pvjwj6~UaQ5g3kdI8mpPvyCTmGh6Sidq3Das5v-PCM97bh4NJSysqZKHmP1gsNXf1BzOfCLlJwA3O4BOlrfL6vqbzH-QLQkQdsiquN8hAjK~lWdpcWIcUGGeh25s0numgE0JKIkh5WNtseO3bG9PEoMdvOhQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Vaccination_during_the_First_Diagnosis_of_Multiple_Myeloma_A_Cohort_Study_of_the_French_National_Health_Insurance_Database","translated_slug":"","page_count":12,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843172,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843172/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/116843172/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Vaccination_during_the_First_Diagnosis_o.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843172/pdf-libre.pdf?1721196858=\u0026response-content-disposition=attachment%3B+filename%3DVaccination_during_the_First_Diagnosis_o.pdf\u0026Expires=1732431771\u0026Signature=aOXpXRyPzta6~pQjQkLzyZTPRA6z-1elCe9Q87OaDjylnH5eNOec7J0Oy10M3grW6wEtK1G4iNndNfwNCjH3~mbv4m~MXClj9lqXqs42JFl8ijSCO1EguwrDFSQV7LREKvjfu-d9jAVwqBcSvsDQYbFIMsLYGUCqOlvjz71fwOsXWo9CPlsmBGKVl1pvjwj6~UaQ5g3kdI8mpPvyCTmGh6Sidq3Das5v-PCM97bh4NJSysqZKHmP1gsNXf1BzOfCLlJwA3O4BOlrfL6vqbzH-QLQkQdsiquN8hAjK~lWdpcWIcUGGeh25s0numgE0JKIkh5WNtseO3bG9PEoMdvOhQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"},{"id":116843173,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843173/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/116843173/download_file","bulk_download_file_name":"Vaccination_during_the_First_Diagnosis_o.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843173/pdf-libre.pdf?1721196855=\u0026response-content-disposition=attachment%3B+filename%3DVaccination_during_the_First_Diagnosis_o.pdf\u0026Expires=1732431771\u0026Signature=QNFf2xLTOf6n9OSZlI8~yWvzy-n-pk03IvyRj-1jA4x~tdu2rXCLU31fBPoQIdsVW9YgxauKaJarKrxrknHBDSuBAzHP0mhqoxGlUsMEcI6WRoOOvf4XTd~MowDD8MxmwCK09-RtLoLU5nrSlusSsjo0wQirhg5N1iRgLShxKNks3ZDc3ox6~ljSNkgK2QRAcfz-wBlIspDFCVH9rrQ2BcTk19y5gK5DKywzJj0eVWT-EN7BEFQ44a55JfzZIETJsSa4vtLbDlhiaViyDtH6d7fhzPOwIagisJT4-liRvYWrsRXtnft8GB0Nhz9TtEuYGsXZnk5WzlFvQt87-tB91A__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":4365,"name":"Vaccines","url":"https://www.academia.edu/Documents/in/Vaccines"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":179934,"name":"Vaccination","url":"https://www.academia.edu/Documents/in/Vaccination"}],"urls":[{"id":43557995,"url":"https://www.mdpi.com/2076-393X/8/4/722/pdf"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114350"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114350/Primary_Care_of_Opioid_use_Disorder_The_End_of_the_French_Model_"><img alt="Research paper thumbnail of Primary Care of Opioid use Disorder: The End of “the French Model”?" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114350/Primary_Care_of_Opioid_use_Disorder_The_End_of_the_French_Model_">Primary Care of Opioid use Disorder: The End of “the French Model”?</a></div><div class="wp-workCard_item"><span>European Addiction Research</span><span>, 2020</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenor...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenorphine, prescribed by general practitioners (GP) in private practice since 1996. This has contributed to building a ‘French model’ facilitating access to treatment based on the involvement of GPs in buprenorphine prescription. Objectives: Our study aimed to assess whether the involvement of primary care in OUD management has changed lately. Materials and Methods: Using data from the French National Health Insurance database, we conducted a yearly repeated cross-sectional study (2009–2015) and described proportion of opioid maintenance treatment (OMT)-prescribing GPs and OMT-dispensing community pharmacies (CP); and number of patients by GP or CP. Results: Whereas the number of buprenorphine-prescribing GPs in private practice remained quite stable (decrease of 3%), a substantial decrease in buprenorphine initial prescribers among private GPs was observed. In 2009, 10.3% of private GPs (6,...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114350"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114350"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114350; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114350]").text(description); $(".js-view-count[data-work-id=122114350]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114350; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114350']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114350, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114350]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114350,"title":"Primary Care of Opioid use Disorder: The End of “the French Model”?","translated_title":"","metadata":{"abstract":"Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenorphine, prescribed by general practitioners (GP) in private practice since 1996. This has contributed to building a ‘French model’ facilitating access to treatment based on the involvement of GPs in buprenorphine prescription. Objectives: Our study aimed to assess whether the involvement of primary care in OUD management has changed lately. Materials and Methods: Using data from the French National Health Insurance database, we conducted a yearly repeated cross-sectional study (2009–2015) and described proportion of opioid maintenance treatment (OMT)-prescribing GPs and OMT-dispensing community pharmacies (CP); and number of patients by GP or CP. Results: Whereas the number of buprenorphine-prescribing GPs in private practice remained quite stable (decrease of 3%), a substantial decrease in buprenorphine initial prescribers among private GPs was observed. In 2009, 10.3% of private GPs (6,...","publisher":"S. Karger AG","publication_date":{"day":null,"month":null,"year":2020,"errors":{}},"publication_name":"European Addiction Research"},"translated_abstract":"Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenorphine, prescribed by general practitioners (GP) in private practice since 1996. This has contributed to building a ‘French model’ facilitating access to treatment based on the involvement of GPs in buprenorphine prescription. Objectives: Our study aimed to assess whether the involvement of primary care in OUD management has changed lately. Materials and Methods: Using data from the French National Health Insurance database, we conducted a yearly repeated cross-sectional study (2009–2015) and described proportion of opioid maintenance treatment (OMT)-prescribing GPs and OMT-dispensing community pharmacies (CP); and number of patients by GP or CP. Results: Whereas the number of buprenorphine-prescribing GPs in private practice remained quite stable (decrease of 3%), a substantial decrease in buprenorphine initial prescribers among private GPs was observed. In 2009, 10.3% of private GPs (6,...","internal_url":"https://www.academia.edu/122114350/Primary_Care_of_Opioid_use_Disorder_The_End_of_the_French_Model_","translated_internal_url":"","created_at":"2024-07-16T22:19:54.258-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Primary_Care_of_Opioid_use_Disorder_The_End_of_the_French_Model_","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":221,"name":"Psychology","url":"https://www.academia.edu/Documents/in/Psychology"},{"id":633,"name":"Primary Care","url":"https://www.academia.edu/Documents/in/Primary_Care"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":143599,"name":"Buprenorphine","url":"https://www.academia.edu/Documents/in/Buprenorphine"},{"id":410370,"name":"Public health systems and services research","url":"https://www.academia.edu/Documents/in/Public_health_systems_and_services_research-1"},{"id":4136525,"name":"Medical prescription","url":"https://www.academia.edu/Documents/in/Medical_prescription"}],"urls":[{"id":43557994,"url":"https://www.karger.com/Article/Pdf/506630"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114349"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114349/Couverture_vaccinale_anti_grippale_insuffisante_dans_l_art%C3%A9rite_%C3%A0_cellules_g%C3%A9antes"><img alt="Research paper thumbnail of Couverture vaccinale anti grippale insuffisante dans l’artérite à cellules géantes" class="work-thumbnail" src="https://attachments.academia-assets.com/116843211/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114349/Couverture_vaccinale_anti_grippale_insuffisante_dans_l_art%C3%A9rite_%C3%A0_cellules_g%C3%A9antes">Couverture vaccinale anti grippale insuffisante dans l’artérite à cellules géantes</a></div><div class="wp-workCard_item"><span>La Revue de Médecine Interne</span><span>, 2019</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="e7d08490e4d363aad840733d534bf0ef" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843211,"asset_id":122114349,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843211/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114349"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114349"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114349; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114349]").text(description); $(".js-view-count[data-work-id=122114349]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114349; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114349']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114349, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "e7d08490e4d363aad840733d534bf0ef" } } $('.js-work-strip[data-work-id=122114349]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114349,"title":"Couverture vaccinale anti grippale insuffisante dans l’artérite à cellules géantes","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":null,"month":null,"year":2019,"errors":{}},"publication_name":"La Revue de Médecine Interne"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114349/Couverture_vaccinale_anti_grippale_insuffisante_dans_l_art%C3%A9rite_%C3%A0_cellules_g%C3%A9antes","translated_internal_url":"","created_at":"2024-07-16T22:19:52.777-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843211,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843211/thumbnails/1.jpg","file_name":"S0248866319311853.pdf","download_url":"https://www.academia.edu/attachments/116843211/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Couverture_vaccinale_anti_grippale_insuf.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843211/S0248866319311853-libre.pdf?1721196841=\u0026response-content-disposition=attachment%3B+filename%3DCouverture_vaccinale_anti_grippale_insuf.pdf\u0026Expires=1732431771\u0026Signature=a2dwxJHJeSfAeLw-SkSH9VB01DxDkdsYcDVA~gs4aOeAgbRHvpeyIxOnr9J-qU8X9gVTbJUmaiFHpJZgGIuyeQXcqtVujOdZ9xHc8s9wHnqz1yqAHQ-~-OeQIOs7Mo~x~3JYh~AztzrbQsNTiZixcPrZPMHxlQOFngNjjxlCmlAsWvIj4o3N10Lat7O0humz8UhDteIKIfzXRiCjp-7akpw3FyhEZETCJKbfXOcne5uJQqqbC1HxV57QSRuPgqeAZ5ZDa81pIrbsG4DauYnyBLS6FctGFnbakIeBVsBYLMh63b2yJWo1GvoSI66mKnilj9CdESMMZArG1TnaNr~3bQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Couverture_vaccinale_anti_grippale_insuffisante_dans_l_artérite_à_cellules_géantes","translated_slug":"","page_count":21,"language":"fr","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843211,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843211/thumbnails/1.jpg","file_name":"S0248866319311853.pdf","download_url":"https://www.academia.edu/attachments/116843211/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Couverture_vaccinale_anti_grippale_insuf.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843211/S0248866319311853-libre.pdf?1721196841=\u0026response-content-disposition=attachment%3B+filename%3DCouverture_vaccinale_anti_grippale_insuf.pdf\u0026Expires=1732431771\u0026Signature=a2dwxJHJeSfAeLw-SkSH9VB01DxDkdsYcDVA~gs4aOeAgbRHvpeyIxOnr9J-qU8X9gVTbJUmaiFHpJZgGIuyeQXcqtVujOdZ9xHc8s9wHnqz1yqAHQ-~-OeQIOs7Mo~x~3JYh~AztzrbQsNTiZixcPrZPMHxlQOFngNjjxlCmlAsWvIj4o3N10Lat7O0humz8UhDteIKIfzXRiCjp-7akpw3FyhEZETCJKbfXOcne5uJQqqbC1HxV57QSRuPgqeAZ5ZDa81pIrbsG4DauYnyBLS6FctGFnbakIeBVsBYLMh63b2yJWo1GvoSI66mKnilj9CdESMMZArG1TnaNr~3bQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":129972,"name":"Rite","url":"https://www.academia.edu/Documents/in/Rite"},{"id":339107,"name":"Gynecology","url":"https://www.academia.edu/Documents/in/Gynecology"}],"urls":[{"id":43557993,"url":"https://api.elsevier.com/content/article/PII:S0248866319311853?httpAccept=text/xml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114348"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114348/Real_world_costs_of_illness_of_Hodgkin_and_the_main_B_Cell_Non_Hodgkin_lymphomas_in_France"><img alt="Research paper thumbnail of Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France" class="work-thumbnail" src="https://attachments.academia-assets.com/116843210/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114348/Real_world_costs_of_illness_of_Hodgkin_and_the_main_B_Cell_Non_Hodgkin_lymphomas_in_France">Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France</a></div><div class="wp-workCard_item"><span>Journal of Medical Economics</span><span>, 2019</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="9d668f1c0fd6b87a072494ebb7d15d39" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843210,"asset_id":122114348,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843210/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114348"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114348"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114348; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114348]").text(description); $(".js-view-count[data-work-id=122114348]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114348; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114348']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114348, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "9d668f1c0fd6b87a072494ebb7d15d39" } } $('.js-work-strip[data-work-id=122114348]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114348,"title":"Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France","translated_title":"","metadata":{"publisher":"Informa UK Limited","publication_date":{"day":null,"month":null,"year":2019,"errors":{}},"publication_name":"Journal of Medical Economics"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114348/Real_world_costs_of_illness_of_Hodgkin_and_the_main_B_Cell_Non_Hodgkin_lymphomas_in_France","translated_internal_url":"","created_at":"2024-07-16T22:19:50.865-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843210,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843210/thumbnails/1.jpg","file_name":"IJME_A_1702990.pdf","download_url":"https://www.academia.edu/attachments/116843210/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Real_world_costs_of_illness_of_Hodgkin_a.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843210/IJME_A_1702990-libre.pdf?1721196834=\u0026response-content-disposition=attachment%3B+filename%3DReal_world_costs_of_illness_of_Hodgkin_a.pdf\u0026Expires=1732431771\u0026Signature=RBxqwcqcV0u0rIFe7SN2ILC8IDJ-4hNPji53iip5jOvEcMwW3KiDcA9jm2WmXkH1CLvleaKSO~bMQRkfjJfwCPcjaBmH0I12~IViWxLkiYFkmclx0T3l3ULamgGfm-LDhg9BDzRroMRpApqjs~l2ppI8d0F6cRKZOLxO8FPvD3WMMiG~FkIDxGSMC4vKo59fbNBUr~7NBTPO~IEwx3TxsLImD1wBotWUNUGy2BoGTAtkUi5-yW7AFKpC1T7ySyTSZ94Ig6N779hRi3ZXfe1jgDQtrLrYJJu9PytlsCNxNMdf2PrXJoMCk8LDrYolAAAADCI~O4jUYtMUmi~QGhCc4g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Real_world_costs_of_illness_of_Hodgkin_and_the_main_B_Cell_Non_Hodgkin_lymphomas_in_France","translated_slug":"","page_count":10,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843210,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843210/thumbnails/1.jpg","file_name":"IJME_A_1702990.pdf","download_url":"https://www.academia.edu/attachments/116843210/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Real_world_costs_of_illness_of_Hodgkin_a.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843210/IJME_A_1702990-libre.pdf?1721196834=\u0026response-content-disposition=attachment%3B+filename%3DReal_world_costs_of_illness_of_Hodgkin_a.pdf\u0026Expires=1732431771\u0026Signature=RBxqwcqcV0u0rIFe7SN2ILC8IDJ-4hNPji53iip5jOvEcMwW3KiDcA9jm2WmXkH1CLvleaKSO~bMQRkfjJfwCPcjaBmH0I12~IViWxLkiYFkmclx0T3l3ULamgGfm-LDhg9BDzRroMRpApqjs~l2ppI8d0F6cRKZOLxO8FPvD3WMMiG~FkIDxGSMC4vKo59fbNBUr~7NBTPO~IEwx3TxsLImD1wBotWUNUGy2BoGTAtkUi5-yW7AFKpC1T7ySyTSZ94Ig6N779hRi3ZXfe1jgDQtrLrYJJu9PytlsCNxNMdf2PrXJoMCk8LDrYolAAAADCI~O4jUYtMUmi~QGhCc4g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":221,"name":"Psychology","url":"https://www.academia.edu/Documents/in/Psychology"},{"id":4441,"name":"Health Care","url":"https://www.academia.edu/Documents/in/Health_Care"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":27659,"name":"Applied Economics","url":"https://www.academia.edu/Documents/in/Applied_Economics"},{"id":55269,"name":"Lymphoma","url":"https://www.academia.edu/Documents/in/Lymphoma"},{"id":64336,"name":"Population","url":"https://www.academia.edu/Documents/in/Population"},{"id":132830,"name":"Medical Economics","url":"https://www.academia.edu/Documents/in/Medical_Economics"},{"id":410370,"name":"Public health systems and services research","url":"https://www.academia.edu/Documents/in/Public_health_systems_and_services_research-1"},{"id":1469454,"name":"Hodgkin Lymphoma","url":"https://www.academia.edu/Documents/in/Hodgkin_Lymphoma"},{"id":2216196,"name":"Cost evaluation","url":"https://www.academia.edu/Documents/in/Cost_evaluation"},{"id":2292202,"name":"Follicular lymphoma","url":"https://www.academia.edu/Documents/in/Follicular_lymphoma"}],"urls":[{"id":43557992,"url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1702990"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114346"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114346/Positivity_Rate_of_Systematic_Bone_Marrow_Smear_Above_60_Year_Old_Patients_with_Newly_Diagnosed_Immune_Thrombocytopenia_to_Screen_for_Associated_Hematological_Malignancy_Results_from_the_French_Prospective_Multicenter_Carmen_Registry"><img alt="Research paper thumbnail of Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114346/Positivity_Rate_of_Systematic_Bone_Marrow_Smear_Above_60_Year_Old_Patients_with_Newly_Diagnosed_Immune_Thrombocytopenia_to_Screen_for_Associated_Hematological_Malignancy_Results_from_the_French_Prospective_Multicenter_Carmen_Registry">Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry</a></div><div class="wp-workCard_item"><span>Blood</span><span>, 2019</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Introduction:There are discrepancies across recommendations about the indication of bone marrow s...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Introduction:There are discrepancies across recommendations about the indication of bone marrow smear in adults diagnosed for immune thrombocytopenia (ITP). The 2011 American Society of Hematology guidelines do not recommend bone marrow smear in case of typical ITP. In contrast, the 2010 international consensus and the 2017 French guidelines recommend systematic bone marrow smear in adults aged &gt;60 years even in case of typical ITP to detect a blood cancer, particularly myelodysplastic syndrome. This recommendation is driven from expert consensus. Data are lacking about the positivity rate of this examination in older patients with typical ITP. The aim of this study was to assess the positivity rate of bone marrow smear at ITP diagnosis in &gt;60-year-old patients with no other clinical or biological sign of hematological malignancy. Methods:Data source was theCARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) registry. All adult patients with an incident diagnosis of ITP ...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114346"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114346"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114346; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114346]").text(description); $(".js-view-count[data-work-id=122114346]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114346; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114346']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114346, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114346]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114346,"title":"Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry","translated_title":"","metadata":{"abstract":"Introduction:There are discrepancies across recommendations about the indication of bone marrow smear in adults diagnosed for immune thrombocytopenia (ITP). The 2011 American Society of Hematology guidelines do not recommend bone marrow smear in case of typical ITP. In contrast, the 2010 international consensus and the 2017 French guidelines recommend systematic bone marrow smear in adults aged \u0026gt;60 years even in case of typical ITP to detect a blood cancer, particularly myelodysplastic syndrome. This recommendation is driven from expert consensus. Data are lacking about the positivity rate of this examination in older patients with typical ITP. The aim of this study was to assess the positivity rate of bone marrow smear at ITP diagnosis in \u0026gt;60-year-old patients with no other clinical or biological sign of hematological malignancy. Methods:Data source was theCARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) registry. All adult patients with an incident diagnosis of ITP ...","publisher":"American Society of Hematology","publication_date":{"day":null,"month":null,"year":2019,"errors":{}},"publication_name":"Blood"},"translated_abstract":"Introduction:There are discrepancies across recommendations about the indication of bone marrow smear in adults diagnosed for immune thrombocytopenia (ITP). The 2011 American Society of Hematology guidelines do not recommend bone marrow smear in case of typical ITP. In contrast, the 2010 international consensus and the 2017 French guidelines recommend systematic bone marrow smear in adults aged \u0026gt;60 years even in case of typical ITP to detect a blood cancer, particularly myelodysplastic syndrome. This recommendation is driven from expert consensus. Data are lacking about the positivity rate of this examination in older patients with typical ITP. The aim of this study was to assess the positivity rate of bone marrow smear at ITP diagnosis in \u0026gt;60-year-old patients with no other clinical or biological sign of hematological malignancy. Methods:Data source was theCARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) registry. All adult patients with an incident diagnosis of ITP ...","internal_url":"https://www.academia.edu/122114346/Positivity_Rate_of_Systematic_Bone_Marrow_Smear_Above_60_Year_Old_Patients_with_Newly_Diagnosed_Immune_Thrombocytopenia_to_Screen_for_Associated_Hematological_Malignancy_Results_from_the_French_Prospective_Multicenter_Carmen_Registry","translated_internal_url":"","created_at":"2024-07-16T22:19:49.544-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Positivity_Rate_of_Systematic_Bone_Marrow_Smear_Above_60_Year_Old_Patients_with_Newly_Diagnosed_Immune_Thrombocytopenia_to_Screen_for_Associated_Hematological_Malignancy_Results_from_the_French_Prospective_Multicenter_Carmen_Registry","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":100732,"name":"Blood","url":"https://www.academia.edu/Documents/in/Blood"},{"id":159239,"name":"Bone marrow","url":"https://www.academia.edu/Documents/in/Bone_marrow"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":2756159,"name":"Malignancy","url":"https://www.academia.edu/Documents/in/Malignancy"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"},{"id":3789883,"name":"Paediatrics and reproductive medicine","url":"https://www.academia.edu/Documents/in/Paediatrics_and_reproductive_medicine"}],"urls":[{"id":43557990,"url":"https://ashpublications.org/blood/article/134/Supplement_1/1083/426734/Positivity-Rate-of-Systematic-Bone-Marrow-Smear"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114344"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114344/Incidence_of_Adverse_Drug_Reactions_Related_to_Immune_Thrombocytopenia_Drugs_A_Prospective_Cohort_Study"><img alt="Research paper thumbnail of Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114344/Incidence_of_Adverse_Drug_Reactions_Related_to_Immune_Thrombocytopenia_Drugs_A_Prospective_Cohort_Study">Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study</a></div><div class="wp-workCard_item"><span>Blood</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background: The incidence ofadverse drug reactions (ADRs) related to immune thrombocytopenia (ITP...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background: The incidence ofadverse drug reactions (ADRs) related to immune thrombocytopenia (ITP) drugs is not well known in the real-life practice. Aim: The principal aim of this study was to assess the incidence of ADRs related to ITP drugs. The secondary aims were to compare the incidence of ADRs depending on the drugs, and to assess the factors associated to corticosteroids-related ADR occurrence. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes: Registre Midi-PyréneEN) registry. This multicenter registry is carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. It is aimed at the prospective follow-up of all newly diagnosed ITP adults in the French Midi-Pyrénées region (3 million inhabitants). Each investigator prospectively follows every patient newly diagnosed for ITP in routine visit or hospital stay, provi...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114344"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114344"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114344; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114344]").text(description); $(".js-view-count[data-work-id=122114344]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114344; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114344']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114344, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114344]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114344,"title":"Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study","translated_title":"","metadata":{"abstract":"Background: The incidence ofadverse drug reactions (ADRs) related to immune thrombocytopenia (ITP) drugs is not well known in the real-life practice. Aim: The principal aim of this study was to assess the incidence of ADRs related to ITP drugs. The secondary aims were to compare the incidence of ADRs depending on the drugs, and to assess the factors associated to corticosteroids-related ADR occurrence. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes: Registre Midi-PyréneEN) registry. This multicenter registry is carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. It is aimed at the prospective follow-up of all newly diagnosed ITP adults in the French Midi-Pyrénées region (3 million inhabitants). Each investigator prospectively follows every patient newly diagnosed for ITP in routine visit or hospital stay, provi...","publisher":"American Society of Hematology","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"Blood"},"translated_abstract":"Background: The incidence ofadverse drug reactions (ADRs) related to immune thrombocytopenia (ITP) drugs is not well known in the real-life practice. Aim: The principal aim of this study was to assess the incidence of ADRs related to ITP drugs. The secondary aims were to compare the incidence of ADRs depending on the drugs, and to assess the factors associated to corticosteroids-related ADR occurrence. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes: Registre Midi-PyréneEN) registry. This multicenter registry is carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. It is aimed at the prospective follow-up of all newly diagnosed ITP adults in the French Midi-Pyrénées region (3 million inhabitants). Each investigator prospectively follows every patient newly diagnosed for ITP in routine visit or hospital stay, provi...","internal_url":"https://www.academia.edu/122114344/Incidence_of_Adverse_Drug_Reactions_Related_to_Immune_Thrombocytopenia_Drugs_A_Prospective_Cohort_Study","translated_internal_url":"","created_at":"2024-07-16T22:19:47.580-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Incidence_of_Adverse_Drug_Reactions_Related_to_Immune_Thrombocytopenia_Drugs_A_Prospective_Cohort_Study","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":631,"name":"Pediatrics","url":"https://www.academia.edu/Documents/in/Pediatrics"},{"id":5500,"name":"Incidence Geometry","url":"https://www.academia.edu/Documents/in/Incidence_Geometry"},{"id":10829,"name":"Pharmacovigilance","url":"https://www.academia.edu/Documents/in/Pharmacovigilance"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":100732,"name":"Blood","url":"https://www.academia.edu/Documents/in/Blood"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":2717351,"name":"Prospective Cohort Study","url":"https://www.academia.edu/Documents/in/Prospective_Cohort_Study"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"},{"id":3789883,"name":"Paediatrics and reproductive medicine","url":"https://www.academia.edu/Documents/in/Paediatrics_and_reproductive_medicine"}],"urls":[{"id":43557989,"url":"https://ashpublications.org/blood/article/126/23/1056/104621/Incidence-of-Adverse-Drug-Reactions-Related-to"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114343"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114343/Clinical_Epidemiology_and_First_Line_Treatment_in_Immune_Thrombocytopenia_Adults_Results_of_the_Carmen_Prospective_Cohort"><img alt="Research paper thumbnail of Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114343/Clinical_Epidemiology_and_First_Line_Treatment_in_Immune_Thrombocytopenia_Adults_Results_of_the_Carmen_Prospective_Cohort">Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort</a></div><div class="wp-workCard_item"><span>Blood</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background: The clinical epidemiology of immune thrombocytopenia (ITP) is not well known. Some is...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background: The clinical epidemiology of immune thrombocytopenia (ITP) is not well known. Some issues (bleeding events at diagnosis, association to other autoimmune diseases, rate of infection prior to ITP onset) are not well described in adults. Little is known as regards first-line treatment choice in the real-life practice. Aim: The aims of this study were to assess i) the clinical epidemiology of incident ITP adults; ii) the use of first-line treatments in this population; and iii) the factors associated with the initial use of intravenous (IV) corticosteroids (CS) and of intravenous immunoglobulin (IVIg) in a real-life setting. This study was carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) multicenter registry. This multicenter re...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114343"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114343"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114343; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114343]").text(description); $(".js-view-count[data-work-id=122114343]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114343; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114343']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114343, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114343]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114343,"title":"Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort","translated_title":"","metadata":{"abstract":"Background: The clinical epidemiology of immune thrombocytopenia (ITP) is not well known. Some issues (bleeding events at diagnosis, association to other autoimmune diseases, rate of infection prior to ITP onset) are not well described in adults. Little is known as regards first-line treatment choice in the real-life practice. Aim: The aims of this study were to assess i) the clinical epidemiology of incident ITP adults; ii) the use of first-line treatments in this population; and iii) the factors associated with the initial use of intravenous (IV) corticosteroids (CS) and of intravenous immunoglobulin (IVIg) in a real-life setting. This study was carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) multicenter registry. This multicenter re...","publisher":"American Society of Hematology","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"Blood"},"translated_abstract":"Background: The clinical epidemiology of immune thrombocytopenia (ITP) is not well known. Some issues (bleeding events at diagnosis, association to other autoimmune diseases, rate of infection prior to ITP onset) are not well described in adults. Little is known as regards first-line treatment choice in the real-life practice. Aim: The aims of this study were to assess i) the clinical epidemiology of incident ITP adults; ii) the use of first-line treatments in this population; and iii) the factors associated with the initial use of intravenous (IV) corticosteroids (CS) and of intravenous immunoglobulin (IVIg) in a real-life setting. This study was carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) multicenter registry. This multicenter re...","internal_url":"https://www.academia.edu/122114343/Clinical_Epidemiology_and_First_Line_Treatment_in_Immune_Thrombocytopenia_Adults_Results_of_the_Carmen_Prospective_Cohort","translated_internal_url":"","created_at":"2024-07-16T22:19:45.775-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Clinical_Epidemiology_and_First_Line_Treatment_in_Immune_Thrombocytopenia_Adults_Results_of_the_Carmen_Prospective_Cohort","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":631,"name":"Pediatrics","url":"https://www.academia.edu/Documents/in/Pediatrics"},{"id":1085,"name":"Epidemiology","url":"https://www.academia.edu/Documents/in/Epidemiology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":64336,"name":"Population","url":"https://www.academia.edu/Documents/in/Population"},{"id":100732,"name":"Blood","url":"https://www.academia.edu/Documents/in/Blood"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"},{"id":3789883,"name":"Paediatrics and reproductive medicine","url":"https://www.academia.edu/Documents/in/Paediatrics_and_reproductive_medicine"}],"urls":[{"id":43557988,"url":"https://ashpublications.org/blood/article/126/23/3473/91152/Clinical-Epidemiology-and-FirstLine-Treatment-in"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114340"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114340/The_value_of_a_health_insurance_database_to_conduct_pharmacoepidemiological_studies_in_oncology"><img alt="Research paper thumbnail of The value of a health insurance database to conduct pharmacoepidemiological studies in oncology" class="work-thumbnail" src="https://attachments.academia-assets.com/116843194/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114340/The_value_of_a_health_insurance_database_to_conduct_pharmacoepidemiological_studies_in_oncology">The value of a health insurance database to conduct pharmacoepidemiological studies in oncology</a></div><div class="wp-workCard_item"><span>Therapies</span><span>, 2019</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="450372c1a5052d98d830e0e0a3611596" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843194,"asset_id":122114340,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843194/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114340"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114340"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114340; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114340]").text(description); $(".js-view-count[data-work-id=122114340]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114340; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114340']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114340, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "450372c1a5052d98d830e0e0a3611596" } } $('.js-work-strip[data-work-id=122114340]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114340,"title":"The value of a health insurance database to conduct pharmacoepidemiological studies in oncology","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":null,"month":null,"year":2019,"errors":{}},"publication_name":"Therapies"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114340/The_value_of_a_health_insurance_database_to_conduct_pharmacoepidemiological_studies_in_oncology","translated_internal_url":"","created_at":"2024-07-16T22:19:43.552-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843194,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843194/thumbnails/1.jpg","file_name":"S0040595719300241.pdf","download_url":"https://www.academia.edu/attachments/116843194/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_value_of_a_health_insurance_database.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843194/S0040595719300241-libre.pdf?1721196842=\u0026response-content-disposition=attachment%3B+filename%3DThe_value_of_a_health_insurance_database.pdf\u0026Expires=1732452503\u0026Signature=Nu1cT1MT1CFzYXJlSgxD5XL9AdFnmk3KuJD3KgqAQ1-AnPXFuTA2z4Olo5~w3Rgq7mNNvVbcepdFwzGtbpgj4gQ2Vy~ntv5bMBgZOXn69Lag-ZfH3nURcURweYz1TpVHpTxBtQqjLl2orNBArjNso8y4vMX0tpHvFbEJPKkIxXasWlNo2OZSVNWcyq5hllHvq~XiRG6EFhVXZCq959grNTUo~LW~SRnR3EHuOPW9odck4HJxxSIQL6~sp-CAX9RQQDzgBhqBGtAtjFdyVaIAk6EHkWgjbTijXuSD-ohhYKScV9QY4EpexxSQOV7gtLRZjyLJzGcW8iKe-t2CpvjAQg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_value_of_a_health_insurance_database_to_conduct_pharmacoepidemiological_studies_in_oncology","translated_slug":"","page_count":26,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843194,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843194/thumbnails/1.jpg","file_name":"S0040595719300241.pdf","download_url":"https://www.academia.edu/attachments/116843194/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_value_of_a_health_insurance_database.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843194/S0040595719300241-libre.pdf?1721196842=\u0026response-content-disposition=attachment%3B+filename%3DThe_value_of_a_health_insurance_database.pdf\u0026Expires=1732452503\u0026Signature=Nu1cT1MT1CFzYXJlSgxD5XL9AdFnmk3KuJD3KgqAQ1-AnPXFuTA2z4Olo5~w3Rgq7mNNvVbcepdFwzGtbpgj4gQ2Vy~ntv5bMBgZOXn69Lag-ZfH3nURcURweYz1TpVHpTxBtQqjLl2orNBArjNso8y4vMX0tpHvFbEJPKkIxXasWlNo2OZSVNWcyq5hllHvq~XiRG6EFhVXZCq959grNTUo~LW~SRnR3EHuOPW9odck4HJxxSIQL6~sp-CAX9RQQDzgBhqBGtAtjFdyVaIAk6EHkWgjbTijXuSD-ohhYKScV9QY4EpexxSQOV7gtLRZjyLJzGcW8iKe-t2CpvjAQg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":1086,"name":"Pharmacoepidemiology","url":"https://www.academia.edu/Documents/in/Pharmacoepidemiology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":816770,"name":"Therapies","url":"https://www.academia.edu/Documents/in/Therapies"},{"id":2380530,"name":"Therapie","url":"https://www.academia.edu/Documents/in/Therapie"}],"urls":[{"id":43557987,"url":"https://api.elsevier.com/content/article/PII:S0040595719300241?httpAccept=text/xml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> </div><div class="profile--tab_content_container js-tab-pane tab-pane" data-section-id="3079920" id="papers"><div class="js-work-strip profile--work_container" data-work-id="122114365"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114365/Risque_de_cancer_sous_anti_TNF_%CE%B1_chez_les_patients_adultes_atteints_de_polyarthrite_rhumato%C3%AFde_m%C3%A9ta_analyse_de_33_essais_cliniques_randomis%C3%A9s"><img alt="Research paper thumbnail of Risque de cancer sous anti-TNF-α chez les patients adultes atteints de polyarthrite rhumatoïde : méta-analyse de 33 essais cliniques randomisés" class="work-thumbnail" src="https://attachments.academia-assets.com/116843218/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114365/Risque_de_cancer_sous_anti_TNF_%CE%B1_chez_les_patients_adultes_atteints_de_polyarthrite_rhumato%C3%AFde_m%C3%A9ta_analyse_de_33_essais_cliniques_randomis%C3%A9s">Risque de cancer sous anti-TNF-α chez les patients adultes atteints de polyarthrite rhumatoïde : méta-analyse de 33 essais cliniques randomisés</a></div><div class="wp-workCard_item"><span>Revue de Médecine Interne</span><span>, Dec 1, 2011</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="bf542336d70865175bf22a683d741d47" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843218,"asset_id":122114365,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843218/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114365"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114365"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114365; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114365]").text(description); $(".js-view-count[data-work-id=122114365]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114365; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114365']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114365, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "bf542336d70865175bf22a683d741d47" } } $('.js-work-strip[data-work-id=122114365]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114365,"title":"Risque de cancer sous anti-TNF-α chez les patients adultes atteints de polyarthrite rhumatoïde : méta-analyse de 33 essais cliniques randomisés","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":12,"year":2011,"errors":{}},"publication_name":"Revue de Médecine Interne"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114365/Risque_de_cancer_sous_anti_TNF_%CE%B1_chez_les_patients_adultes_atteints_de_polyarthrite_rhumato%C3%AFde_m%C3%A9ta_analyse_de_33_essais_cliniques_randomis%C3%A9s","translated_internal_url":"","created_at":"2024-07-16T22:20:07.037-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843218,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843218/thumbnails/1.jpg","file_name":"j.revmed.2011.10.32220240717-1-b8ydjk.pdf","download_url":"https://www.academia.edu/attachments/116843218/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Risque_de_cancer_sous_anti_TNF__chez_le.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843218/j.revmed.2011.10.32220240717-1-b8ydjk-libre.pdf?1721196832=\u0026response-content-disposition=attachment%3B+filename%3DRisque_de_cancer_sous_anti_TNF__chez_le.pdf\u0026Expires=1732431771\u0026Signature=UM5JlYE8HKVhP2VZ7~aIPAciKKqdwRd0I1RLE7FaK5MHdzoCaYKQBV--LgsixOeLHFk2NBdL3R8vY-IZUrWCKlBJhSoUIkPYp0e3gA5lUmy5dSXfo2Bm5XwgskKStvrC-2WmEkNIu5bwV8U7ITRC6nlIkhVa6xFMb2xr4rFwedCFFpiOeBeTbuSXZ74KfQlJn~~Piim73Anf1SEQ9R1fm3gUCFf0sWRQAsL5-1cH7cmAg~IqG3M-OWkbanteu-QH5c8IbViwybCvMJ5vwckCieT8q8Vugii9tgdG-zY8JpMGRpQ-E0bw640d8ADOcR6Z2oGJOrn-mzAjShO6Biy-BA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Risque_de_cancer_sous_anti_TNF_α_chez_les_patients_adultes_atteints_de_polyarthrite_rhumatoïde_méta_analyse_de_33_essais_cliniques_randomisés","translated_slug":"","page_count":2,"language":"fr","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843218,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843218/thumbnails/1.jpg","file_name":"j.revmed.2011.10.32220240717-1-b8ydjk.pdf","download_url":"https://www.academia.edu/attachments/116843218/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Risque_de_cancer_sous_anti_TNF__chez_le.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843218/j.revmed.2011.10.32220240717-1-b8ydjk-libre.pdf?1721196832=\u0026response-content-disposition=attachment%3B+filename%3DRisque_de_cancer_sous_anti_TNF__chez_le.pdf\u0026Expires=1732431771\u0026Signature=UM5JlYE8HKVhP2VZ7~aIPAciKKqdwRd0I1RLE7FaK5MHdzoCaYKQBV--LgsixOeLHFk2NBdL3R8vY-IZUrWCKlBJhSoUIkPYp0e3gA5lUmy5dSXfo2Bm5XwgskKStvrC-2WmEkNIu5bwV8U7ITRC6nlIkhVa6xFMb2xr4rFwedCFFpiOeBeTbuSXZ74KfQlJn~~Piim73Anf1SEQ9R1fm3gUCFf0sWRQAsL5-1cH7cmAg~IqG3M-OWkbanteu-QH5c8IbViwybCvMJ5vwckCieT8q8Vugii9tgdG-zY8JpMGRpQ-E0bw640d8ADOcR6Z2oGJOrn-mzAjShO6Biy-BA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"}],"urls":[{"id":43558007,"url":"https://doi.org/10.1016/j.revmed.2011.10.322"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114363"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114363/Dermatological_adverse_drug_reactions_of_anticancer_drugs_International_data_of_pharmacovigilance_VigiBase_"><img alt="Research paper thumbnail of Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114363/Dermatological_adverse_drug_reactions_of_anticancer_drugs_International_data_of_pharmacovigilance_VigiBase_">Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®</a></div><div class="wp-workCard_item"><span>Therapie</span><span>, Mar 1, 2022</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">In the 2000s, newer generations of drugs appeared on the market called drugs of targeted therapy ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">In the 2000s, newer generations of drugs appeared on the market called drugs of targeted therapy (TT) drugs. The introduction of TT in oncology has profoundly changed the prognosis of many cancers but also introduced a wide variety of adverse drugs reactions (ADR), including in particular dermatological adverse drug reactions (DADRs). We investigated the evolutions of the notifications of DADRs of anticancer drugs since 2000s in international pharmacovigilance data. For this purpose, we separated non-targeted therapy and targeted therapy. During the period from 01/01/2000 to 31/12/2017, 1,226,252 ICSRs (8.7%) were related to anticancer drugs, among them concerning anticancer drugs, 192,108 cases (15.6%) contained at least one MedDRA term for &quot;skin and subcutaneous tissue disorders&quot; system organ classes. The DADRs of anticancer drugs are in constant increase on the period 2000 to 2017, from 0.91% to 1.90% of the total ADR of Vigibase®. The number of DADRs drugs in the non-targeted therapies class remained stable during this period, while the DADRs of targeted therapy drugs increased and exceeded those of non-targeted therapy in recent years. Using a disproportionality analysis, we found that targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: dermatitis acneiform, hair color changes, acne, and hyperkeratosis and skin toxicity. While, non-targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: skin hyperpigmentation, nail discoloration, dermatitis exfoliative, Hyperhidrosis and alopecia. TT drugs are used more and more for cancer indications and even beyond. This problematic of DADR will become more and more common and should benefit from specialized support with the organization of a coordinated network of professionals.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114363"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114363"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114363; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114363]").text(description); $(".js-view-count[data-work-id=122114363]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114363; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114363']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114363, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114363]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114363,"title":"Dermatological adverse drug reactions of anticancer drugs: International data of pharmacovigilance: VigiBase®","translated_title":"","metadata":{"abstract":"In the 2000s, newer generations of drugs appeared on the market called drugs of targeted therapy (TT) drugs. The introduction of TT in oncology has profoundly changed the prognosis of many cancers but also introduced a wide variety of adverse drugs reactions (ADR), including in particular dermatological adverse drug reactions (DADRs). We investigated the evolutions of the notifications of DADRs of anticancer drugs since 2000s in international pharmacovigilance data. For this purpose, we separated non-targeted therapy and targeted therapy. During the period from 01/01/2000 to 31/12/2017, 1,226,252 ICSRs (8.7%) were related to anticancer drugs, among them concerning anticancer drugs, 192,108 cases (15.6%) contained at least one MedDRA term for \u0026quot;skin and subcutaneous tissue disorders\u0026quot; system organ classes. The DADRs of anticancer drugs are in constant increase on the period 2000 to 2017, from 0.91% to 1.90% of the total ADR of Vigibase®. The number of DADRs drugs in the non-targeted therapies class remained stable during this period, while the DADRs of targeted therapy drugs increased and exceeded those of non-targeted therapy in recent years. Using a disproportionality analysis, we found that targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: dermatitis acneiform, hair color changes, acne, and hyperkeratosis and skin toxicity. While, non-targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: skin hyperpigmentation, nail discoloration, dermatitis exfoliative, Hyperhidrosis and alopecia. TT drugs are used more and more for cancer indications and even beyond. This problematic of DADR will become more and more common and should benefit from specialized support with the organization of a coordinated network of professionals.","publisher":"Elsevier BV","publication_date":{"day":1,"month":3,"year":2022,"errors":{}},"publication_name":"Therapie"},"translated_abstract":"In the 2000s, newer generations of drugs appeared on the market called drugs of targeted therapy (TT) drugs. The introduction of TT in oncology has profoundly changed the prognosis of many cancers but also introduced a wide variety of adverse drugs reactions (ADR), including in particular dermatological adverse drug reactions (DADRs). We investigated the evolutions of the notifications of DADRs of anticancer drugs since 2000s in international pharmacovigilance data. For this purpose, we separated non-targeted therapy and targeted therapy. During the period from 01/01/2000 to 31/12/2017, 1,226,252 ICSRs (8.7%) were related to anticancer drugs, among them concerning anticancer drugs, 192,108 cases (15.6%) contained at least one MedDRA term for \u0026quot;skin and subcutaneous tissue disorders\u0026quot; system organ classes. The DADRs of anticancer drugs are in constant increase on the period 2000 to 2017, from 0.91% to 1.90% of the total ADR of Vigibase®. The number of DADRs drugs in the non-targeted therapies class remained stable during this period, while the DADRs of targeted therapy drugs increased and exceeded those of non-targeted therapy in recent years. Using a disproportionality analysis, we found that targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: dermatitis acneiform, hair color changes, acne, and hyperkeratosis and skin toxicity. While, non-targeted therapy drugs are associated with a higher risk of reporting DADRs of the type: skin hyperpigmentation, nail discoloration, dermatitis exfoliative, Hyperhidrosis and alopecia. TT drugs are used more and more for cancer indications and even beyond. This problematic of DADR will become more and more common and should benefit from specialized support with the organization of a coordinated network of professionals.","internal_url":"https://www.academia.edu/122114363/Dermatological_adverse_drug_reactions_of_anticancer_drugs_International_data_of_pharmacovigilance_VigiBase_","translated_internal_url":"","created_at":"2024-07-16T22:20:03.953-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Dermatological_adverse_drug_reactions_of_anticancer_drugs_International_data_of_pharmacovigilance_VigiBase_","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":140,"name":"Pharmacology","url":"https://www.academia.edu/Documents/in/Pharmacology"},{"id":10829,"name":"Pharmacovigilance","url":"https://www.academia.edu/Documents/in/Pharmacovigilance"},{"id":12729,"name":"Dermatology","url":"https://www.academia.edu/Documents/in/Dermatology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":42135,"name":"Drug","url":"https://www.academia.edu/Documents/in/Drug"},{"id":602602,"name":"Drug Reaction","url":"https://www.academia.edu/Documents/in/Drug_Reaction"},{"id":816770,"name":"Therapies","url":"https://www.academia.edu/Documents/in/Therapies"},{"id":2380530,"name":"Therapie","url":"https://www.academia.edu/Documents/in/Therapie"},{"id":2601211,"name":"Adverse effect","url":"https://www.academia.edu/Documents/in/Adverse_effect"}],"urls":[{"id":43558006,"url":"https://doi.org/10.1016/j.therap.2021.12.006"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114362"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114362/Les_facteurs_influen%C3%A7ant_la_prescription_de_benzodiaz%C3%A9pines_devant_une_plainte_anxieuse_chez_une_personne_%C3%A2g%C3%A9e"><img alt="Research paper thumbnail of Les facteurs influençant la prescription de benzodiazépines devant une plainte anxieuse chez une personne âgée" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114362/Les_facteurs_influen%C3%A7ant_la_prescription_de_benzodiaz%C3%A9pines_devant_une_plainte_anxieuse_chez_une_personne_%C3%A2g%C3%A9e">Les facteurs influençant la prescription de benzodiazépines devant une plainte anxieuse chez une personne âgée</a></div><div class="wp-workCard_item"><span>Médecine</span><span>, Apr 1, 2017</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Le nombre de prescriptions de benzodiazepines chez les personnes de plus de 65 ans semble superie...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Le nombre de prescriptions de benzodiazepines chez les personnes de plus de 65 ans semble superieur a la prevalence des pathologies repondant a l’autorisation de mise sur le marche. Les facteurs influencant la prescription de benzodiazepines anxiolytiques, en initiation ou en renouvellement, chez la personne de plus de 65 ans ne sont pas connus. L’objectif de cette etude etait de determiner les facteurs influencant l’initiation de ce type de traitement par un echantillon de medecins generalistes en France. Un scenario clinique a ete soumis (etude descriptive transversale) aux medecins generalistes d’un bassin de sante de la region Midi-Pyrenees. Sur l’ensemble des variables etudiees, une analyse univariee, puis en regression logistique multivariee a ete realisee. Trois types de facteurs significatifs (p ≤ 0,05), influencant la prescription, ont ete retrouves chez le medecin de famille : sa perception de la situation clinique, l’offre de soins autour de lui, ses croyances et ses connaissances dans le domaine. Ces facteurs ont permis de mieux expliquer le taux important de recours aux benzodiazepines dans cette population. Des etudes complementaires seraient necessaires pour mieux les expliquer.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114362"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114362"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114362; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114362]").text(description); $(".js-view-count[data-work-id=122114362]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114362; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114362']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114362, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114362]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114362,"title":"Les facteurs influençant la prescription de benzodiazépines devant une plainte anxieuse chez une personne âgée","translated_title":"","metadata":{"abstract":"Le nombre de prescriptions de benzodiazepines chez les personnes de plus de 65 ans semble superieur a la prevalence des pathologies repondant a l’autorisation de mise sur le marche. Les facteurs influencant la prescription de benzodiazepines anxiolytiques, en initiation ou en renouvellement, chez la personne de plus de 65 ans ne sont pas connus. L’objectif de cette etude etait de determiner les facteurs influencant l’initiation de ce type de traitement par un echantillon de medecins generalistes en France. Un scenario clinique a ete soumis (etude descriptive transversale) aux medecins generalistes d’un bassin de sante de la region Midi-Pyrenees. Sur l’ensemble des variables etudiees, une analyse univariee, puis en regression logistique multivariee a ete realisee. Trois types de facteurs significatifs (p ≤ 0,05), influencant la prescription, ont ete retrouves chez le medecin de famille : sa perception de la situation clinique, l’offre de soins autour de lui, ses croyances et ses connaissances dans le domaine. Ces facteurs ont permis de mieux expliquer le taux important de recours aux benzodiazepines dans cette population. Des etudes complementaires seraient necessaires pour mieux les expliquer.","publication_date":{"day":1,"month":4,"year":2017,"errors":{}},"publication_name":"Médecine"},"translated_abstract":"Le nombre de prescriptions de benzodiazepines chez les personnes de plus de 65 ans semble superieur a la prevalence des pathologies repondant a l’autorisation de mise sur le marche. Les facteurs influencant la prescription de benzodiazepines anxiolytiques, en initiation ou en renouvellement, chez la personne de plus de 65 ans ne sont pas connus. L’objectif de cette etude etait de determiner les facteurs influencant l’initiation de ce type de traitement par un echantillon de medecins generalistes en France. Un scenario clinique a ete soumis (etude descriptive transversale) aux medecins generalistes d’un bassin de sante de la region Midi-Pyrenees. Sur l’ensemble des variables etudiees, une analyse univariee, puis en regression logistique multivariee a ete realisee. Trois types de facteurs significatifs (p ≤ 0,05), influencant la prescription, ont ete retrouves chez le medecin de famille : sa perception de la situation clinique, l’offre de soins autour de lui, ses croyances et ses connaissances dans le domaine. Ces facteurs ont permis de mieux expliquer le taux important de recours aux benzodiazepines dans cette population. Des etudes complementaires seraient necessaires pour mieux les expliquer.","internal_url":"https://www.academia.edu/122114362/Les_facteurs_influen%C3%A7ant_la_prescription_de_benzodiaz%C3%A9pines_devant_une_plainte_anxieuse_chez_une_personne_%C3%A2g%C3%A9e","translated_internal_url":"","created_at":"2024-07-16T22:20:03.443-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Les_facteurs_influençant_la_prescription_de_benzodiazépines_devant_une_plainte_anxieuse_chez_une_personne_âgée","translated_slug":"","page_count":null,"language":"fr","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":356921,"name":"Médecine","url":"https://www.academia.edu/Documents/in/M%C3%A9decine"}],"urls":[{"id":43558005,"url":"http://www.jle.com/fr/revues/med/e-docs/les_facteurs_influencant_la_prescription_de_benzodiazepines_devant_une_plainte_anxieuse_chez_une_personne_agee_309540/article.phtml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114361"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114361/Thomboprophylaxis_In_Multiple_Myeloma_Patients_Treated_With_Lenalidomide_or_Thalidomide"><img alt="Research paper thumbnail of Thomboprophylaxis In Multiple Myeloma Patients Treated With Lenalidomide or Thalidomide" class="work-thumbnail" src="https://attachments.academia-assets.com/116843217/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114361/Thomboprophylaxis_In_Multiple_Myeloma_Patients_Treated_With_Lenalidomide_or_Thalidomide">Thomboprophylaxis In Multiple Myeloma Patients Treated With Lenalidomide or Thalidomide</a></div><div class="wp-workCard_item"><span>Clinical Therapeutics</span><span>, Aug 1, 2015</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="90f8d25fdc3adfef1b0a81df9237a784" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843217,"asset_id":122114361,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843217/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114361"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114361"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114361; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114361]").text(description); $(".js-view-count[data-work-id=122114361]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114361; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114361']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114361, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "90f8d25fdc3adfef1b0a81df9237a784" } } $('.js-work-strip[data-work-id=122114361]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114361,"title":"Thomboprophylaxis In Multiple Myeloma Patients Treated With Lenalidomide or Thalidomide","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":8,"year":2015,"errors":{}},"publication_name":"Clinical Therapeutics"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114361/Thomboprophylaxis_In_Multiple_Myeloma_Patients_Treated_With_Lenalidomide_or_Thalidomide","translated_internal_url":"","created_at":"2024-07-16T22:20:02.752-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843217,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843217/thumbnails/1.jpg","file_name":"j.clinthera.2015.05.19520240717-1-e7gj9z.pdf","download_url":"https://www.academia.edu/attachments/116843217/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Thomboprophylaxis_In_Multiple_Myeloma_Pa.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843217/j.clinthera.2015.05.19520240717-1-e7gj9z-libre.pdf?1721196832=\u0026response-content-disposition=attachment%3B+filename%3DThomboprophylaxis_In_Multiple_Myeloma_Pa.pdf\u0026Expires=1732431771\u0026Signature=AZygD5VuGHQeNtb4CstnHs8VDXfw5mmQJLhW4d7gI5toIbjexh8FWfKtymIfE4C1~3QFQzc721SnaKoCrV2NDDnsN7SzjdXiKDegSpl1qhaMKJKFlcpXiPieV6hqvoNjXfO1CX9QYG0vbHgLiz6-wdre12XsGo~NcMu1ySLtvgTcfyBX9GIdzp2fF6qrO7f1Oy9xy-XXUFQi-sDsmFDILIyQftprUMLshBfR0ebQsJhvWemOoJmLP6MCGks4Ezgq4D6TQMD0485P9fLKOow~fzxrQ3fmRHZ2QKgZ5tCP6vsudlZTM4TXN16xiPGTHU~QWa04QR3Vl~Ge-yNPStqRMg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Thomboprophylaxis_In_Multiple_Myeloma_Patients_Treated_With_Lenalidomide_or_Thalidomide","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843217,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843217/thumbnails/1.jpg","file_name":"j.clinthera.2015.05.19520240717-1-e7gj9z.pdf","download_url":"https://www.academia.edu/attachments/116843217/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Thomboprophylaxis_In_Multiple_Myeloma_Pa.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843217/j.clinthera.2015.05.19520240717-1-e7gj9z-libre.pdf?1721196832=\u0026response-content-disposition=attachment%3B+filename%3DThomboprophylaxis_In_Multiple_Myeloma_Pa.pdf\u0026Expires=1732431771\u0026Signature=AZygD5VuGHQeNtb4CstnHs8VDXfw5mmQJLhW4d7gI5toIbjexh8FWfKtymIfE4C1~3QFQzc721SnaKoCrV2NDDnsN7SzjdXiKDegSpl1qhaMKJKFlcpXiPieV6hqvoNjXfO1CX9QYG0vbHgLiz6-wdre12XsGo~NcMu1ySLtvgTcfyBX9GIdzp2fF6qrO7f1Oy9xy-XXUFQi-sDsmFDILIyQftprUMLshBfR0ebQsJhvWemOoJmLP6MCGks4Ezgq4D6TQMD0485P9fLKOow~fzxrQ3fmRHZ2QKgZ5tCP6vsudlZTM4TXN16xiPGTHU~QWa04QR3Vl~Ge-yNPStqRMg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":5500,"name":"Incidence Geometry","url":"https://www.academia.edu/Documents/in/Incidence_Geometry"},{"id":12733,"name":"Rheumatoid Arthritis","url":"https://www.academia.edu/Documents/in/Rheumatoid_Arthritis"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":111110,"name":"Multiple Myeloma","url":"https://www.academia.edu/Documents/in/Multiple_Myeloma"},{"id":220450,"name":"Carpal Tunnel Syndrome","url":"https://www.academia.edu/Documents/in/Carpal_Tunnel_Syndrome"},{"id":254203,"name":"Ambulatory","url":"https://www.academia.edu/Documents/in/Ambulatory"},{"id":711582,"name":"Opioid","url":"https://www.academia.edu/Documents/in/Opioid"},{"id":1451470,"name":"Thalidomide","url":"https://www.academia.edu/Documents/in/Thalidomide"},{"id":2484074,"name":"lenalidomide","url":"https://www.academia.edu/Documents/in/lenalidomide"},{"id":2815854,"name":"Clinical Pharmacology and Therapeutics","url":"https://www.academia.edu/Documents/in/Clinical_Pharmacology_and_Therapeutics"},{"id":3789884,"name":"Pharmacology and pharmaceutical sciences","url":"https://www.academia.edu/Documents/in/Pharmacology_and_pharmaceutical_sciences"}],"urls":[{"id":43558004,"url":"https://doi.org/10.1016/j.clinthera.2015.05.195"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114360"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114360/Identifying_Potential_Drug_Drug_Interactions_In_The_French_Health_Insurance_Databases_Application_In_Multiple_Myeloma_Patients"><img alt="Research paper thumbnail of Identifying Potential Drug–Drug Interactions In The French Health Insurance Databases: Application In Multiple Myeloma Patients" class="work-thumbnail" src="https://attachments.academia-assets.com/116843216/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114360/Identifying_Potential_Drug_Drug_Interactions_In_The_French_Health_Insurance_Databases_Application_In_Multiple_Myeloma_Patients">Identifying Potential Drug–Drug Interactions In The French Health Insurance Databases: Application In Multiple Myeloma Patients</a></div><div class="wp-workCard_item"><span>Clinical Therapeutics</span><span>, Aug 1, 2017</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="159539ce98befd1bf5ff09a2f353c09d" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843216,"asset_id":122114360,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843216/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114360"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114360"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114360; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114360]").text(description); $(".js-view-count[data-work-id=122114360]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114360; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114360']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114360, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "159539ce98befd1bf5ff09a2f353c09d" } } $('.js-work-strip[data-work-id=122114360]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114360,"title":"Identifying Potential Drug–Drug Interactions In The French Health Insurance Databases: Application In Multiple Myeloma Patients","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":1,"month":8,"year":2017,"errors":{}},"publication_name":"Clinical Therapeutics"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114360/Identifying_Potential_Drug_Drug_Interactions_In_The_French_Health_Insurance_Databases_Application_In_Multiple_Myeloma_Patients","translated_internal_url":"","created_at":"2024-07-16T22:20:02.137-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843216,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843216/thumbnails/1.jpg","file_name":"j.clinthera.2017.05.10320240717-1-dydwpy.pdf","download_url":"https://www.academia.edu/attachments/116843216/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Identifying_Potential_Drug_Drug_Interact.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843216/j.clinthera.2017.05.10320240717-1-dydwpy-libre.pdf?1721196831=\u0026response-content-disposition=attachment%3B+filename%3DIdentifying_Potential_Drug_Drug_Interact.pdf\u0026Expires=1732452503\u0026Signature=b9ICrJtGV7gebc3YzWtYOTpkR~0oM2ABneyApGRtLHdLWCwBHCRPXaG9ZlsDg7wriyCPXgkNJ6SqBEmnQaPTx7jwItgKRANt9Dsar1xVHBva~wnFy2X0vDEy9kbq0TAYxnRIrbK4HMyjAIaIKyrLW1qXVi6nEomhbHtwn7DOSMtSgCTAvMHsgMi-HinOGnBsGsaTvxQsZIOJZEBOi1UqtXQ0JLm7H6IGPcUmb12P1lCQwSRHb8hmht63BYtNsoDL5sPWdy-2-fGnBBux6TRG~OsryKp52OWpxRW4D1S2K1Bp0B7bG1gn7WCZYFNxh7D87HklPT2hSAlYhoYShNb7gg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Identifying_Potential_Drug_Drug_Interactions_In_The_French_Health_Insurance_Databases_Application_In_Multiple_Myeloma_Patients","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843216,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843216/thumbnails/1.jpg","file_name":"j.clinthera.2017.05.10320240717-1-dydwpy.pdf","download_url":"https://www.academia.edu/attachments/116843216/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Identifying_Potential_Drug_Drug_Interact.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843216/j.clinthera.2017.05.10320240717-1-dydwpy-libre.pdf?1721196831=\u0026response-content-disposition=attachment%3B+filename%3DIdentifying_Potential_Drug_Drug_Interact.pdf\u0026Expires=1732452503\u0026Signature=b9ICrJtGV7gebc3YzWtYOTpkR~0oM2ABneyApGRtLHdLWCwBHCRPXaG9ZlsDg7wriyCPXgkNJ6SqBEmnQaPTx7jwItgKRANt9Dsar1xVHBva~wnFy2X0vDEy9kbq0TAYxnRIrbK4HMyjAIaIKyrLW1qXVi6nEomhbHtwn7DOSMtSgCTAvMHsgMi-HinOGnBsGsaTvxQsZIOJZEBOi1UqtXQ0JLm7H6IGPcUmb12P1lCQwSRHb8hmht63BYtNsoDL5sPWdy-2-fGnBBux6TRG~OsryKp52OWpxRW4D1S2K1Bp0B7bG1gn7WCZYFNxh7D87HklPT2hSAlYhoYShNb7gg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":42135,"name":"Drug","url":"https://www.academia.edu/Documents/in/Drug"},{"id":111110,"name":"Multiple Myeloma","url":"https://www.academia.edu/Documents/in/Multiple_Myeloma"},{"id":2815854,"name":"Clinical Pharmacology and Therapeutics","url":"https://www.academia.edu/Documents/in/Clinical_Pharmacology_and_Therapeutics"},{"id":3789884,"name":"Pharmacology and pharmaceutical sciences","url":"https://www.academia.edu/Documents/in/Pharmacology_and_pharmaceutical_sciences"}],"urls":[{"id":43558003,"url":"http://www.clinicaltherapeutics.com/article/S0149291817304009/pdf"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114358"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114358/Infections_graves_et_non_graves_chez_les_patients_non_spl%C3%A9nectomis%C3%A9s_trait%C3%A9s_pour_une_thrombop%C3%A9nie_immunologique_persistante_ou_chronique_r%C3%B4les_des_traitements_et_effet_des_vaccins_antipneumococcique_et_antigrippal_%C3%89tude_dans_la_cohorte_FAITH"><img alt="Research paper thumbnail of Infections graves et non graves chez les patients non splénectomisés traités pour une thrombopénie immunologique persistante ou chronique : rôles des traitements et effet des vaccins antipneumococcique et antigrippal. Étude dans la cohorte FAITH" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114358/Infections_graves_et_non_graves_chez_les_patients_non_spl%C3%A9nectomis%C3%A9s_trait%C3%A9s_pour_une_thrombop%C3%A9nie_immunologique_persistante_ou_chronique_r%C3%B4les_des_traitements_et_effet_des_vaccins_antipneumococcique_et_antigrippal_%C3%89tude_dans_la_cohorte_FAITH">Infections graves et non graves chez les patients non splénectomisés traités pour une thrombopénie immunologique persistante ou chronique : rôles des traitements et effet des vaccins antipneumococcique et antigrippal. Étude dans la cohorte FAITH</a></div><div class="wp-workCard_item"><span>Revue de Médecine Interne</span><span>, Dec 1, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Introduction Les facteurs de risque d’infection chez les patients atteints de thrombopenie immuno...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Introduction Les facteurs de risque d’infection chez les patients atteints de thrombopenie immunologique (TI) depuis l’ere du rituximab sont mal connus, tout comme l’effet reel des vaccins antipneumococcique et antigrippal. L’objectif de cette etude etait d’evaluer les facteurs de risque d’infections graves (necessitant une hospitalisation) et non graves chez les patients adultes non splenectomises traites pour une TI persistante ou chronique (durant plus de 3 mois) et l’eventuel effet protecteur des vaccins antipneumococcique et antigrippal en vie reelle. Patients et methodes La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Resultats La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Conclusion Les infections graves sont essentiellement pulmonaires dans la TI. Une maladie pulmonaire chronique, l’exposition aux corticoides et au rituximab etaient les principaux facteurs de risque d’infection graves et non graves, alors que les vaccinations antipneumococcique et antigrippale etaient protectrices.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114358"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114358"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114358; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114358]").text(description); $(".js-view-count[data-work-id=122114358]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114358; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114358']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114358, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114358]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114358,"title":"Infections graves et non graves chez les patients non splénectomisés traités pour une thrombopénie immunologique persistante ou chronique : rôles des traitements et effet des vaccins antipneumococcique et antigrippal. Étude dans la cohorte FAITH","translated_title":"","metadata":{"abstract":"Introduction Les facteurs de risque d’infection chez les patients atteints de thrombopenie immunologique (TI) depuis l’ere du rituximab sont mal connus, tout comme l’effet reel des vaccins antipneumococcique et antigrippal. L’objectif de cette etude etait d’evaluer les facteurs de risque d’infections graves (necessitant une hospitalisation) et non graves chez les patients adultes non splenectomises traites pour une TI persistante ou chronique (durant plus de 3 mois) et l’eventuel effet protecteur des vaccins antipneumococcique et antigrippal en vie reelle. Patients et methodes La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Resultats La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Conclusion Les infections graves sont essentiellement pulmonaires dans la TI. Une maladie pulmonaire chronique, l’exposition aux corticoides et au rituximab etaient les principaux facteurs de risque d’infection graves et non graves, alors que les vaccinations antipneumococcique et antigrippale etaient protectrices.","publisher":"Elsevier BV","publication_date":{"day":1,"month":12,"year":2015,"errors":{}},"publication_name":"Revue de Médecine Interne"},"translated_abstract":"Introduction Les facteurs de risque d’infection chez les patients atteints de thrombopenie immunologique (TI) depuis l’ere du rituximab sont mal connus, tout comme l’effet reel des vaccins antipneumococcique et antigrippal. L’objectif de cette etude etait d’evaluer les facteurs de risque d’infections graves (necessitant une hospitalisation) et non graves chez les patients adultes non splenectomises traites pour une TI persistante ou chronique (durant plus de 3 mois) et l’eventuel effet protecteur des vaccins antipneumococcique et antigrippal en vie reelle. Patients et methodes La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Resultats La population d’etude etait l’ensemble des patients entres dans la cohorte French Adult Immune Thrombocytopenia: a pHarmacological study (FAITH) entre le 1/7/2009 et le 31/6/2012. La cohorte FAITH est la cohorte des patients adultes incidents atteints de TI et traites de facon persistante (≥ 3 mois), bâtie dans le Systeme national d’information inter-regimes de l’Assurance Maladie (no ENCePP 4574). Pour les infections graves, le critere de jugement etait la survenue d’hospitalisation pour infection (code en diagnostic principal). Pour les infections non graves, le critere de jugement etait la delivrance d’antibiotiques en ville. Des modeles de Cox ont ete realises. La date de debut de suivi etait la date de premiere exposition a un traitement de la TI (date d’entree dans la cohorte FAITH). Le suivi etait censure lors du premier des evenements suivants : critere de jugement, splenectomie, deces, fin de suivi (31 decembre 2012). Les variables introduites dans le modele etaient : l’âge, le genre, la presence de saignement muqueux au diagnostic, le diabete, les maladies pulmonaires, cardiaques et renales chroniques et l’exposition aux traitements de la TI et aux vaccins, mesuree de facon dependante du temps. L’exposition au rituximab etait definie par les 6 mois suivant une perfusion et l’exposition aux vaccins pendant cette periode etait consideree comme nulle. Conclusion Les infections graves sont essentiellement pulmonaires dans la TI. Une maladie pulmonaire chronique, l’exposition aux corticoides et au rituximab etaient les principaux facteurs de risque d’infection graves et non graves, alors que les vaccinations antipneumococcique et antigrippale etaient protectrices.","internal_url":"https://www.academia.edu/122114358/Infections_graves_et_non_graves_chez_les_patients_non_spl%C3%A9nectomis%C3%A9s_trait%C3%A9s_pour_une_thrombop%C3%A9nie_immunologique_persistante_ou_chronique_r%C3%B4les_des_traitements_et_effet_des_vaccins_antipneumococcique_et_antigrippal_%C3%89tude_dans_la_cohorte_FAITH","translated_internal_url":"","created_at":"2024-07-16T22:20:01.434-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Infections_graves_et_non_graves_chez_les_patients_non_splénectomisés_traités_pour_une_thrombopénie_immunologique_persistante_ou_chronique_rôles_des_traitements_et_effet_des_vaccins_antipneumococcique_et_antigrippal_Étude_dans_la_cohorte_FAITH","translated_slug":"","page_count":null,"language":"fr","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":339107,"name":"Gynecology","url":"https://www.academia.edu/Documents/in/Gynecology"}],"urls":[{"id":43558002,"url":"https://doi.org/10.1016/j.revmed.2015.10.296"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114357"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114357/Analgesic_Drug_Prescription_After_Carpal_Tunnel_Surgery"><img alt="Research paper thumbnail of Analgesic Drug Prescription After Carpal Tunnel Surgery" class="work-thumbnail" src="https://attachments.academia-assets.com/116843220/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114357/Analgesic_Drug_Prescription_After_Carpal_Tunnel_Surgery">Analgesic Drug Prescription After Carpal Tunnel Surgery</a></div><div class="wp-workCard_item"><span>Regional Anesthesia and Pain Medicine</span><span>, 2018</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="7fce454dba613194e55c6eb592cfdb7b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843220,"asset_id":122114357,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843220/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114357"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114357"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114357; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114357]").text(description); $(".js-view-count[data-work-id=122114357]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114357; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114357']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114357, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "7fce454dba613194e55c6eb592cfdb7b" } } $('.js-work-strip[data-work-id=122114357]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114357,"title":"Analgesic Drug Prescription After Carpal Tunnel Surgery","translated_title":"","metadata":{"publisher":"Lippincott Williams \u0026 Wilkins","publication_date":{"day":null,"month":null,"year":2018,"errors":{}},"publication_name":"Regional Anesthesia and Pain Medicine"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114357/Analgesic_Drug_Prescription_After_Carpal_Tunnel_Surgery","translated_internal_url":"","created_at":"2024-07-16T22:20:00.949-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843220,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843220/thumbnails/1.jpg","file_name":"AAP.000000000000068520240717-1-8h9i04.pdf","download_url":"https://www.academia.edu/attachments/116843220/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Analgesic_Drug_Prescription_After_Carpal.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843220/AAP.000000000000068520240717-1-8h9i04-libre.pdf?1721196833=\u0026response-content-disposition=attachment%3B+filename%3DAnalgesic_Drug_Prescription_After_Carpal.pdf\u0026Expires=1732431771\u0026Signature=T6w00tStV-uX~V4sQoLItvuLaMD1o73QGX3TbK1lVKaY384hJJVTUuICif4puP7gOFNfzF5Ebxo0w0iEmLt6XoxhtmE7Q2g1bLedUeywPJw8HWITP7zOUOjwWRuEge05RWSbuSlaxsipEltezUwIiXWp6QYJJHECAx7bvLXwVSUXaF04Mg8hZ5gDoVgtZz3HTwR~CihAJZYL7DAcnmaABTdha6EOFKwO5eo45rJeOweZfVeod0RODxM~rEgJZi9KsTAPsLbuKHzA7zkXvLJerBYjudB0zigjX0PK32P5o-PRBw~9rc25IWhOa0zosIQg1KK0ex7wsonpLQE4dZiSWw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Analgesic_Drug_Prescription_After_Carpal_Tunnel_Surgery","translated_slug":"","page_count":6,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843220,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843220/thumbnails/1.jpg","file_name":"AAP.000000000000068520240717-1-8h9i04.pdf","download_url":"https://www.academia.edu/attachments/116843220/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Analgesic_Drug_Prescription_After_Carpal.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843220/AAP.000000000000068520240717-1-8h9i04-libre.pdf?1721196833=\u0026response-content-disposition=attachment%3B+filename%3DAnalgesic_Drug_Prescription_After_Carpal.pdf\u0026Expires=1732431771\u0026Signature=T6w00tStV-uX~V4sQoLItvuLaMD1o73QGX3TbK1lVKaY384hJJVTUuICif4puP7gOFNfzF5Ebxo0w0iEmLt6XoxhtmE7Q2g1bLedUeywPJw8HWITP7zOUOjwWRuEge05RWSbuSlaxsipEltezUwIiXWp6QYJJHECAx7bvLXwVSUXaF04Mg8hZ5gDoVgtZz3HTwR~CihAJZYL7DAcnmaABTdha6EOFKwO5eo45rJeOweZfVeod0RODxM~rEgJZi9KsTAPsLbuKHzA7zkXvLJerBYjudB0zigjX0PK32P5o-PRBw~9rc25IWhOa0zosIQg1KK0ex7wsonpLQE4dZiSWw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":27336,"name":"France","url":"https://www.academia.edu/Documents/in/France"},{"id":41482,"name":"Multivariate Analysis","url":"https://www.academia.edu/Documents/in/Multivariate_Analysis"},{"id":64568,"name":"Humans","url":"https://www.academia.edu/Documents/in/Humans"},{"id":83200,"name":"Neuropathic pain","url":"https://www.academia.edu/Documents/in/Neuropathic_pain"},{"id":98925,"name":"Female","url":"https://www.academia.edu/Documents/in/Female"},{"id":111545,"name":"Male","url":"https://www.academia.edu/Documents/in/Male"},{"id":129739,"name":"Anesthesia","url":"https://www.academia.edu/Documents/in/Anesthesia"},{"id":220450,"name":"Carpal Tunnel Syndrome","url":"https://www.academia.edu/Documents/in/Carpal_Tunnel_Syndrome"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":289271,"name":"Aged","url":"https://www.academia.edu/Documents/in/Aged"},{"id":295155,"name":"Middle Aged","url":"https://www.academia.edu/Documents/in/Middle_Aged"},{"id":382075,"name":"Adult","url":"https://www.academia.edu/Documents/in/Adult"},{"id":437772,"name":"Odds ratio","url":"https://www.academia.edu/Documents/in/Odds_ratio"},{"id":584601,"name":"Chi Square Distribution","url":"https://www.academia.edu/Documents/in/Chi_Square_Distribution"},{"id":820245,"name":"Analgesic","url":"https://www.academia.edu/Documents/in/Analgesic"},{"id":1294607,"name":"Logistic Models","url":"https://www.academia.edu/Documents/in/Logistic_Models"},{"id":3809682,"name":"Drug utilization review","url":"https://www.academia.edu/Documents/in/Drug_utilization_review"},{"id":4053561,"name":"Drug prescriptions","url":"https://www.academia.edu/Documents/in/Drug_prescriptions"},{"id":4136525,"name":"Medical prescription","url":"https://www.academia.edu/Documents/in/Medical_prescription"}],"urls":[{"id":43558001,"url":"https://doi.org/10.1097/aap.0000000000000685"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114356"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114356/Cancer_Risk_of_Anti_TNF_%CE%B1_at_Recommended_Doses_in_Adult_Rheumatoid_Arthritis_A_Meta_Analysis_with_Intention_to_Treat_and_per_Protocol_Analyses"><img alt="Research paper thumbnail of Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses" class="work-thumbnail" src="https://attachments.academia-assets.com/116843176/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114356/Cancer_Risk_of_Anti_TNF_%CE%B1_at_Recommended_Doses_in_Adult_Rheumatoid_Arthritis_A_Meta_Analysis_with_Intention_to_Treat_and_per_Protocol_Analyses">Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses</a></div><div class="wp-workCard_item"><span>PLOS ONE</span><span>, Nov 14, 2012</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="993878b028b2539d06a7de71f0ddcf61" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843176,"asset_id":122114356,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843176/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114356"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114356"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114356; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114356]").text(description); $(".js-view-count[data-work-id=122114356]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114356; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114356']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114356, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "993878b028b2539d06a7de71f0ddcf61" } } $('.js-work-strip[data-work-id=122114356]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114356,"title":"Cancer Risk of Anti-TNF-α at Recommended Doses in Adult Rheumatoid Arthritis: A Meta-Analysis with Intention to Treat and per Protocol Analyses","translated_title":"","metadata":{"publisher":"Public Library of Science","publication_date":{"day":14,"month":11,"year":2012,"errors":{}},"publication_name":"PLOS ONE"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114356/Cancer_Risk_of_Anti_TNF_%CE%B1_at_Recommended_Doses_in_Adult_Rheumatoid_Arthritis_A_Meta_Analysis_with_Intention_to_Treat_and_per_Protocol_Analyses","translated_internal_url":"","created_at":"2024-07-16T22:20:00.663-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843176,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843176/thumbnails/1.jpg","file_name":"file.pdf","download_url":"https://www.academia.edu/attachments/116843176/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Cancer_Risk_of_Anti_TNF__at_Recommended.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843176/file-libre.pdf?1721196845=\u0026response-content-disposition=attachment%3B+filename%3DCancer_Risk_of_Anti_TNF__at_Recommended.pdf\u0026Expires=1732431771\u0026Signature=S0bKfBv4ytcnIRFVi7IEp3~IJPoYCoyb8HCnxkgNfb8oI0SuBvryaKiwxcQF57eNUz2q~O~aMEL1NzKINTW8YCptrpEZDnK4phj4dc4rK6ExMvD6vmyVr~RBeKam2sZMQql8zZZSgSOeIvETejVoubRaaqse3QHngHDDcaTxIfv1EvTaV3gmR5nECVLJKg5SHepIaI-MxsOVrcCdzkyrr84AzhjoitOQHcU054z5ZT8j83eytmNoEdSlAltXB8TeQy2D9uOO3FhyrQCiTE2r~dkLTBmYzVx54r8oOIwWpsfr1Hab3OtWdUazhBQqhGSfMXsPYIuPk2ij74uGD~00tw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Cancer_Risk_of_Anti_TNF_α_at_Recommended_Doses_in_Adult_Rheumatoid_Arthritis_A_Meta_Analysis_with_Intention_to_Treat_and_per_Protocol_Analyses","translated_slug":"","page_count":7,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843176,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843176/thumbnails/1.jpg","file_name":"file.pdf","download_url":"https://www.academia.edu/attachments/116843176/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Cancer_Risk_of_Anti_TNF__at_Recommended.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843176/file-libre.pdf?1721196845=\u0026response-content-disposition=attachment%3B+filename%3DCancer_Risk_of_Anti_TNF__at_Recommended.pdf\u0026Expires=1732431771\u0026Signature=S0bKfBv4ytcnIRFVi7IEp3~IJPoYCoyb8HCnxkgNfb8oI0SuBvryaKiwxcQF57eNUz2q~O~aMEL1NzKINTW8YCptrpEZDnK4phj4dc4rK6ExMvD6vmyVr~RBeKam2sZMQql8zZZSgSOeIvETejVoubRaaqse3QHngHDDcaTxIfv1EvTaV3gmR5nECVLJKg5SHepIaI-MxsOVrcCdzkyrr84AzhjoitOQHcU054z5ZT8j83eytmNoEdSlAltXB8TeQy2D9uOO3FhyrQCiTE2r~dkLTBmYzVx54r8oOIwWpsfr1Hab3OtWdUazhBQqhGSfMXsPYIuPk2ij74uGD~00tw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"},{"id":116843175,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843175/thumbnails/1.jpg","file_name":"file.pdf","download_url":"https://www.academia.edu/attachments/116843175/download_file","bulk_download_file_name":"Cancer_Risk_of_Anti_TNF__at_Recommended.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843175/file-libre.pdf?1721196847=\u0026response-content-disposition=attachment%3B+filename%3DCancer_Risk_of_Anti_TNF__at_Recommended.pdf\u0026Expires=1732431771\u0026Signature=JuXjka9B4WtYW~jVR5Vv0psBq22EHBMqc2k4G8nnZ2ijWzNQ6fz64DOnCxkHNfDvJuRp6uPRvD6aZxWimInPToTf6AsJ7~EI7fiHN3RTAzngn1tnJCORgKaDNEvrJnD-hvn-kWy25UvZy7fgYxinvtQEVo0Df8OEe80R~V66KcXba0KXggV7z2eFWKWX9uzvuss2MYOyt44lrqZrIYZH8GHWSItW-jkhAWStUjKbZ2Bnq0OemPSHNhxMESoDb7teRfCMvEhs9Xx0rmFHvk4TcdI6cgndICv5qqXI7PCSIqH1SW80247YniAiz0FM5a9fEmkiAizo4DxgD0WJEV2ZXw__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":140,"name":"Pharmacology","url":"https://www.academia.edu/Documents/in/Pharmacology"},{"id":5398,"name":"Biotechnology","url":"https://www.academia.edu/Documents/in/Biotechnology"},{"id":6021,"name":"Cancer","url":"https://www.academia.edu/Documents/in/Cancer"},{"id":8207,"name":"Risk","url":"https://www.academia.edu/Documents/in/Risk"},{"id":9846,"name":"Ecology","url":"https://www.academia.edu/Documents/in/Ecology"},{"id":12733,"name":"Rheumatoid Arthritis","url":"https://www.academia.edu/Documents/in/Rheumatoid_Arthritis"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":28235,"name":"Multidisciplinary","url":"https://www.academia.edu/Documents/in/Multidisciplinary"},{"id":64568,"name":"Humans","url":"https://www.academia.edu/Documents/in/Humans"},{"id":65390,"name":"Internal Medicine","url":"https://www.academia.edu/Documents/in/Internal_Medicine"},{"id":218206,"name":"Meta Analysis","url":"https://www.academia.edu/Documents/in/Meta_Analysis"},{"id":220780,"name":"PLoS one","url":"https://www.academia.edu/Documents/in/PLoS_one"},{"id":469018,"name":"Neoplasms","url":"https://www.academia.edu/Documents/in/Neoplasms"},{"id":969687,"name":"Rheumatoid","url":"https://www.academia.edu/Documents/in/Rheumatoid"},{"id":1009476,"name":"Analyses","url":"https://www.academia.edu/Documents/in/Analyses"},{"id":1946240,"name":"Adalimumab","url":"https://www.academia.edu/Documents/in/Adalimumab"},{"id":2189033,"name":"Etanercept","url":"https://www.academia.edu/Documents/in/Etanercept"},{"id":2844327,"name":"Infliximab","url":"https://www.academia.edu/Documents/in/Infliximab"},{"id":2956448,"name":"Doses","url":"https://www.academia.edu/Documents/in/Doses"},{"id":3495461,"name":"recommended","url":"https://www.academia.edu/Documents/in/recommended"}],"urls":[{"id":43558000,"url":"https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0048991\u0026type=printable"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114355"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114355/Potential_inappropriate_use_of_strong_opioid_analgesics_in_cancer_outpatients_during_the_last_year_of_life_in_France_and_associated_factors"><img alt="Research paper thumbnail of Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors" class="work-thumbnail" src="https://attachments.academia-assets.com/116843215/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114355/Potential_inappropriate_use_of_strong_opioid_analgesics_in_cancer_outpatients_during_the_last_year_of_life_in_France_and_associated_factors">Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors</a></div><div class="wp-workCard_item"><span>British Journal of Clinical Pharmacology</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="2a83ca148a57d43a50aa44c8bee5a892" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843215,"asset_id":122114355,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843215/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114355"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114355"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114355; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114355]").text(description); $(".js-view-count[data-work-id=122114355]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114355; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114355']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114355, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "2a83ca148a57d43a50aa44c8bee5a892" } } $('.js-work-strip[data-work-id=122114355]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114355,"title":"Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors","translated_title":"","metadata":{"publisher":"Wiley","publication_name":"British Journal of Clinical Pharmacology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114355/Potential_inappropriate_use_of_strong_opioid_analgesics_in_cancer_outpatients_during_the_last_year_of_life_in_France_and_associated_factors","translated_internal_url":"","created_at":"2024-07-16T22:20:00.057-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843215,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843215/thumbnails/1.jpg","file_name":"au.162256051.pdf","download_url":"https://www.academia.edu/attachments/116843215/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Potential_inappropriate_use_of_strong_op.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843215/au.162256051-libre.pdf?1721196831=\u0026response-content-disposition=attachment%3B+filename%3DPotential_inappropriate_use_of_strong_op.pdf\u0026Expires=1732431771\u0026Signature=Z5U7fROaC7koE1Kzt2NGzJUm3vCZErAOSS8PZ004oceCRmJP7j~d9Bs2yGl0yr2j2fhWkM6wC~axufJiI~4EPtQeh9IfOFu-BTdo3x7PF-1nAwt4KFQcMezNCLItigZPaStlxZJviU3VKvPwtS9SRjO0lpnMYAjQChh9a7E4H3gGUFYovjrW7Cn-hyWqTTKXSCnYOwiD~wXRWkUbN3J0UVLD1C6ybIwbvr~9BA4YYXnH7ytM46ylv15OokgXvKKVFGJOcPurjE~DBwyIuJVRQidJWM-w5QpyX-bqGTx1N4PwnN-~LrMpI3mPk84y6P-y1iwMVce81LokcpAMg9uZ6w__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Potential_inappropriate_use_of_strong_opioid_analgesics_in_cancer_outpatients_during_the_last_year_of_life_in_France_and_associated_factors","translated_slug":"","page_count":1,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843215,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843215/thumbnails/1.jpg","file_name":"au.162256051.pdf","download_url":"https://www.academia.edu/attachments/116843215/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Potential_inappropriate_use_of_strong_op.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843215/au.162256051-libre.pdf?1721196831=\u0026response-content-disposition=attachment%3B+filename%3DPotential_inappropriate_use_of_strong_op.pdf\u0026Expires=1732431771\u0026Signature=Z5U7fROaC7koE1Kzt2NGzJUm3vCZErAOSS8PZ004oceCRmJP7j~d9Bs2yGl0yr2j2fhWkM6wC~axufJiI~4EPtQeh9IfOFu-BTdo3x7PF-1nAwt4KFQcMezNCLItigZPaStlxZJviU3VKvPwtS9SRjO0lpnMYAjQChh9a7E4H3gGUFYovjrW7Cn-hyWqTTKXSCnYOwiD~wXRWkUbN3J0UVLD1C6ybIwbvr~9BA4YYXnH7ytM46ylv15OokgXvKKVFGJOcPurjE~DBwyIuJVRQidJWM-w5QpyX-bqGTx1N4PwnN-~LrMpI3mPk84y6P-y1iwMVce81LokcpAMg9uZ6w__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":72845,"name":"Cancer pain","url":"https://www.academia.edu/Documents/in/Cancer_pain"},{"id":437772,"name":"Odds ratio","url":"https://www.academia.edu/Documents/in/Odds_ratio"},{"id":711582,"name":"Opioid","url":"https://www.academia.edu/Documents/in/Opioid"},{"id":820245,"name":"Analgesic","url":"https://www.academia.edu/Documents/in/Analgesic"},{"id":1223924,"name":"Fentanyl","url":"https://www.academia.edu/Documents/in/Fentanyl"},{"id":1587858,"name":"Confidence Interval","url":"https://www.academia.edu/Documents/in/Confidence_Interval"},{"id":1619700,"name":"Hydrocodone","url":"https://www.academia.edu/Documents/in/Hydrocodone"},{"id":3789884,"name":"Pharmacology and pharmaceutical sciences","url":"https://www.academia.edu/Documents/in/Pharmacology_and_pharmaceutical_sciences"},{"id":4136525,"name":"Medical prescription","url":"https://www.academia.edu/Documents/in/Medical_prescription"}],"urls":[{"id":43557999,"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/bcp.15011"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114354"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114354/Cardiovascular_risk_factors_in_immune_thrombocytopenia_adults_Results_from_the_CARMEN_registry"><img alt="Research paper thumbnail of Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry" class="work-thumbnail" src="https://attachments.academia-assets.com/116843214/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114354/Cardiovascular_risk_factors_in_immune_thrombocytopenia_adults_Results_from_the_CARMEN_registry">Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry</a></div><div class="wp-workCard_item"><span>American Journal of Hematology</span><span>, 2018</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="4f9ee73ba0ccd4b09142d9c7fee8a50b" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843214,"asset_id":122114354,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843214/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114354"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114354"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114354; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114354]").text(description); $(".js-view-count[data-work-id=122114354]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114354; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114354']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114354, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "4f9ee73ba0ccd4b09142d9c7fee8a50b" } } $('.js-work-strip[data-work-id=122114354]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114354,"title":"Cardiovascular risk factors in immune thrombocytopenia adults: Results from the CARMEN registry","translated_title":"","metadata":{"publisher":"Wiley","publication_date":{"day":null,"month":null,"year":2018,"errors":{}},"publication_name":"American Journal of Hematology"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114354/Cardiovascular_risk_factors_in_immune_thrombocytopenia_adults_Results_from_the_CARMEN_registry","translated_internal_url":"","created_at":"2024-07-16T22:19:59.479-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843214,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843214/thumbnails/1.jpg","file_name":"ajh.pdf","download_url":"https://www.academia.edu/attachments/116843214/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Cardiovascular_risk_factors_in_immune_th.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843214/ajh-libre.pdf?1721196849=\u0026response-content-disposition=attachment%3B+filename%3DCardiovascular_risk_factors_in_immune_th.pdf\u0026Expires=1732431771\u0026Signature=QlJwMVZWxxbfWrSINrodVx7j4lUdzaz4ZUvyEyokYC1hSMk21ufu4zYluDbI8eBcqo25Cg7GHK-WLx1tIvW1jOW4nSVthF-nnGpK4p~6RiTDCHyBnJ2~7kVhJg69thETeNAeKd5crt9MtdqQ2zQy6eeZopREFJbhiNJ4wSzJFL7xvWacEhFiR3PLLyaHb9AGOQYfKCDssWIeaReE~Y-bteTTE7EWGVZGesN7bqLa0UEot6AQ2yt9ex8kZW22SLIln~f7RfOlxxKqlSi6sUu4ozsTTiTB1vIty2JkmMBKU-D2RQvo6czYf6lszfCdfirGCGlCzqS9KGkcjV33NvjtXg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Cardiovascular_risk_factors_in_immune_thrombocytopenia_adults_Results_from_the_CARMEN_registry","translated_slug":"","page_count":26,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843214,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843214/thumbnails/1.jpg","file_name":"ajh.pdf","download_url":"https://www.academia.edu/attachments/116843214/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Cardiovascular_risk_factors_in_immune_th.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843214/ajh-libre.pdf?1721196849=\u0026response-content-disposition=attachment%3B+filename%3DCardiovascular_risk_factors_in_immune_th.pdf\u0026Expires=1732431771\u0026Signature=QlJwMVZWxxbfWrSINrodVx7j4lUdzaz4ZUvyEyokYC1hSMk21ufu4zYluDbI8eBcqo25Cg7GHK-WLx1tIvW1jOW4nSVthF-nnGpK4p~6RiTDCHyBnJ2~7kVhJg69thETeNAeKd5crt9MtdqQ2zQy6eeZopREFJbhiNJ4wSzJFL7xvWacEhFiR3PLLyaHb9AGOQYfKCDssWIeaReE~Y-bteTTE7EWGVZGesN7bqLa0UEot6AQ2yt9ex8kZW22SLIln~f7RfOlxxKqlSi6sUu4ozsTTiTB1vIty2JkmMBKU-D2RQvo6czYf6lszfCdfirGCGlCzqS9KGkcjV33NvjtXg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":2374856,"name":"Immune thrombocytopenia","url":"https://www.academia.edu/Documents/in/Immune_thrombocytopenia"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":43557998,"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.25127"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114353"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114353/Correspondence_on_Risk_of_systemic_lupus_erythematosus_after_immune_thrombocytopenia_and_autoimmune_haemolytic_anaemia_a_nationwide_French_study_"><img alt="Research paper thumbnail of Correspondence on ‘Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study’" class="work-thumbnail" src="https://attachments.academia-assets.com/116843213/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114353/Correspondence_on_Risk_of_systemic_lupus_erythematosus_after_immune_thrombocytopenia_and_autoimmune_haemolytic_anaemia_a_nationwide_French_study_">Correspondence on ‘Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study’</a></div><div class="wp-workCard_item"><span>Annals of the Rheumatic Diseases</span><span>, 2020</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="362af78143375fe7cdd82d74f36d4bca" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843213,"asset_id":122114353,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843213/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114353"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114353"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114353; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114353]").text(description); $(".js-view-count[data-work-id=122114353]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114353; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114353']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114353, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "362af78143375fe7cdd82d74f36d4bca" } } $('.js-work-strip[data-work-id=122114353]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114353,"title":"Correspondence on ‘Risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia: a nationwide French study’","translated_title":"","metadata":{"publisher":"BMJ","publication_date":{"day":null,"month":null,"year":2020,"errors":{}},"publication_name":"Annals of the Rheumatic Diseases"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114353/Correspondence_on_Risk_of_systemic_lupus_erythematosus_after_immune_thrombocytopenia_and_autoimmune_haemolytic_anaemia_a_nationwide_French_study_","translated_internal_url":"","created_at":"2024-07-16T22:19:58.982-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843213,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843213/thumbnails/1.jpg","file_name":"annrheumdis-2020-219470.full.pdf","download_url":"https://www.academia.edu/attachments/116843213/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Correspondence_on_Risk_of_systemic_lupus.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843213/annrheumdis-2020-219470.full-libre.pdf?1721196834=\u0026response-content-disposition=attachment%3B+filename%3DCorrespondence_on_Risk_of_systemic_lupus.pdf\u0026Expires=1732431771\u0026Signature=EoIedLbixZwWtcYT7Da83REXdz96wBqLq9MzZsEY80e181c3n5yY2eqtcN5fIE5aD2IKhpnfQtclAIoiJtOzwsQwQ0MpVaq2NnrlvpJiHK5Jr0og7cDhiO8ODl0f5ECXDsUPbTPyKvVkw95SD-ZZlxqTc~01dRwqlulzHhLnhMoCTowxZFvdoKWlKsvOI7wNUYlKRdM0X2vdRlY0JToHEgBfA8swJ3~IwVxtfFA8H3r8HY-Cx~r~CG8MkV1f~Yj2Ji5aDlBYk5PFcpAY8OX03i0Ybs69uS9hFcNCE4JZYEuinpBykj3scBS0lBiA-903hopljNLBu~CwTPi6XLRGZA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Correspondence_on_Risk_of_systemic_lupus_erythematosus_after_immune_thrombocytopenia_and_autoimmune_haemolytic_anaemia_a_nationwide_French_study_","translated_slug":"","page_count":2,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843213,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843213/thumbnails/1.jpg","file_name":"annrheumdis-2020-219470.full.pdf","download_url":"https://www.academia.edu/attachments/116843213/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Correspondence_on_Risk_of_systemic_lupus.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843213/annrheumdis-2020-219470.full-libre.pdf?1721196834=\u0026response-content-disposition=attachment%3B+filename%3DCorrespondence_on_Risk_of_systemic_lupus.pdf\u0026Expires=1732431771\u0026Signature=EoIedLbixZwWtcYT7Da83REXdz96wBqLq9MzZsEY80e181c3n5yY2eqtcN5fIE5aD2IKhpnfQtclAIoiJtOzwsQwQ0MpVaq2NnrlvpJiHK5Jr0og7cDhiO8ODl0f5ECXDsUPbTPyKvVkw95SD-ZZlxqTc~01dRwqlulzHhLnhMoCTowxZFvdoKWlKsvOI7wNUYlKRdM0X2vdRlY0JToHEgBfA8swJ3~IwVxtfFA8H3r8HY-Cx~r~CG8MkV1f~Yj2Ji5aDlBYk5PFcpAY8OX03i0Ybs69uS9hFcNCE4JZYEuinpBykj3scBS0lBiA-903hopljNLBu~CwTPi6XLRGZA__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":1290,"name":"Immunology","url":"https://www.academia.edu/Documents/in/Immunology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":64336,"name":"Population","url":"https://www.academia.edu/Documents/in/Population"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":410370,"name":"Public health systems and services research","url":"https://www.academia.edu/Documents/in/Public_health_systems_and_services_research-1"},{"id":2374856,"name":"Immune thrombocytopenia","url":"https://www.academia.edu/Documents/in/Immune_thrombocytopenia"}],"urls":[{"id":43557997,"url":"https://syndication.highwire.org/content/doi/10.1136/annrheumdis-2020-219470"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114352"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114352/Eltrombopag_in_adult_patients_with_immune_thrombocytopenia_in_the_real_world_in_France_including_off_label_use_before_6_months_of_disease_duration_The_multicenter_prospective_ELEXTRA_study"><img alt="Research paper thumbnail of Eltrombopag in adult patients with immune thrombocytopenia in the real‐world in France, including off‐label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114352/Eltrombopag_in_adult_patients_with_immune_thrombocytopenia_in_the_real_world_in_France_including_off_label_use_before_6_months_of_disease_duration_The_multicenter_prospective_ELEXTRA_study">Eltrombopag in adult patients with immune thrombocytopenia in the real‐world in France, including off‐label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study</a></div><div class="wp-workCard_item"><span>American Journal of Hematology</span><span>, 2021</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">kocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review ...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">kocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019; 3(11):1729-1737. 6. Shahneh F, Grill A, Klein M, et al. Specialized regulatory T cells control venous blood clot resolution through SPARC. Blood. 2021;137(11): 1517-1526. 7. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One. 2012;7(9):e45427. 8. Gadomska G, Stankowska K, Boinska J, Bartoszewska-Kubiak A, Haus O, Ro s c D. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Blood Coagul Fibrinolysis. 2016;27(7): 817-821. 9. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thrombosis Haemostasis. 2006;4(12):2593-2598.</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114352"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114352"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114352; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114352]").text(description); $(".js-view-count[data-work-id=122114352]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114352; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114352']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114352, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114352]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114352,"title":"Eltrombopag in adult patients with immune thrombocytopenia in the real‐world in France, including off‐label use before 6 months of disease duration: The multicenter, prospective ELEXTRA study","translated_title":"","metadata":{"abstract":"kocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019; 3(11):1729-1737. 6. Shahneh F, Grill A, Klein M, et al. Specialized regulatory T cells control venous blood clot resolution through SPARC. Blood. 2021;137(11): 1517-1526. 7. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One. 2012;7(9):e45427. 8. Gadomska G, Stankowska K, Boinska J, Bartoszewska-Kubiak A, Haus O, Ro s c D. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Blood Coagul Fibrinolysis. 2016;27(7): 817-821. 9. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thrombosis Haemostasis. 2006;4(12):2593-2598.","publisher":"Wiley","publication_date":{"day":null,"month":null,"year":2021,"errors":{}},"publication_name":"American Journal of Hematology"},"translated_abstract":"kocytosis and thrombosis in essential thrombocythemia and polycythemia vera: a systematic review and meta-analysis. Blood Adv. 2019; 3(11):1729-1737. 6. Shahneh F, Grill A, Klein M, et al. Specialized regulatory T cells control venous blood clot resolution through SPARC. Blood. 2021;137(11): 1517-1526. 7. Kambas K, Mitroulis I, Apostolidou E, et al. Autophagy mediates the delivery of thrombogenic tissue factor to neutrophil extracellular traps in human sepsis. PLoS One. 2012;7(9):e45427. 8. Gadomska G, Stankowska K, Boinska J, Bartoszewska-Kubiak A, Haus O, Ro s c D. Activation of the tissue factor-dependent extrinsic pathway and its relation to JAK2 V617F mutation status in patients with essential thrombocythemia. Blood Coagul Fibrinolysis. 2016;27(7): 817-821. 9. Maugeri N, Giordano G, Petrilli MP, et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leukocytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thrombosis Haemostasis. 2006;4(12):2593-2598.","internal_url":"https://www.academia.edu/122114352/Eltrombopag_in_adult_patients_with_immune_thrombocytopenia_in_the_real_world_in_France_including_off_label_use_before_6_months_of_disease_duration_The_multicenter_prospective_ELEXTRA_study","translated_internal_url":"","created_at":"2024-07-16T22:19:58.456-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Eltrombopag_in_adult_patients_with_immune_thrombocytopenia_in_the_real_world_in_France_including_off_label_use_before_6_months_of_disease_duration_The_multicenter_prospective_ELEXTRA_study","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":99773,"name":"Disease","url":"https://www.academia.edu/Documents/in/Disease"},{"id":1423064,"name":"Multicenter Study","url":"https://www.academia.edu/Documents/in/Multicenter_Study"},{"id":2374856,"name":"Immune thrombocytopenia","url":"https://www.academia.edu/Documents/in/Immune_thrombocytopenia"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"}],"urls":[{"id":43557996,"url":"https://onlinelibrary.wiley.com/doi/pdf/10.1002/ajh.26404"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114351"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114351/Vaccination_during_the_First_Diagnosis_of_Multiple_Myeloma_A_Cohort_Study_of_the_French_National_Health_Insurance_Database"><img alt="Research paper thumbnail of Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database" class="work-thumbnail" src="https://attachments.academia-assets.com/116843172/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114351/Vaccination_during_the_First_Diagnosis_of_Multiple_Myeloma_A_Cohort_Study_of_the_French_National_Health_Insurance_Database">Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database</a></div><div class="wp-workCard_item"><span>Vaccines</span><span>, 2020</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Purpose: Infections are frequent and often result in serious complications in patients with multi...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Purpose: Infections are frequent and often result in serious complications in patients with multiple myeloma (MM). Prophylactic vaccination is recommended for influenza virus, Streptococcus pneumoniae (SP), and Hemophilus influenzaeb (Hib). The aims of this study were to measure the vaccination rates within 24 months after the diagnosis of multiple myeloma and to identify factors associated with vaccine use. Methods: MM patients were selected through the French national health insurance database from 1 January 2010 to 31 December 2015. Patients with a previous history of MM were excluded. Results: Vaccination rates against influenza, SP, and Hib among 22,831 newly diagnosed MM patients were, respectively, 28.5%, 10.3%, and 1.4%. Only 0.7% received all three vaccines. Factors associated with vaccination were young age, male gender, an absence of comorbidity, a history of higher medication and vaccine consumption, Herpes simplex virus (HSV), Varicella zoster virus (VZV), and the use o...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="e6cfe67cf48d3f2616170fd44a209ef8" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843172,"asset_id":122114351,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843172/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114351"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114351"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114351; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114351]").text(description); $(".js-view-count[data-work-id=122114351]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114351; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114351']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114351, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "e6cfe67cf48d3f2616170fd44a209ef8" } } $('.js-work-strip[data-work-id=122114351]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114351,"title":"Vaccination during the First Diagnosis of Multiple Myeloma: A Cohort Study of the French National Health Insurance Database","translated_title":"","metadata":{"abstract":"Purpose: Infections are frequent and often result in serious complications in patients with multiple myeloma (MM). Prophylactic vaccination is recommended for influenza virus, Streptococcus pneumoniae (SP), and Hemophilus influenzaeb (Hib). The aims of this study were to measure the vaccination rates within 24 months after the diagnosis of multiple myeloma and to identify factors associated with vaccine use. Methods: MM patients were selected through the French national health insurance database from 1 January 2010 to 31 December 2015. Patients with a previous history of MM were excluded. Results: Vaccination rates against influenza, SP, and Hib among 22,831 newly diagnosed MM patients were, respectively, 28.5%, 10.3%, and 1.4%. Only 0.7% received all three vaccines. Factors associated with vaccination were young age, male gender, an absence of comorbidity, a history of higher medication and vaccine consumption, Herpes simplex virus (HSV), Varicella zoster virus (VZV), and the use o...","publisher":"MDPI AG","publication_date":{"day":null,"month":null,"year":2020,"errors":{}},"publication_name":"Vaccines"},"translated_abstract":"Purpose: Infections are frequent and often result in serious complications in patients with multiple myeloma (MM). Prophylactic vaccination is recommended for influenza virus, Streptococcus pneumoniae (SP), and Hemophilus influenzaeb (Hib). The aims of this study were to measure the vaccination rates within 24 months after the diagnosis of multiple myeloma and to identify factors associated with vaccine use. Methods: MM patients were selected through the French national health insurance database from 1 January 2010 to 31 December 2015. Patients with a previous history of MM were excluded. Results: Vaccination rates against influenza, SP, and Hib among 22,831 newly diagnosed MM patients were, respectively, 28.5%, 10.3%, and 1.4%. Only 0.7% received all three vaccines. Factors associated with vaccination were young age, male gender, an absence of comorbidity, a history of higher medication and vaccine consumption, Herpes simplex virus (HSV), Varicella zoster virus (VZV), and the use o...","internal_url":"https://www.academia.edu/122114351/Vaccination_during_the_First_Diagnosis_of_Multiple_Myeloma_A_Cohort_Study_of_the_French_National_Health_Insurance_Database","translated_internal_url":"","created_at":"2024-07-16T22:19:56.036-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843172,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843172/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/116843172/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Vaccination_during_the_First_Diagnosis_o.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843172/pdf-libre.pdf?1721196858=\u0026response-content-disposition=attachment%3B+filename%3DVaccination_during_the_First_Diagnosis_o.pdf\u0026Expires=1732431771\u0026Signature=aOXpXRyPzta6~pQjQkLzyZTPRA6z-1elCe9Q87OaDjylnH5eNOec7J0Oy10M3grW6wEtK1G4iNndNfwNCjH3~mbv4m~MXClj9lqXqs42JFl8ijSCO1EguwrDFSQV7LREKvjfu-d9jAVwqBcSvsDQYbFIMsLYGUCqOlvjz71fwOsXWo9CPlsmBGKVl1pvjwj6~UaQ5g3kdI8mpPvyCTmGh6Sidq3Das5v-PCM97bh4NJSysqZKHmP1gsNXf1BzOfCLlJwA3O4BOlrfL6vqbzH-QLQkQdsiquN8hAjK~lWdpcWIcUGGeh25s0numgE0JKIkh5WNtseO3bG9PEoMdvOhQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Vaccination_during_the_First_Diagnosis_of_Multiple_Myeloma_A_Cohort_Study_of_the_French_National_Health_Insurance_Database","translated_slug":"","page_count":12,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843172,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843172/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/116843172/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Vaccination_during_the_First_Diagnosis_o.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843172/pdf-libre.pdf?1721196858=\u0026response-content-disposition=attachment%3B+filename%3DVaccination_during_the_First_Diagnosis_o.pdf\u0026Expires=1732431771\u0026Signature=aOXpXRyPzta6~pQjQkLzyZTPRA6z-1elCe9Q87OaDjylnH5eNOec7J0Oy10M3grW6wEtK1G4iNndNfwNCjH3~mbv4m~MXClj9lqXqs42JFl8ijSCO1EguwrDFSQV7LREKvjfu-d9jAVwqBcSvsDQYbFIMsLYGUCqOlvjz71fwOsXWo9CPlsmBGKVl1pvjwj6~UaQ5g3kdI8mpPvyCTmGh6Sidq3Das5v-PCM97bh4NJSysqZKHmP1gsNXf1BzOfCLlJwA3O4BOlrfL6vqbzH-QLQkQdsiquN8hAjK~lWdpcWIcUGGeh25s0numgE0JKIkh5WNtseO3bG9PEoMdvOhQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"},{"id":116843173,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843173/thumbnails/1.jpg","file_name":"pdf.pdf","download_url":"https://www.academia.edu/attachments/116843173/download_file","bulk_download_file_name":"Vaccination_during_the_First_Diagnosis_o.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843173/pdf-libre.pdf?1721196855=\u0026response-content-disposition=attachment%3B+filename%3DVaccination_during_the_First_Diagnosis_o.pdf\u0026Expires=1732431771\u0026Signature=QNFf2xLTOf6n9OSZlI8~yWvzy-n-pk03IvyRj-1jA4x~tdu2rXCLU31fBPoQIdsVW9YgxauKaJarKrxrknHBDSuBAzHP0mhqoxGlUsMEcI6WRoOOvf4XTd~MowDD8MxmwCK09-RtLoLU5nrSlusSsjo0wQirhg5N1iRgLShxKNks3ZDc3ox6~ljSNkgK2QRAcfz-wBlIspDFCVH9rrQ2BcTk19y5gK5DKywzJj0eVWT-EN7BEFQ44a55JfzZIETJsSa4vtLbDlhiaViyDtH6d7fhzPOwIagisJT4-liRvYWrsRXtnft8GB0Nhz9TtEuYGsXZnk5WzlFvQt87-tB91A__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":4365,"name":"Vaccines","url":"https://www.academia.edu/Documents/in/Vaccines"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":179934,"name":"Vaccination","url":"https://www.academia.edu/Documents/in/Vaccination"}],"urls":[{"id":43557995,"url":"https://www.mdpi.com/2076-393X/8/4/722/pdf"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114350"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114350/Primary_Care_of_Opioid_use_Disorder_The_End_of_the_French_Model_"><img alt="Research paper thumbnail of Primary Care of Opioid use Disorder: The End of “the French Model”?" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114350/Primary_Care_of_Opioid_use_Disorder_The_End_of_the_French_Model_">Primary Care of Opioid use Disorder: The End of “the French Model”?</a></div><div class="wp-workCard_item"><span>European Addiction Research</span><span>, 2020</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenor...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenorphine, prescribed by general practitioners (GP) in private practice since 1996. This has contributed to building a ‘French model’ facilitating access to treatment based on the involvement of GPs in buprenorphine prescription. Objectives: Our study aimed to assess whether the involvement of primary care in OUD management has changed lately. Materials and Methods: Using data from the French National Health Insurance database, we conducted a yearly repeated cross-sectional study (2009–2015) and described proportion of opioid maintenance treatment (OMT)-prescribing GPs and OMT-dispensing community pharmacies (CP); and number of patients by GP or CP. Results: Whereas the number of buprenorphine-prescribing GPs in private practice remained quite stable (decrease of 3%), a substantial decrease in buprenorphine initial prescribers among private GPs was observed. In 2009, 10.3% of private GPs (6,...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114350"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114350"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114350; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114350]").text(description); $(".js-view-count[data-work-id=122114350]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114350; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114350']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114350, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114350]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114350,"title":"Primary Care of Opioid use Disorder: The End of “the French Model”?","translated_title":"","metadata":{"abstract":"Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenorphine, prescribed by general practitioners (GP) in private practice since 1996. This has contributed to building a ‘French model’ facilitating access to treatment based on the involvement of GPs in buprenorphine prescription. Objectives: Our study aimed to assess whether the involvement of primary care in OUD management has changed lately. Materials and Methods: Using data from the French National Health Insurance database, we conducted a yearly repeated cross-sectional study (2009–2015) and described proportion of opioid maintenance treatment (OMT)-prescribing GPs and OMT-dispensing community pharmacies (CP); and number of patients by GP or CP. Results: Whereas the number of buprenorphine-prescribing GPs in private practice remained quite stable (decrease of 3%), a substantial decrease in buprenorphine initial prescribers among private GPs was observed. In 2009, 10.3% of private GPs (6,...","publisher":"S. Karger AG","publication_date":{"day":null,"month":null,"year":2020,"errors":{}},"publication_name":"European Addiction Research"},"translated_abstract":"Background: In France, most patients with opioid use disorder (OUD) have been treated by buprenorphine, prescribed by general practitioners (GP) in private practice since 1996. This has contributed to building a ‘French model’ facilitating access to treatment based on the involvement of GPs in buprenorphine prescription. Objectives: Our study aimed to assess whether the involvement of primary care in OUD management has changed lately. Materials and Methods: Using data from the French National Health Insurance database, we conducted a yearly repeated cross-sectional study (2009–2015) and described proportion of opioid maintenance treatment (OMT)-prescribing GPs and OMT-dispensing community pharmacies (CP); and number of patients by GP or CP. Results: Whereas the number of buprenorphine-prescribing GPs in private practice remained quite stable (decrease of 3%), a substantial decrease in buprenorphine initial prescribers among private GPs was observed. In 2009, 10.3% of private GPs (6,...","internal_url":"https://www.academia.edu/122114350/Primary_Care_of_Opioid_use_Disorder_The_End_of_the_French_Model_","translated_internal_url":"","created_at":"2024-07-16T22:19:54.258-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Primary_Care_of_Opioid_use_Disorder_The_End_of_the_French_Model_","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":221,"name":"Psychology","url":"https://www.academia.edu/Documents/in/Psychology"},{"id":633,"name":"Primary Care","url":"https://www.academia.edu/Documents/in/Primary_Care"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":143599,"name":"Buprenorphine","url":"https://www.academia.edu/Documents/in/Buprenorphine"},{"id":410370,"name":"Public health systems and services research","url":"https://www.academia.edu/Documents/in/Public_health_systems_and_services_research-1"},{"id":4136525,"name":"Medical prescription","url":"https://www.academia.edu/Documents/in/Medical_prescription"}],"urls":[{"id":43557994,"url":"https://www.karger.com/Article/Pdf/506630"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114349"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114349/Couverture_vaccinale_anti_grippale_insuffisante_dans_l_art%C3%A9rite_%C3%A0_cellules_g%C3%A9antes"><img alt="Research paper thumbnail of Couverture vaccinale anti grippale insuffisante dans l’artérite à cellules géantes" class="work-thumbnail" src="https://attachments.academia-assets.com/116843211/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114349/Couverture_vaccinale_anti_grippale_insuffisante_dans_l_art%C3%A9rite_%C3%A0_cellules_g%C3%A9antes">Couverture vaccinale anti grippale insuffisante dans l’artérite à cellules géantes</a></div><div class="wp-workCard_item"><span>La Revue de Médecine Interne</span><span>, 2019</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="e7d08490e4d363aad840733d534bf0ef" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843211,"asset_id":122114349,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843211/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114349"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114349"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114349; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114349]").text(description); $(".js-view-count[data-work-id=122114349]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114349; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114349']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114349, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "e7d08490e4d363aad840733d534bf0ef" } } $('.js-work-strip[data-work-id=122114349]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114349,"title":"Couverture vaccinale anti grippale insuffisante dans l’artérite à cellules géantes","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":null,"month":null,"year":2019,"errors":{}},"publication_name":"La Revue de Médecine Interne"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114349/Couverture_vaccinale_anti_grippale_insuffisante_dans_l_art%C3%A9rite_%C3%A0_cellules_g%C3%A9antes","translated_internal_url":"","created_at":"2024-07-16T22:19:52.777-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843211,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843211/thumbnails/1.jpg","file_name":"S0248866319311853.pdf","download_url":"https://www.academia.edu/attachments/116843211/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Couverture_vaccinale_anti_grippale_insuf.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843211/S0248866319311853-libre.pdf?1721196841=\u0026response-content-disposition=attachment%3B+filename%3DCouverture_vaccinale_anti_grippale_insuf.pdf\u0026Expires=1732431771\u0026Signature=a2dwxJHJeSfAeLw-SkSH9VB01DxDkdsYcDVA~gs4aOeAgbRHvpeyIxOnr9J-qU8X9gVTbJUmaiFHpJZgGIuyeQXcqtVujOdZ9xHc8s9wHnqz1yqAHQ-~-OeQIOs7Mo~x~3JYh~AztzrbQsNTiZixcPrZPMHxlQOFngNjjxlCmlAsWvIj4o3N10Lat7O0humz8UhDteIKIfzXRiCjp-7akpw3FyhEZETCJKbfXOcne5uJQqqbC1HxV57QSRuPgqeAZ5ZDa81pIrbsG4DauYnyBLS6FctGFnbakIeBVsBYLMh63b2yJWo1GvoSI66mKnilj9CdESMMZArG1TnaNr~3bQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Couverture_vaccinale_anti_grippale_insuffisante_dans_l_artérite_à_cellules_géantes","translated_slug":"","page_count":21,"language":"fr","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843211,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843211/thumbnails/1.jpg","file_name":"S0248866319311853.pdf","download_url":"https://www.academia.edu/attachments/116843211/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Couverture_vaccinale_anti_grippale_insuf.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843211/S0248866319311853-libre.pdf?1721196841=\u0026response-content-disposition=attachment%3B+filename%3DCouverture_vaccinale_anti_grippale_insuf.pdf\u0026Expires=1732431771\u0026Signature=a2dwxJHJeSfAeLw-SkSH9VB01DxDkdsYcDVA~gs4aOeAgbRHvpeyIxOnr9J-qU8X9gVTbJUmaiFHpJZgGIuyeQXcqtVujOdZ9xHc8s9wHnqz1yqAHQ-~-OeQIOs7Mo~x~3JYh~AztzrbQsNTiZixcPrZPMHxlQOFngNjjxlCmlAsWvIj4o3N10Lat7O0humz8UhDteIKIfzXRiCjp-7akpw3FyhEZETCJKbfXOcne5uJQqqbC1HxV57QSRuPgqeAZ5ZDa81pIrbsG4DauYnyBLS6FctGFnbakIeBVsBYLMh63b2yJWo1GvoSI66mKnilj9CdESMMZArG1TnaNr~3bQ__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":129972,"name":"Rite","url":"https://www.academia.edu/Documents/in/Rite"},{"id":339107,"name":"Gynecology","url":"https://www.academia.edu/Documents/in/Gynecology"}],"urls":[{"id":43557993,"url":"https://api.elsevier.com/content/article/PII:S0248866319311853?httpAccept=text/xml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114348"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114348/Real_world_costs_of_illness_of_Hodgkin_and_the_main_B_Cell_Non_Hodgkin_lymphomas_in_France"><img alt="Research paper thumbnail of Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France" class="work-thumbnail" src="https://attachments.academia-assets.com/116843210/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114348/Real_world_costs_of_illness_of_Hodgkin_and_the_main_B_Cell_Non_Hodgkin_lymphomas_in_France">Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France</a></div><div class="wp-workCard_item"><span>Journal of Medical Economics</span><span>, 2019</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="9d668f1c0fd6b87a072494ebb7d15d39" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843210,"asset_id":122114348,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843210/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114348"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114348"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114348; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114348]").text(description); $(".js-view-count[data-work-id=122114348]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114348; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114348']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114348, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "9d668f1c0fd6b87a072494ebb7d15d39" } } $('.js-work-strip[data-work-id=122114348]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114348,"title":"Real-world costs of illness of Hodgkin and the main B-Cell Non-Hodgkin lymphomas in France","translated_title":"","metadata":{"publisher":"Informa UK Limited","publication_date":{"day":null,"month":null,"year":2019,"errors":{}},"publication_name":"Journal of Medical Economics"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114348/Real_world_costs_of_illness_of_Hodgkin_and_the_main_B_Cell_Non_Hodgkin_lymphomas_in_France","translated_internal_url":"","created_at":"2024-07-16T22:19:50.865-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843210,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843210/thumbnails/1.jpg","file_name":"IJME_A_1702990.pdf","download_url":"https://www.academia.edu/attachments/116843210/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Real_world_costs_of_illness_of_Hodgkin_a.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843210/IJME_A_1702990-libre.pdf?1721196834=\u0026response-content-disposition=attachment%3B+filename%3DReal_world_costs_of_illness_of_Hodgkin_a.pdf\u0026Expires=1732431771\u0026Signature=RBxqwcqcV0u0rIFe7SN2ILC8IDJ-4hNPji53iip5jOvEcMwW3KiDcA9jm2WmXkH1CLvleaKSO~bMQRkfjJfwCPcjaBmH0I12~IViWxLkiYFkmclx0T3l3ULamgGfm-LDhg9BDzRroMRpApqjs~l2ppI8d0F6cRKZOLxO8FPvD3WMMiG~FkIDxGSMC4vKo59fbNBUr~7NBTPO~IEwx3TxsLImD1wBotWUNUGy2BoGTAtkUi5-yW7AFKpC1T7ySyTSZ94Ig6N779hRi3ZXfe1jgDQtrLrYJJu9PytlsCNxNMdf2PrXJoMCk8LDrYolAAAADCI~O4jUYtMUmi~QGhCc4g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"Real_world_costs_of_illness_of_Hodgkin_and_the_main_B_Cell_Non_Hodgkin_lymphomas_in_France","translated_slug":"","page_count":10,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843210,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843210/thumbnails/1.jpg","file_name":"IJME_A_1702990.pdf","download_url":"https://www.academia.edu/attachments/116843210/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"Real_world_costs_of_illness_of_Hodgkin_a.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843210/IJME_A_1702990-libre.pdf?1721196834=\u0026response-content-disposition=attachment%3B+filename%3DReal_world_costs_of_illness_of_Hodgkin_a.pdf\u0026Expires=1732431771\u0026Signature=RBxqwcqcV0u0rIFe7SN2ILC8IDJ-4hNPji53iip5jOvEcMwW3KiDcA9jm2WmXkH1CLvleaKSO~bMQRkfjJfwCPcjaBmH0I12~IViWxLkiYFkmclx0T3l3ULamgGfm-LDhg9BDzRroMRpApqjs~l2ppI8d0F6cRKZOLxO8FPvD3WMMiG~FkIDxGSMC4vKo59fbNBUr~7NBTPO~IEwx3TxsLImD1wBotWUNUGy2BoGTAtkUi5-yW7AFKpC1T7ySyTSZ94Ig6N779hRi3ZXfe1jgDQtrLrYJJu9PytlsCNxNMdf2PrXJoMCk8LDrYolAAAADCI~O4jUYtMUmi~QGhCc4g__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":221,"name":"Psychology","url":"https://www.academia.edu/Documents/in/Psychology"},{"id":4441,"name":"Health Care","url":"https://www.academia.edu/Documents/in/Health_Care"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":27659,"name":"Applied Economics","url":"https://www.academia.edu/Documents/in/Applied_Economics"},{"id":55269,"name":"Lymphoma","url":"https://www.academia.edu/Documents/in/Lymphoma"},{"id":64336,"name":"Population","url":"https://www.academia.edu/Documents/in/Population"},{"id":132830,"name":"Medical Economics","url":"https://www.academia.edu/Documents/in/Medical_Economics"},{"id":410370,"name":"Public health systems and services research","url":"https://www.academia.edu/Documents/in/Public_health_systems_and_services_research-1"},{"id":1469454,"name":"Hodgkin Lymphoma","url":"https://www.academia.edu/Documents/in/Hodgkin_Lymphoma"},{"id":2216196,"name":"Cost evaluation","url":"https://www.academia.edu/Documents/in/Cost_evaluation"},{"id":2292202,"name":"Follicular lymphoma","url":"https://www.academia.edu/Documents/in/Follicular_lymphoma"}],"urls":[{"id":43557992,"url":"https://www.tandfonline.com/doi/pdf/10.1080/13696998.2019.1702990"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114346"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114346/Positivity_Rate_of_Systematic_Bone_Marrow_Smear_Above_60_Year_Old_Patients_with_Newly_Diagnosed_Immune_Thrombocytopenia_to_Screen_for_Associated_Hematological_Malignancy_Results_from_the_French_Prospective_Multicenter_Carmen_Registry"><img alt="Research paper thumbnail of Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114346/Positivity_Rate_of_Systematic_Bone_Marrow_Smear_Above_60_Year_Old_Patients_with_Newly_Diagnosed_Immune_Thrombocytopenia_to_Screen_for_Associated_Hematological_Malignancy_Results_from_the_French_Prospective_Multicenter_Carmen_Registry">Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry</a></div><div class="wp-workCard_item"><span>Blood</span><span>, 2019</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Introduction:There are discrepancies across recommendations about the indication of bone marrow s...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Introduction:There are discrepancies across recommendations about the indication of bone marrow smear in adults diagnosed for immune thrombocytopenia (ITP). The 2011 American Society of Hematology guidelines do not recommend bone marrow smear in case of typical ITP. In contrast, the 2010 international consensus and the 2017 French guidelines recommend systematic bone marrow smear in adults aged &gt;60 years even in case of typical ITP to detect a blood cancer, particularly myelodysplastic syndrome. This recommendation is driven from expert consensus. Data are lacking about the positivity rate of this examination in older patients with typical ITP. The aim of this study was to assess the positivity rate of bone marrow smear at ITP diagnosis in &gt;60-year-old patients with no other clinical or biological sign of hematological malignancy. Methods:Data source was theCARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) registry. All adult patients with an incident diagnosis of ITP ...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114346"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114346"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114346; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114346]").text(description); $(".js-view-count[data-work-id=122114346]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114346; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114346']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114346, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114346]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114346,"title":"Positivity Rate of Systematic Bone Marrow Smear Above 60-Year-Old Patients with Newly Diagnosed Immune Thrombocytopenia to Screen for Associated Hematological Malignancy. Results from the French Prospective Multicenter Carmen Registry","translated_title":"","metadata":{"abstract":"Introduction:There are discrepancies across recommendations about the indication of bone marrow smear in adults diagnosed for immune thrombocytopenia (ITP). The 2011 American Society of Hematology guidelines do not recommend bone marrow smear in case of typical ITP. In contrast, the 2010 international consensus and the 2017 French guidelines recommend systematic bone marrow smear in adults aged \u0026gt;60 years even in case of typical ITP to detect a blood cancer, particularly myelodysplastic syndrome. This recommendation is driven from expert consensus. Data are lacking about the positivity rate of this examination in older patients with typical ITP. The aim of this study was to assess the positivity rate of bone marrow smear at ITP diagnosis in \u0026gt;60-year-old patients with no other clinical or biological sign of hematological malignancy. Methods:Data source was theCARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) registry. All adult patients with an incident diagnosis of ITP ...","publisher":"American Society of Hematology","publication_date":{"day":null,"month":null,"year":2019,"errors":{}},"publication_name":"Blood"},"translated_abstract":"Introduction:There are discrepancies across recommendations about the indication of bone marrow smear in adults diagnosed for immune thrombocytopenia (ITP). The 2011 American Society of Hematology guidelines do not recommend bone marrow smear in case of typical ITP. In contrast, the 2010 international consensus and the 2017 French guidelines recommend systematic bone marrow smear in adults aged \u0026gt;60 years even in case of typical ITP to detect a blood cancer, particularly myelodysplastic syndrome. This recommendation is driven from expert consensus. Data are lacking about the positivity rate of this examination in older patients with typical ITP. The aim of this study was to assess the positivity rate of bone marrow smear at ITP diagnosis in \u0026gt;60-year-old patients with no other clinical or biological sign of hematological malignancy. Methods:Data source was theCARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) registry. All adult patients with an incident diagnosis of ITP ...","internal_url":"https://www.academia.edu/122114346/Positivity_Rate_of_Systematic_Bone_Marrow_Smear_Above_60_Year_Old_Patients_with_Newly_Diagnosed_Immune_Thrombocytopenia_to_Screen_for_Associated_Hematological_Malignancy_Results_from_the_French_Prospective_Multicenter_Carmen_Registry","translated_internal_url":"","created_at":"2024-07-16T22:19:49.544-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Positivity_Rate_of_Systematic_Bone_Marrow_Smear_Above_60_Year_Old_Patients_with_Newly_Diagnosed_Immune_Thrombocytopenia_to_Screen_for_Associated_Hematological_Malignancy_Results_from_the_French_Prospective_Multicenter_Carmen_Registry","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":100732,"name":"Blood","url":"https://www.academia.edu/Documents/in/Blood"},{"id":159239,"name":"Bone marrow","url":"https://www.academia.edu/Documents/in/Bone_marrow"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":2756159,"name":"Malignancy","url":"https://www.academia.edu/Documents/in/Malignancy"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"},{"id":3789883,"name":"Paediatrics and reproductive medicine","url":"https://www.academia.edu/Documents/in/Paediatrics_and_reproductive_medicine"}],"urls":[{"id":43557990,"url":"https://ashpublications.org/blood/article/134/Supplement_1/1083/426734/Positivity-Rate-of-Systematic-Bone-Marrow-Smear"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114344"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114344/Incidence_of_Adverse_Drug_Reactions_Related_to_Immune_Thrombocytopenia_Drugs_A_Prospective_Cohort_Study"><img alt="Research paper thumbnail of Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114344/Incidence_of_Adverse_Drug_Reactions_Related_to_Immune_Thrombocytopenia_Drugs_A_Prospective_Cohort_Study">Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study</a></div><div class="wp-workCard_item"><span>Blood</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background: The incidence ofadverse drug reactions (ADRs) related to immune thrombocytopenia (ITP...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background: The incidence ofadverse drug reactions (ADRs) related to immune thrombocytopenia (ITP) drugs is not well known in the real-life practice. Aim: The principal aim of this study was to assess the incidence of ADRs related to ITP drugs. The secondary aims were to compare the incidence of ADRs depending on the drugs, and to assess the factors associated to corticosteroids-related ADR occurrence. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes: Registre Midi-PyréneEN) registry. This multicenter registry is carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. It is aimed at the prospective follow-up of all newly diagnosed ITP adults in the French Midi-Pyrénées region (3 million inhabitants). Each investigator prospectively follows every patient newly diagnosed for ITP in routine visit or hospital stay, provi...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114344"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114344"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114344; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114344]").text(description); $(".js-view-count[data-work-id=122114344]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114344; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114344']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114344, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114344]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114344,"title":"Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study","translated_title":"","metadata":{"abstract":"Background: The incidence ofadverse drug reactions (ADRs) related to immune thrombocytopenia (ITP) drugs is not well known in the real-life practice. Aim: The principal aim of this study was to assess the incidence of ADRs related to ITP drugs. The secondary aims were to compare the incidence of ADRs depending on the drugs, and to assess the factors associated to corticosteroids-related ADR occurrence. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes: Registre Midi-PyréneEN) registry. This multicenter registry is carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. It is aimed at the prospective follow-up of all newly diagnosed ITP adults in the French Midi-Pyrénées region (3 million inhabitants). Each investigator prospectively follows every patient newly diagnosed for ITP in routine visit or hospital stay, provi...","publisher":"American Society of Hematology","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"Blood"},"translated_abstract":"Background: The incidence ofadverse drug reactions (ADRs) related to immune thrombocytopenia (ITP) drugs is not well known in the real-life practice. Aim: The principal aim of this study was to assess the incidence of ADRs related to ITP drugs. The secondary aims were to compare the incidence of ADRs depending on the drugs, and to assess the factors associated to corticosteroids-related ADR occurrence. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes: Registre Midi-PyréneEN) registry. This multicenter registry is carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. It is aimed at the prospective follow-up of all newly diagnosed ITP adults in the French Midi-Pyrénées region (3 million inhabitants). Each investigator prospectively follows every patient newly diagnosed for ITP in routine visit or hospital stay, provi...","internal_url":"https://www.academia.edu/122114344/Incidence_of_Adverse_Drug_Reactions_Related_to_Immune_Thrombocytopenia_Drugs_A_Prospective_Cohort_Study","translated_internal_url":"","created_at":"2024-07-16T22:19:47.580-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Incidence_of_Adverse_Drug_Reactions_Related_to_Immune_Thrombocytopenia_Drugs_A_Prospective_Cohort_Study","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":631,"name":"Pediatrics","url":"https://www.academia.edu/Documents/in/Pediatrics"},{"id":5500,"name":"Incidence Geometry","url":"https://www.academia.edu/Documents/in/Incidence_Geometry"},{"id":10829,"name":"Pharmacovigilance","url":"https://www.academia.edu/Documents/in/Pharmacovigilance"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":100732,"name":"Blood","url":"https://www.academia.edu/Documents/in/Blood"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":2717351,"name":"Prospective Cohort Study","url":"https://www.academia.edu/Documents/in/Prospective_Cohort_Study"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"},{"id":3789883,"name":"Paediatrics and reproductive medicine","url":"https://www.academia.edu/Documents/in/Paediatrics_and_reproductive_medicine"}],"urls":[{"id":43557989,"url":"https://ashpublications.org/blood/article/126/23/1056/104621/Incidence-of-Adverse-Drug-Reactions-Related-to"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114343"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" rel="nofollow" href="https://www.academia.edu/122114343/Clinical_Epidemiology_and_First_Line_Treatment_in_Immune_Thrombocytopenia_Adults_Results_of_the_Carmen_Prospective_Cohort"><img alt="Research paper thumbnail of Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort" class="work-thumbnail" src="https://a.academia-assets.com/images/blank-paper.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" rel="nofollow" href="https://www.academia.edu/122114343/Clinical_Epidemiology_and_First_Line_Treatment_in_Immune_Thrombocytopenia_Adults_Results_of_the_Carmen_Prospective_Cohort">Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort</a></div><div class="wp-workCard_item"><span>Blood</span><span>, 2015</span></div><div class="wp-workCard_item"><span class="js-work-more-abstract-truncated">Background: The clinical epidemiology of immune thrombocytopenia (ITP) is not well known. Some is...</span><a class="js-work-more-abstract" data-broccoli-component="work_strip.more_abstract" data-click-track="profile-work-strip-more-abstract" href="javascript:;"><span> more </span><span><i class="fa fa-caret-down"></i></span></a><span class="js-work-more-abstract-untruncated hidden">Background: The clinical epidemiology of immune thrombocytopenia (ITP) is not well known. Some issues (bleeding events at diagnosis, association to other autoimmune diseases, rate of infection prior to ITP onset) are not well described in adults. Little is known as regards first-line treatment choice in the real-life practice. Aim: The aims of this study were to assess i) the clinical epidemiology of incident ITP adults; ii) the use of first-line treatments in this population; and iii) the factors associated with the initial use of intravenous (IV) corticosteroids (CS) and of intravenous immunoglobulin (IVIg) in a real-life setting. This study was carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) multicenter registry. This multicenter re...</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114343"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114343"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114343; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114343]").text(description); $(".js-view-count[data-work-id=122114343]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114343; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114343']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114343, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (false){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "-1" } } $('.js-work-strip[data-work-id=122114343]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114343,"title":"Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort","translated_title":"","metadata":{"abstract":"Background: The clinical epidemiology of immune thrombocytopenia (ITP) is not well known. Some issues (bleeding events at diagnosis, association to other autoimmune diseases, rate of infection prior to ITP onset) are not well described in adults. Little is known as regards first-line treatment choice in the real-life practice. Aim: The aims of this study were to assess i) the clinical epidemiology of incident ITP adults; ii) the use of first-line treatments in this population; and iii) the factors associated with the initial use of intravenous (IV) corticosteroids (CS) and of intravenous immunoglobulin (IVIg) in a real-life setting. This study was carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) multicenter registry. This multicenter re...","publisher":"American Society of Hematology","publication_date":{"day":null,"month":null,"year":2015,"errors":{}},"publication_name":"Blood"},"translated_abstract":"Background: The clinical epidemiology of immune thrombocytopenia (ITP) is not well known. Some issues (bleeding events at diagnosis, association to other autoimmune diseases, rate of infection prior to ITP onset) are not well described in adults. Little is known as regards first-line treatment choice in the real-life practice. Aim: The aims of this study were to assess i) the clinical epidemiology of incident ITP adults; ii) the use of first-line treatments in this population; and iii) the factors associated with the initial use of intravenous (IV) corticosteroids (CS) and of intravenous immunoglobulin (IVIg) in a real-life setting. This study was carried out on behalf of the French national center for autoimmune cytopenia and the French national center for rare diseases in immunohematology. Methods: Study population was the patients included between June 2013 and December 2014 in the CARMEN (Cytopénies Auto-immunes : Registre Midi-PyréneEN) multicenter registry. This multicenter re...","internal_url":"https://www.academia.edu/122114343/Clinical_Epidemiology_and_First_Line_Treatment_in_Immune_Thrombocytopenia_Adults_Results_of_the_Carmen_Prospective_Cohort","translated_internal_url":"","created_at":"2024-07-16T22:19:45.775-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[],"slug":"Clinical_Epidemiology_and_First_Line_Treatment_in_Immune_Thrombocytopenia_Adults_Results_of_the_Carmen_Prospective_Cohort","translated_slug":"","page_count":null,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[],"research_interests":[{"id":631,"name":"Pediatrics","url":"https://www.academia.edu/Documents/in/Pediatrics"},{"id":1085,"name":"Epidemiology","url":"https://www.academia.edu/Documents/in/Epidemiology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":64336,"name":"Population","url":"https://www.academia.edu/Documents/in/Population"},{"id":100732,"name":"Blood","url":"https://www.academia.edu/Documents/in/Blood"},{"id":244814,"name":"Clinical Sciences","url":"https://www.academia.edu/Documents/in/Clinical_Sciences"},{"id":3789879,"name":"Cardiovascular medicine and haematology","url":"https://www.academia.edu/Documents/in/Cardiovascular_medicine_and_haematology"},{"id":3789883,"name":"Paediatrics and reproductive medicine","url":"https://www.academia.edu/Documents/in/Paediatrics_and_reproductive_medicine"}],"urls":[{"id":43557988,"url":"https://ashpublications.org/blood/article/126/23/3473/91152/Clinical-Epidemiology-and-FirstLine-Treatment-in"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> <div class="js-work-strip profile--work_container" data-work-id="122114340"><div class="profile--work_thumbnail hidden-xs"><a class="js-work-strip-work-link" data-click-track="profile-work-strip-thumbnail" href="https://www.academia.edu/122114340/The_value_of_a_health_insurance_database_to_conduct_pharmacoepidemiological_studies_in_oncology"><img alt="Research paper thumbnail of The value of a health insurance database to conduct pharmacoepidemiological studies in oncology" class="work-thumbnail" src="https://attachments.academia-assets.com/116843194/thumbnails/1.jpg" /></a></div><div class="wp-workCard wp-workCard_itemContainer"><div class="wp-workCard_item wp-workCard--title"><a class="js-work-strip-work-link text-gray-darker" data-click-track="profile-work-strip-title" href="https://www.academia.edu/122114340/The_value_of_a_health_insurance_database_to_conduct_pharmacoepidemiological_studies_in_oncology">The value of a health insurance database to conduct pharmacoepidemiological studies in oncology</a></div><div class="wp-workCard_item"><span>Therapies</span><span>, 2019</span></div><div class="wp-workCard_item wp-workCard--actions"><span class="work-strip-bookmark-button-container"></span><a id="450372c1a5052d98d830e0e0a3611596" class="wp-workCard--action" rel="nofollow" data-click-track="profile-work-strip-download" data-download="{"attachment_id":116843194,"asset_id":122114340,"asset_type":"Work","button_location":"profile"}" href="https://www.academia.edu/attachments/116843194/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&s=profile"><span><i class="fa fa-arrow-down"></i></span><span>Download</span></a><span class="wp-workCard--action visible-if-viewed-by-owner inline-block" style="display: none;"><span class="js-profile-work-strip-edit-button-wrapper profile-work-strip-edit-button-wrapper" data-work-id="122114340"><a class="js-profile-work-strip-edit-button" tabindex="0"><span><i class="fa fa-pencil"></i></span><span>Edit</span></a></span></span><span id="work-strip-rankings-button-container"></span></div><div class="wp-workCard_item wp-workCard--stats"><span><span><span class="js-view-count view-count u-mr2x" data-work-id="122114340"><i class="fa fa-spinner fa-spin"></i></span><script>$(function () { var workId = 122114340; window.Academia.workViewCountsFetcher.queue(workId, function (count) { var description = window.$h.commaizeInt(count) + " " + window.$h.pluralize(count, 'View'); $(".js-view-count[data-work-id=122114340]").text(description); $(".js-view-count[data-work-id=122114340]").attr('title', description).tooltip(); }); });</script></span></span><span><span class="percentile-widget hidden"><span class="u-mr2x work-percentile"></span></span><script>$(function () { var workId = 122114340; window.Academia.workPercentilesFetcher.queue(workId, function (percentileText) { var container = $(".js-work-strip[data-work-id='122114340']"); container.find('.work-percentile').text(percentileText.charAt(0).toUpperCase() + percentileText.slice(1)); container.find('.percentile-widget').show(); container.find('.percentile-widget').removeClass('hidden'); }); });</script></span><span><script>$(function() { new Works.PaperRankView({ workId: 122114340, container: "", }); });</script></span></div><div id="work-strip-premium-row-container"></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/work_edit-ad038b8c047c1a8d4fa01b402d530ff93c45fee2137a149a4a5398bc8ad67560.js"], function() { // from javascript_helper.rb var dispatcherData = {} if (true){ window.WowProfile.dispatcher = window.WowProfile.dispatcher || _.clone(Backbone.Events); dispatcherData = { dispatcher: window.WowProfile.dispatcher, downloadLinkId: "450372c1a5052d98d830e0e0a3611596" } } $('.js-work-strip[data-work-id=122114340]').each(function() { if (!$(this).data('initialized')) { new WowProfile.WorkStripView({ el: this, workJSON: {"id":122114340,"title":"The value of a health insurance database to conduct pharmacoepidemiological studies in oncology","translated_title":"","metadata":{"publisher":"Elsevier BV","publication_date":{"day":null,"month":null,"year":2019,"errors":{}},"publication_name":"Therapies"},"translated_abstract":null,"internal_url":"https://www.academia.edu/122114340/The_value_of_a_health_insurance_database_to_conduct_pharmacoepidemiological_studies_in_oncology","translated_internal_url":"","created_at":"2024-07-16T22:19:43.552-07:00","preview_url":null,"current_user_can_edit":null,"current_user_is_owner":null,"owner_id":32462798,"coauthors_can_edit":true,"document_type":"paper","co_author_tags":[],"downloadable_attachments":[{"id":116843194,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843194/thumbnails/1.jpg","file_name":"S0040595719300241.pdf","download_url":"https://www.academia.edu/attachments/116843194/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_value_of_a_health_insurance_database.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843194/S0040595719300241-libre.pdf?1721196842=\u0026response-content-disposition=attachment%3B+filename%3DThe_value_of_a_health_insurance_database.pdf\u0026Expires=1732452503\u0026Signature=Nu1cT1MT1CFzYXJlSgxD5XL9AdFnmk3KuJD3KgqAQ1-AnPXFuTA2z4Olo5~w3Rgq7mNNvVbcepdFwzGtbpgj4gQ2Vy~ntv5bMBgZOXn69Lag-ZfH3nURcURweYz1TpVHpTxBtQqjLl2orNBArjNso8y4vMX0tpHvFbEJPKkIxXasWlNo2OZSVNWcyq5hllHvq~XiRG6EFhVXZCq959grNTUo~LW~SRnR3EHuOPW9odck4HJxxSIQL6~sp-CAX9RQQDzgBhqBGtAtjFdyVaIAk6EHkWgjbTijXuSD-ohhYKScV9QY4EpexxSQOV7gtLRZjyLJzGcW8iKe-t2CpvjAQg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"slug":"The_value_of_a_health_insurance_database_to_conduct_pharmacoepidemiological_studies_in_oncology","translated_slug":"","page_count":26,"language":"en","content_type":"Work","owner":{"id":32462798,"first_name":"Maryse","middle_initials":"","last_name":"Lapeyre-mestre","page_name":"MaryseLapeyremestre","domain_name":"univ-toulouse","created_at":"2015-06-23T06:27:47.928-07:00","display_name":"Maryse Lapeyre-mestre","url":"https://univ-toulouse.academia.edu/MaryseLapeyremestre"},"attachments":[{"id":116843194,"title":"","file_type":"pdf","scribd_thumbnail_url":"https://attachments.academia-assets.com/116843194/thumbnails/1.jpg","file_name":"S0040595719300241.pdf","download_url":"https://www.academia.edu/attachments/116843194/download_file?st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&st=MTczMjQ0ODkwMyw4LjIyMi4yMDguMTQ2&","bulk_download_file_name":"The_value_of_a_health_insurance_database.pdf","bulk_download_url":"https://d1wqtxts1xzle7.cloudfront.net/116843194/S0040595719300241-libre.pdf?1721196842=\u0026response-content-disposition=attachment%3B+filename%3DThe_value_of_a_health_insurance_database.pdf\u0026Expires=1732452503\u0026Signature=Nu1cT1MT1CFzYXJlSgxD5XL9AdFnmk3KuJD3KgqAQ1-AnPXFuTA2z4Olo5~w3Rgq7mNNvVbcepdFwzGtbpgj4gQ2Vy~ntv5bMBgZOXn69Lag-ZfH3nURcURweYz1TpVHpTxBtQqjLl2orNBArjNso8y4vMX0tpHvFbEJPKkIxXasWlNo2OZSVNWcyq5hllHvq~XiRG6EFhVXZCq959grNTUo~LW~SRnR3EHuOPW9odck4HJxxSIQL6~sp-CAX9RQQDzgBhqBGtAtjFdyVaIAk6EHkWgjbTijXuSD-ohhYKScV9QY4EpexxSQOV7gtLRZjyLJzGcW8iKe-t2CpvjAQg__\u0026Key-Pair-Id=APKAJLOHF5GGSLRBV4ZA"}],"research_interests":[{"id":1086,"name":"Pharmacoepidemiology","url":"https://www.academia.edu/Documents/in/Pharmacoepidemiology"},{"id":26327,"name":"Medicine","url":"https://www.academia.edu/Documents/in/Medicine"},{"id":816770,"name":"Therapies","url":"https://www.academia.edu/Documents/in/Therapies"},{"id":2380530,"name":"Therapie","url":"https://www.academia.edu/Documents/in/Therapie"}],"urls":[{"id":43557987,"url":"https://api.elsevier.com/content/article/PII:S0040595719300241?httpAccept=text/xml"}]}, dispatcherData: dispatcherData }); $(this).data('initialized', true); } }); $a.trackClickSource(".js-work-strip-work-link", "profile_work_strip") }); </script> </div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js","https://a.academia-assets.com/assets/google_contacts-0dfb882d836b94dbcb4a2d123d6933fc9533eda5be911641f20b4eb428429600.js"], function() { // from javascript_helper.rb $('.js-google-connect-button').click(function(e) { e.preventDefault(); GoogleContacts.authorize_and_show_contacts(); Aedu.Dismissibles.recordClickthrough("WowProfileImportContactsPrompt"); }); $('.js-update-biography-button').click(function(e) { e.preventDefault(); Aedu.Dismissibles.recordClickthrough("UpdateUserBiographyPrompt"); $.ajax({ url: $r.api_v0_profiles_update_about_path({ subdomain_param: 'api', about: "", }), type: 'PUT', success: function(response) { location.reload(); } }); }); $('.js-work-creator-button').click(function (e) { e.preventDefault(); window.location = $r.upload_funnel_document_path({ source: encodeURIComponent(""), }); }); $('.js-video-upload-button').click(function (e) { e.preventDefault(); window.location = $r.upload_funnel_video_path({ source: encodeURIComponent(""), }); }); $('.js-do-this-later-button').click(function() { $(this).closest('.js-profile-nag-panel').remove(); Aedu.Dismissibles.recordDismissal("WowProfileImportContactsPrompt"); }); $('.js-update-biography-do-this-later-button').click(function(){ $(this).closest('.js-profile-nag-panel').remove(); Aedu.Dismissibles.recordDismissal("UpdateUserBiographyPrompt"); }); $('.wow-profile-mentions-upsell--close').click(function(){ $('.wow-profile-mentions-upsell--panel').hide(); Aedu.Dismissibles.recordDismissal("WowProfileMentionsUpsell"); }); $('.wow-profile-mentions-upsell--button').click(function(){ Aedu.Dismissibles.recordClickthrough("WowProfileMentionsUpsell"); }); new WowProfile.SocialRedesignUserWorks({ initialWorksOffset: 20, allWorksOffset: 20, maxSections: 1 }) }); </script> </div></div></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/wow_profile_edit-5ea339ee107c863779f560dd7275595239fed73f1a13d279d2b599a28c0ecd33.js","https://a.academia-assets.com/assets/add_coauthor-22174b608f9cb871d03443cafa7feac496fb50d7df2d66a53f5ee3c04ba67f53.js","https://a.academia-assets.com/assets/tab-dcac0130902f0cc2d8cb403714dd47454f11fc6fb0e99ae6a0827b06613abc20.js","https://a.academia-assets.com/assets/wow_profile-f77ea15d77ce96025a6048a514272ad8becbad23c641fc2b3bd6e24ca6ff1932.js"], function() { // from javascript_helper.rb window.ae = window.ae || {}; window.ae.WowProfile = window.ae.WowProfile || {}; if(Aedu.User.current && Aedu.User.current.id === $viewedUser.id) { window.ae.WowProfile.current_user_edit = {}; new WowProfileEdit.EditUploadView({ el: '.js-edit-upload-button-wrapper', model: window.$current_user, }); new AddCoauthor.AddCoauthorsController(); } var userInfoView = new WowProfile.SocialRedesignUserInfo({ recaptcha_key: "6LdxlRMTAAAAADnu_zyLhLg0YF9uACwz78shpjJB" }); WowProfile.router = new WowProfile.Router({ userInfoView: userInfoView }); Backbone.history.start({ pushState: true, root: "/" + $viewedUser.page_name }); new WowProfile.UserWorksNav() }); </script> </div> <div class="bootstrap login"><div class="modal fade login-modal" id="login-modal"><div class="login-modal-dialog modal-dialog"><div class="modal-content"><div class="modal-header"><button class="close close" data-dismiss="modal" type="button"><span aria-hidden="true">×</span><span class="sr-only">Close</span></button><h4 class="modal-title text-center"><strong>Log In</strong></h4></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><button class="btn btn-fb btn-lg btn-block btn-v-center-content" id="login-facebook-oauth-button"><svg style="float: left; width: 19px; line-height: 1em; margin-right: .3em;" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="facebook-square" class="svg-inline--fa fa-facebook-square fa-w-14" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 448 512"><path fill="currentColor" d="M400 32H48A48 48 0 0 0 0 80v352a48 48 0 0 0 48 48h137.25V327.69h-63V256h63v-54.64c0-62.15 37-96.48 93.67-96.48 27.14 0 55.52 4.84 55.52 4.84v61h-31.27c-30.81 0-40.42 19.12-40.42 38.73V256h68.78l-11 71.69h-57.78V480H400a48 48 0 0 0 48-48V80a48 48 0 0 0-48-48z"></path></svg><small><strong>Log in</strong> with <strong>Facebook</strong></small></button><br /><button class="btn btn-google btn-lg btn-block btn-v-center-content" id="login-google-oauth-button"><svg style="float: left; width: 22px; line-height: 1em; margin-right: .3em;" aria-hidden="true" focusable="false" data-prefix="fab" data-icon="google-plus" class="svg-inline--fa fa-google-plus fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M256,8C119.1,8,8,119.1,8,256S119.1,504,256,504,504,392.9,504,256,392.9,8,256,8ZM185.3,380a124,124,0,0,1,0-248c31.3,0,60.1,11,83,32.3l-33.6,32.6c-13.2-12.9-31.3-19.1-49.4-19.1-42.9,0-77.2,35.5-77.2,78.1S142.3,334,185.3,334c32.6,0,64.9-19.1,70.1-53.3H185.3V238.1H302.2a109.2,109.2,0,0,1,1.9,20.7c0,70.8-47.5,121.2-118.8,121.2ZM415.5,273.8v35.5H380V273.8H344.5V238.3H380V202.8h35.5v35.5h35.2v35.5Z"></path></svg><small><strong>Log in</strong> with <strong>Google</strong></small></button><br /><style type="text/css">.sign-in-with-apple-button { width: 100%; height: 52px; border-radius: 3px; border: 1px solid black; cursor: pointer; }</style><script src="https://appleid.cdn-apple.com/appleauth/static/jsapi/appleid/1/en_US/appleid.auth.js" type="text/javascript"></script><div class="sign-in-with-apple-button" data-border="false" data-color="white" id="appleid-signin"><span   ="Sign Up with Apple" class="u-fs11"></span></div><script>AppleID.auth.init({ clientId: 'edu.academia.applesignon', scope: 'name email', redirectURI: 'https://www.academia.edu/sessions', state: "541b2b2b23bffbd46dc59651faf4862dd3fb118520eb3abf3ffc71d566af4dc3", });</script><script>// Hacky way of checking if on fast loswp if (window.loswp == null) { (function() { const Google = window?.Aedu?.Auth?.OauthButton?.Login?.Google; const Facebook = window?.Aedu?.Auth?.OauthButton?.Login?.Facebook; if (Google) { new Google({ el: '#login-google-oauth-button', rememberMeCheckboxId: 'remember_me', track: null }); } if (Facebook) { new Facebook({ el: '#login-facebook-oauth-button', rememberMeCheckboxId: 'remember_me', track: null }); } })(); }</script></div></div></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><div class="hr-heading login-hr-heading"><span class="hr-heading-text">or</span></div></div></div></div><div class="modal-body"><div class="row"><div class="col-xs-10 col-xs-offset-1"><form class="js-login-form" action="https://www.academia.edu/sessions" accept-charset="UTF-8" method="post"><input name="utf8" type="hidden" value="✓" autocomplete="off" /><input type="hidden" name="authenticity_token" value="axukALf3ONa5NjTx4CsmL4DcXjoeDB/OSICg87N8PpsyxcuM4LJNHY3La6MBLs59U9R4FnxNDJMxOO4uUDw/Aw==" autocomplete="off" /><div class="form-group"><label class="control-label" for="login-modal-email-input" style="font-size: 14px;">Email</label><input class="form-control" id="login-modal-email-input" name="login" type="email" /></div><div class="form-group"><label class="control-label" for="login-modal-password-input" style="font-size: 14px;">Password</label><input class="form-control" id="login-modal-password-input" name="password" type="password" /></div><input type="hidden" name="post_login_redirect_url" id="post_login_redirect_url" value="https://univ-toulouse.academia.edu/MaryseLapeyremestre" autocomplete="off" /><div class="checkbox"><label><input type="checkbox" name="remember_me" id="remember_me" value="1" checked="checked" /><small style="font-size: 12px; margin-top: 2px; display: inline-block;">Remember me on this computer</small></label></div><br><input type="submit" name="commit" value="Log In" class="btn btn-primary btn-block btn-lg js-login-submit" data-disable-with="Log In" /></br></form><script>typeof window?.Aedu?.recaptchaManagedForm === 'function' && window.Aedu.recaptchaManagedForm( document.querySelector('.js-login-form'), document.querySelector('.js-login-submit') );</script><small style="font-size: 12px;"><br />or <a data-target="#login-modal-reset-password-container" data-toggle="collapse" href="javascript:void(0)">reset password</a></small><div class="collapse" id="login-modal-reset-password-container"><br /><div class="well margin-0x"><form class="js-password-reset-form" action="https://www.academia.edu/reset_password" accept-charset="UTF-8" method="post"><input name="utf8" type="hidden" value="✓" autocomplete="off" /><input type="hidden" name="authenticity_token" value="vlbp9rB7yGXm2ln99eIzV88Gj0hgwG4uRAPqKgd+oqvniIZ65z69rtInBq8U59sFHA6pZAKBfXM9u6T35D6jMw==" autocomplete="off" /><p>Enter the email address you signed up with and we'll email you a reset link.</p><div class="form-group"><input class="form-control" name="email" type="email" /></div><script src="https://recaptcha.net/recaptcha/api.js" async defer></script> <script> var invisibleRecaptchaSubmit = function () { var closestForm = function (ele) { var curEle = ele.parentNode; while (curEle.nodeName !== 'FORM' && curEle.nodeName !== 'BODY'){ curEle = curEle.parentNode; } return curEle.nodeName === 'FORM' ? curEle : null }; var eles = document.getElementsByClassName('g-recaptcha'); if (eles.length > 0) { var form = closestForm(eles[0]); if (form) { form.submit(); } } }; </script> <input type="submit" data-sitekey="6Lf3KHUUAAAAACggoMpmGJdQDtiyrjVlvGJ6BbAj" data-callback="invisibleRecaptchaSubmit" class="g-recaptcha btn btn-primary btn-block" value="Email me a link" value=""/> </form></div></div><script> require.config({ waitSeconds: 90 })(["https://a.academia-assets.com/assets/collapse-45805421cf446ca5adf7aaa1935b08a3a8d1d9a6cc5d91a62a2a3a00b20b3e6a.js"], function() { // from javascript_helper.rb $("#login-modal-reset-password-container").on("shown.bs.collapse", function() { $(this).find("input[type=email]").focus(); }); }); </script> </div></div></div><div class="modal-footer"><div class="text-center"><small style="font-size: 12px;">Need an account? <a rel="nofollow" href="https://www.academia.edu/signup">Click here to sign up</a></small></div></div></div></div></div></div><script>// If we are on subdomain or non-bootstrapped page, redirect to login page instead of showing modal (function(){ if (typeof $ === 'undefined') return; var host = window.location.hostname; if ((host === $domain || host === "www."+$domain) && (typeof $().modal === 'function')) { $("#nav_log_in").click(function(e) { // Don't follow the link and open the modal e.preventDefault(); $("#login-modal").on('shown.bs.modal', function() { $(this).find("#login-modal-email-input").focus() }).modal('show'); }); } })()</script> <div class="bootstrap" id="footer"><div class="footer-content clearfix text-center padding-top-7x" style="width:100%;"><ul class="footer-links-secondary footer-links-wide list-inline margin-bottom-1x"><li><a href="https://www.academia.edu/about">About</a></li><li><a href="https://www.academia.edu/press">Press</a></li><li><a rel="nofollow" href="https://medium.com/academia">Blog</a></li><li><a href="https://www.academia.edu/documents">Papers</a></li><li><a href="https://www.academia.edu/topics">Topics</a></li><li><a href="https://www.academia.edu/journals">Academia.edu Journals</a></li><li><a rel="nofollow" href="https://www.academia.edu/hiring"><svg style="width: 13px; height: 13px;" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="briefcase" class="svg-inline--fa fa-briefcase fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M320 336c0 8.84-7.16 16-16 16h-96c-8.84 0-16-7.16-16-16v-48H0v144c0 25.6 22.4 48 48 48h416c25.6 0 48-22.4 48-48V288H320v48zm144-208h-80V80c0-25.6-22.4-48-48-48H176c-25.6 0-48 22.4-48 48v48H48c-25.6 0-48 22.4-48 48v80h512v-80c0-25.6-22.4-48-48-48zm-144 0H192V96h128v32z"></path></svg> <strong>We're Hiring!</strong></a></li><li><a rel="nofollow" href="https://support.academia.edu/"><svg style="width: 12px; height: 12px;" aria-hidden="true" focusable="false" data-prefix="fas" data-icon="question-circle" class="svg-inline--fa fa-question-circle fa-w-16" role="img" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512"><path fill="currentColor" d="M504 256c0 136.997-111.043 248-248 248S8 392.997 8 256C8 119.083 119.043 8 256 8s248 111.083 248 248zM262.655 90c-54.497 0-89.255 22.957-116.549 63.758-3.536 5.286-2.353 12.415 2.715 16.258l34.699 26.31c5.205 3.947 12.621 3.008 16.665-2.122 17.864-22.658 30.113-35.797 57.303-35.797 20.429 0 45.698 13.148 45.698 32.958 0 14.976-12.363 22.667-32.534 33.976C247.128 238.528 216 254.941 216 296v4c0 6.627 5.373 12 12 12h56c6.627 0 12-5.373 12-12v-1.333c0-28.462 83.186-29.647 83.186-106.667 0-58.002-60.165-102-116.531-102zM256 338c-25.365 0-46 20.635-46 46 0 25.364 20.635 46 46 46s46-20.636 46-46c0-25.365-20.635-46-46-46z"></path></svg> <strong>Help Center</strong></a></li></ul><ul class="footer-links-tertiary list-inline margin-bottom-1x"><li class="small">Find new research papers in:</li><li class="small"><a href="https://www.academia.edu/Documents/in/Physics">Physics</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Chemistry">Chemistry</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Biology">Biology</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Health_Sciences">Health Sciences</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Ecology">Ecology</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Earth_Sciences">Earth Sciences</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Cognitive_Science">Cognitive Science</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Mathematics">Mathematics</a></li><li class="small"><a href="https://www.academia.edu/Documents/in/Computer_Science">Computer Science</a></li></ul></div></div><div class="DesignSystem" id="credit" style="width:100%;"><ul class="u-pl0x footer-links-legal list-inline"><li><a rel="nofollow" href="https://www.academia.edu/terms">Terms</a></li><li><a rel="nofollow" href="https://www.academia.edu/privacy">Privacy</a></li><li><a rel="nofollow" href="https://www.academia.edu/copyright">Copyright</a></li><li>Academia ©2024</li></ul></div><script> //<![CDATA[ window.detect_gmtoffset = true; window.Academia && window.Academia.set_gmtoffset && Academia.set_gmtoffset('/gmtoffset'); //]]> </script> <div id='overlay_background'></div> <div id='bootstrap-modal-container' class='bootstrap'></div> <div id='ds-modal-container' class='bootstrap DesignSystem'></div> <div id='full-screen-modal'></div> </div> </body> </html>